論文業績一覧
1.

一元化登録（2009年4月以降）データ利用申請・WG研究

論文タイトル

論文業績

著者

雑誌名

発行
年

日本さい帯血バンクネットワーク設立10 2009
周年記念 そして明日から

刊・号・
頁

業績
番号

54-7.

U1

1

小児へのさい帯血移植.

加藤剛二.

2

Pre-transplant imatinib-based therapy
improves the outcome of allogeneic
hematopoietic stem cell transplantationfor BCR-ABL-positive acutelymphoblastic leukemia.

Mizuta S, Matsuo K, Yagasaki F, Yujiri T,
Hatta Y, Kimura Y, Ueda Y, Kanamori H,
Usui N, Akiyama H, Miyazaki Y, Ohtake S, Leukemia
Atsuta Y, Sakamaki H, Kawa K,
Morishima Y, Ohnishi K, Naoe T, Ohno R.

2011

25(1):417.

U2

3

A suggested total size for the cord bloodbanks of Japan.

Takanashi M, Tanaka H, Kohsaki M,
Bone Marrow
2011
Nakajima K, Tadokoro K, Nakabayashi M. Transplant46(7):101
4-5.

U3

4

Successful cord blood transplantation in a
Yagasaki H, Kato M, Ishige M, Shichino H,
42-day-old boy with infantile Krabbe
Int J Hematol 2011
Chin M, Mugishima H.
disease.

93(4):566
-8.

U4

5

Allogeneic hematopoietic stem cell
Ishiyama K, Takami A, Kanda Y, Nakao S,
transplantation for acute myeloid leukemia
Hidaka M, Maeda T, Naoe T, Taniguchi S,
with t(6;9)(p23;q34) dramatically improves
Leukemia
Kawa K, Nagamura T, Atsuta Y, Sakamaki
the patient prognosis: a matched-pairH.
analysis.

2012

26(3):461
-4.

U5

6

Prognostic factors for acute myeloid
Ishiyama K, Takami A, Kanda Y, Nakao S,
leukemia patients with t(6;9)(p23;q34) who Hidaka M, Maeda T, Naoe T, Taniguchi S,
Leukemia
underwent an allogeneic hematopoietic
Kawa K, Nagamura T, Tabuchi K, Atsuta
stem cell transplant.
Y, Sakamaki H.

2012

26(6):141
6-9.

U6

7

Peripheral blood as a preferable source ofFuji S, Nakamura F, Hatanaka K,
stem cells for salvage transplantation in
Taniguchi S, Sato M, Mori S, Sakamaki H, Biol Bloodpatients with graft failure after cord blood
Yabe H, Miyamoto T, Kanamori H, Ueda Marrowtransplantation: a retrospective analysis of
Y, Kawa K, Kato K, Suzuki R, Atsuta Y,
Transplant
the registry data of the Japanese Society
Tamaki T, Kanda Y.
for Hematopoietic Cell Transplantation.

2012

18(9):140
7-14.

U7

2012

119(9):21
41-8.

U8

2012

119(10):2
409-16.

U9

Kanda J, Hishizawa M, Utsunomiya A,
Taniguchi S, Eto T, Moriuchi Y, Tanosaki
R, Kawano F, Miyazaki Y, Masuda M,
Nagafuji K, Hara M, Takanashi M, Kai S,
Blood
Atsuta Y, Suzuki R, Kawase T, Matsuo K,
Nagamura-Inoue T, Kato S, Sakamaki H,
Morishima Y, Okamura J, Ichinohe T,
Uchiyama T.

8Impact of graft-versus-host disease on
outcomes after allogeneic hematopoietic
cell transplantation for adult T-cellleukemia: a retrospective cohort study.

9

Kanda J, Saji H, Fukuda T, Kobayashi T,
Related transplantation with HLA-1 Ag
Miyamura K, Eto T, Kurokawa M,
mismatch in the GVH direction and HLAKanamori H, Mori T, Hidaka M, Iwato K,
8/8 allele-matched unrelated
Yoshida T, Sakamaki H, Tanaka J, Kawa
transplantation: a nationwide retrospective
K, Morishima Y, Suzuki R, Atsuta Y,
study.
Kanda Y.

Blood

Efficacy and long-term outcome oftreatment for pure red cell aplasia after
10
allogeneic stem cell transplantation frommajor ABO-incompatible donors.

Hirokawa M, Fukuda T, Ohashi K, Hidaka
M, Ichinohe T, Iwato K, Kanamori H,
Biol Blood
Murata M, Sakura T, Imamura M, Adachi Marrow
S, Suzuki R, Morishima Y, Sakamaki H;
Transplant
PRCA Collaborative Study Group.

2013

19(7):102
6-32.

U10

Changes in incidence and causes of nonKurosawa S, Yakushijin K, Yamaguchi T,
relapse mortality after allogeneic
Atsuta Y, Nagamura-Inoue T, Akiyama H,
hematopoietic cell transplantation in
Taniguchi S, Miyamura K, Takahashi S,
Bone Marrow
11 patients with acute2013
Eto T, Ogawa H, Kurokawa M, Tanaka J, Transplantleukemia/myelodysplastic syndrome: an
Kawa K, Kato K, Suzuki R, Morishima Y,
analysis of the Japan Transplant Outcome
Sakamaki H, Fukuda T.
Registry.

48(4):529
-36.

U11

Recent decrease in non-relapse mortality
due to GVHD and infection after
12 allogeneic hematopoietic celltransplantation in non-remission acuteleukemia.

Kurosawa S, Yakushijin K, Yamaguchi T,
Atsuta Y, Nagamura-Inoue T, Akiyama H,
Taniguchi S, Miyamura K, Takahashi S,
Bone Marrow
2013
Eto T, Ogawa H, Kurokawa M, Tanaka J, Transplant
Kawa K, Kato K, Suzuki R, Morishima Y,
Sakamaki H, Fukuda T.

48(9):119
8-204.

U12

PBSCT is associated with poorer survival
and increased chronic GvHD than BMT in
13 Japanese paediatric patients with acuteleukaemia and an HLA-matched sibling
donor.

Shinzato A, Tabuchi K, Atsuta Y, Inoue
M, Inagaki J, Yabe H, Koh K, Kato K,
Pediatr Blood
Ohta H, Kigasawa H, Kitoh T, Ogawa A,
2013
CancerTakahashi Y, Sasahara Y, Kato S, AdachiS.

60(9):151
3-9.

U13

Allogeneic hematopoietic stem cell
14 transplantation for intermediate
cytogenetic risk AML in first CR.

Imahashi N, Suzuki R, Fukuda T,
Kakihana K, Kanamori H, Eto T, Mori T,
Kobayashi N, Iwato K, Sakura T, Ikegame Bone Marrow
2013
K, Kurokawa M, Kondo T, Iida H,
Transplant
Sakamaki H, Tanaka J, Kawa K,
Morishima Y, Atsuta Y, Miyamura K.

48(1):5662.

U14

Feasibility of reduced-intensity
conditioning followed by unrelated cord
blood transplantation for primary
15
hemophagocytic lymphohistiocytosis: anationwide retrospective analysis inJapan.

Sawada A, Ohga S, Ishii E, Inoue M,
Okada K, Inagaki J, Goto H, Suzuki N,
Koike K, Atsuta Y, Suzuki R, Yabe H,
Kawa K, Kato K, Yasutomo K.

Int J Hematol 2013

98(2):223
-30.

U15

血液事業

35(4):703
-5.

U16

16

移植に必要なAB型の血漿・血小板製剤の永澤雅秀.
需給動向について.

2013

Association between decreasing trend in
the mortality of adult T-cellleukemia/lymphoma and allogeneic
hematopoietic stem cell transplants in
17
Japan: analysis of Japanese vitalstatistics and Japan Society for
Hematopoietic Cell Transplantation(JSHCT).

Chihara D, Ito H, Matsuda T, Katanoda K,
Blood Cancer
Shibata A, Taniguchi S, Utsunomiya A,
2013
J
Sobue T, Matsuo K.

3:e159.

U17

Granulocyte colony-stimulating factor
combined regimen in cord blood
18 transplantation for acute myeloid
leukemia: a nationwide retrospective
analysis in Japan.

Konuma T, Ooi J, Uchida N, Ogawa H,
Ohashi K, Kanamori H, Aotsuka N, Onishi
Haematologic
Y, Yamaguchi H, Kozai Y, Nagamura2014
aInoue T, Kato K, Suzuki R, Atsuta Y,
Kato S, Asano S, Takahashi S.

99(12):e2
64-8.

U18

28(9):980-9.

U19

Mycophenolate mofetil use after unrelated Iida M, Fukuda T, Uchida N, Murata M,
hematopoietic stem cell transplantation
Aotsuka N, Minagawa K, Oohashi K,
Clin
19 for prophylaxis and treatment of graftFukushima K, Kondo T, Eto T, Miyamoto
Transplantvs.-host disease in adult patients in
T, Morishima Y, Nagamura T, Atsuta Y,
Japan.
Suzuki R.

2014Murata M, Nishida T, Taniguchi S, Ohashi
Allogeneic transplantation for primaryK, Ogawa H, Fukuda T, Mori T, Kobayashi
myelofibrosis with BM, peripheral blood orBone Marrow
20
H, Nakaseko C, Yamagata N, Morishima
2014
umbilical cord blood: an analysis of theTransplant
Y, Nagamura-Inoue T, Sakamaki H,
JSHCT.
Atsuta Y, Suzuki R, Naoe T.
Hematopoietic stem cell transplantation
for inborn errors of metabolism: A reportfrom the Research Committee on
Transplantation for Inborn Errors of
21 Metabolism of the Japanese Ministry of
Health, Labour and Welfare and theWorking Group of the Japan Society for
Hematopoietic Cell Transplantation.

Kato S, Yabe H, Takakura H, Mugishima
H, Ishige M, Tanaka A, Kato K, Yoshida N, Pediatr
Adachi S, Sakai N, Hashii Y, Ohashi T,
Transplant
Sasahara Y, Suzuki Y, Tabuchi K.

2016

Kurita N, Gosho M, Yokoyama Y, Kato T,
Obara N, Sakata-Yanagimoto M,
A phase I/II trial of intrabone marrow cord
Hasegawa Y, Uchida N, Takahashi S,
blood transplantation and comparison ofBone Marrow
22
Kouzai Y, Atsuta Y, Kurata M, Ichinohe T,2017
the hematological recovery with theTransplant
Chiba S.
Japanese nationwide database.

49(3):355
-60.

U20

20(2):203
-14.

U21

52(4):574-9.

U22Comparison of Conditioning with
Fludarabine/Busulfan and
23 Fludarabine/Melphalan in Allogeneic
Transplantation Recipients 50 Years or
Older.

Kawamura K, Kako S, Mizuta S, Ishiyama
K, Aoki J, Yano S, Fukuda T, Uchida N, Biol Blood
Ozawa Y, Eto T, Iwato K, Kanamori H,
Marrow
Kahata K, Kondo T, Sawa M, Ichinohe T, Transplant
Atsuta Y, Kanda Y.

201723(12):20
79-87.

U23

Impact of a Low CD34+ Cell Dose on
24 Allogeneic Peripheral Blood Stem Cell
Transplantation.

Yamamoto C, Ogawa H, Fukuda T,
Biol Blood
Igarashi A, Okumura H, Uchida N, Hidaka
Marrow
M, Nakamae H, Matsuoka KI, Eto T,
Transplant
Ichinohe T, Atsuta Y, Kanda Y.

201824(4):708
-16.

U24

Impact of HIV Infection on Transplant
Yoshinaga N, Kanda J, Aisa Y, Hagiwara
Outcomes after Autologous Peripheral
S, Mori T, Fukuda T, Ishida Y, Hashimoto Biol Blood
25 Blood Stem Cell Transplantation: A
H, Iwato K, Kanda Y, Kurokawa M,
Marrow
Retrospective Study of Japanese Registry Nakazawa H, Ota S, Uchida N, Ichinohe Transplant
Data.
T, Atsuta Y, Takaori-Kondo A.

201824(8):159
6-601.

U25

Yoshizato T, Dumitriu B, Hosokawa K,
Makishima H, Yoshida K, Townsley D,
Sato-Otsubo A, Sato Y, Liu D, Suzuki H,
Wu CO, Shiraishi Y, Clemente MJ,
Kataoka K, Shiozawa Y, Okuno Y, Chiba N Engl J Med 2015
K, Tanaka H, Nagata Y, Katagiri T, Kon A,
Sanada M, Scheinberg P, Miyano S,
Maciejewski JP, Nakao S, Young NS,
Ogawa S.

373(1):35
-47.

U26

2018

24(10):21
39-44.

U27

Bone Marrow
2018
Transplant53(4):478
-82.

U28

26

Somatic Mutations and Clonal
Hematopoiesis in Aplastic Anemia.

Kako S, Fujiwara S, Sato M, Kimura SI,
Safety and Efficacy of Once-Daily
Nakasone H, Ohashi K, Kawakita T,
Biol Blood
27 Intravenous Busulfan in Allogeneic
Maeda T, Morishita T, Suzuki R, Fukuda Marrow
Transplantation: A Matched-Pair Analysis. T, Ichinohe T, Kurata M, Atsuta Y, Kanda TransplantY.
Impact of pretransplant leukemic blast% in
Ogawa H, Ikegame K, Daimon T, Uchidabone marrow and peripheral blood on
N, Fukuda T, Kakihana K, Eto T, Ozawa
transplantation outcomes of patients with
28
Y, Kanamori H, Hidaka M, Iwato Y,
acute myeloid leukemia undergoing
Ichinohe T, Takanashi M, Atsuta Y,
allogeneic stem cell transplantation in
Kanda Y.
non-CR.

Kawajiri-Manako C, Sakaida E, Ohwada
C, Miyamoto T, Azuma T, Taguchi J, Mori
Biol Blood
T, Hasegawa Y, Kondo T, Yujiri T,
Marrow
Yoshimitsu M, Imada K, Kurahashi S,
Transplant
Kahata K, Ichinohe T, Hirokawa M, Atsuta
Y, Nakaseko C.

201824(6):118
0-6.

U29

折原勝己, 吾郷浩厚, 奥山美樹, 落合亮
日本造血細日本骨髄バンクドナーの2回骨髄提供に関 一, 澤 正史, 田野﨑隆二, 玉井佳子, 豊
30
胞移植学会
する検討.
嶋崇徳, 中尾康夫, 日野雅之, 宮﨑泰司,
雑誌
神田善伸, 金森平和.

2017

6(2):10814.

U30

Successful preemptive donor lymphocyte
Hirai M, Yagasaki H, Fujimura J, Inoue M,
infusions from a haploidentical donor in a
Leuk
Shimozawa K, Okuma H, Chin M,
boy with E2A-HLF-positive ALL.
Lymphoma
Takahashi S.

201859(3):746-8.

U31Prophylaxis and treatment withmycophenolate mofetil in children withgraft-versus-host disease undergoing32
allogeneic hematopoietic stem celltransplantation: a nationwide survey inJapan.

Kawashima N, Iida M, Suzuki R, Fukuda
T, Atsuta Y, Hashii Y, Inoue M, Kobayashi
Int J Hematol 2019
M, Yabe H, Okada K, Adachi S, Yuza Y,
Kawa K, Kato K.

109(4):49
1-8.

U32

High probability of follow-up termination
33 among AYA survivors after allogeneic
hematopoietic cell transplantation.

Miyamura K, Yamashita T, Atsuta Y,
Ichinohe T, Kato K, Uchida N, Fukuda T,
Ohashi K, Ogawa H, Eto T, Inoue M,
Takahashi S, Mori T, Kanamori H, Yabe
H, Hama A, Okamoto S, Inamoto Y.

2019

3(3):397405.

U33

A consideration for efficient unrelated
34 hematopoietic stem cell source
acquisition-from an experience of Japan.

Nishiwaki S, Miyamura K, Kanda Y,
Takanashi M, Uchida N, Fukuda T,
Ikegame K, Ohashi K, Eto T, Ozawa Y,
Bone Marrow
2020
Shiratori S, Iwato K, Matsuoka KI, Hidaka TransplantM, Ichinohe T, Atsuta Y, Kodera Y,
Okamoto S.

55(3):657
-60.

U34

Retrospective analysis of children with
Hyakuna N, Hashii Y, Ishida H, Umeda K,
high-risk acute myeloid leukemia who
Takahashi Y, Nagasawa M, Yabe H,
underwent allogeneic hematopoietic stem Nakazawa Y, Koh K, Goto H, Fujisaki H, Pediatr Blood35
2019
cell transplantation following complete
Matsumoto K, Kakuda H, Yano M, Tawa Cancer
remission with initial induction
A, Tomizawa D, Taga T, Adachi S, Kato
chemotherapy in the AML-05 clinical trial. K.

66(10):e2
7875.

U35

Kudo K, Maeda M, Suzuki N, Kanegane H,
Ohga S, Ishii E, Shioda Y, Imamura T,
Nationwide retrospective review of
Imashuku S, Tsunematsu Y, Endo M,
hematopoietic stem cell transplantation in Shimada A, Koga Y, Hashii Y, Noguchi M,
36
Int J Hematol 2020children with refractory Langerhans cell
Inoue M, Tabuchi K, Morimoto A;
histiocytosis.
Histiocytosis study group of theJapanese Society of PediatricHematology/Oncology.

111(1):13
7-48.

U36

A high CD34+ cell dose is associated with
Yokoyama Y, Maie K, Fukuda T, Uchida
better disease-free survival in patients
N, Mukae J, Sawa M, Kubo K, Kurokawa
37 with low-risk diseases undergoing
M, Nakamae H, Ichinohe T, Atsuta Y,
peripheral blood stem cell transplantation
Chiba S.
from HLA-matched related donors.

55(9):172
6-35.

U37

12(2):E42
4.

U38

Efficacy and Long-Term Outcomes ofAutologous Stem Cell Transplantation in
29
POEMS Syndrome: A Nationwide Survey
in Japan.

31

Blood
Advances

Bone Marrow
2020
Transplant

Horio T, Morishita E, Mizuno S, Uchino K,
Donor Heme Oxygenase-1 Promoter Gene
Hanamura I, Espinoza JL, Morishima Y,
Polymorphism Predicts Survival after
38
Kodera Y, Onizuka M, Kashiwase K,
Cancers
Unrelated Bone Marrow Transplantation
Fukuda T, Doki N, Miyamura K, Mori T,
for High-Risk Patients.
Nakao S, Takami A.

2020

Could the minimum number of
Yabe H, Tabuchi K, Uchida N, Takahashi
haematopoietic stem cells to obtain
S, Onishi Y, Aotsuka N, Sugio Y, Ikegame Br J
39
engraftment exist in unrelated, single cord K, Ichinohe T, Takahashi M, Kato K,
Haematolblood transplantation?
Atsuta Y, Kanda Y.

2020

189(2):e5
6-60.

U39

Kaito S, Nakajima Y, Hara K, Toya T,
Heterogeneous impact of cytomegalovirus Nishida T, Uchida N, Mukae J, Fukuda T,
Blood
40 reactivation on nonrelapse mortality inOzawa Y, Tanaka M, Ikegame K,
Advances
hematopoietic stem cell transplantation. Katayama Y, Kuriyama T, Kanda J,
Atsuta Y, Ogata M, Taguchi A, Ohashi K.

2020

4(6):1051
-61.

U40

Kuwatsuka Y,Atsuta Y,
Hirakawa A,Uchida N, Inamoto Y, Najima
Y, Ikegame K,Eto T , Ozawa Y,Ichinohe T, Int J Hematol 2020
Inoue M,Kimura T, Okamoto S, Miyamura
K, Fukuda T.

112(6):84
1-50.

U41

2020

59(16):19
47-56.

U42

Yanada M, Uchida N, Ichinohe T, Fukuda
Bone Marrow
T, Kanda J, Kanda Y,Atsuta Y, Nakasone
2021
TransplantH.

56(7):172
0-22.

U43

185(1):16
6-69.

U44

56(7):169
1-99.

U45

2021

6(22):e15
3551.

U46

Bone Marrow
2021
Transplant56(11):27
71-78.

U47

Use of unapproved or off‑label drugs inJapan for the treatment of graft‑versus‑
41
host disease and post‑transplant viral
infection.

Murata M, Suzuki R,Nishida T, Shirane
Allogeneic Hematopoietic Stem Cell
S,Shimazu Y,Minami Y, Mori T, Doki N,
Transplantation for Post-essential
42
Kanda Y, Uchida N, Tanaka M, Ishikawa Intern Med
Thrombocythemia and Post-polycythemia
J, Togitani K,Fukuda T, Ichinohe T,Atsuta
Vera Myelofibrosis.
Y, Nagamura -Inoue T,Kiyoi H.

Does one model fit all? Predicting non43 relapse mortality after allogeneic
hematopoietic cell transplantation.

Nakasone H,Tabuchi K,Uchida N,Ohno
Which is more important for the selection
Y,Matsuhashi Y, Takahashi S, Onishi Y,of cord blood units for haematopoietic cell
Br J
44Onizuka M, Kobayashi H, Fukuda T,transplantation: the number of CD34Haematol
Ichinohe T, Takanashi M, Kato K, Atsuta
positive cells or total nucleated cells?
Y, Yabe H, Kanda Y.

2019

Adding melphalan to fludarabine and amyeloablative dose of
Shimomura Y, Hara M, Yamamoto H,
busulfan improved survival after allogeneic Uchida N, Kawakita T, Ashida T, Takada
Bone Marrow
45 hematopoietic stem cellT, Ikeda T, Morishige S, Maruyama Y,
Transplanttransplantation in a propensity scoreWake A, Ichinohe T, Fukuda T, Takanashi
matched cohort ofM, Atsuta Y, Ishikawa T.
hematological malignancies.
Inoue T,Koyama M, Kaida K,Ikegame K,
Kathleen S Ensbey,Luke Samson,
Takahashi S, Ping Zhang, Simone A
Peritransplant glucocorticoids redistribute
Minnie, Maruyama S, Ishii S,Daimon T,
46 donor T cells to the bone marrow andFukuda T,Nakamae H, Ara T,Maruyama
prevent relapse after haploidentical SCT.
Y, Ishiyama K, Ichinohe T,Atsuta Y,
Bruce R Blazar, Scott N Furlan, Ogawa
H,Geoffrey R Hill.

47

Cord blood index predicts engraftment
and early non-relapse mortality in adultpatients with single-unit cord bloodtransplantation.

Kondo G,Ishimaru F, Konuma T,
Takahashi S, Atsuta Y,Ogawa A,
Minemoto M, Kashiwase K, Azuma F,Ito
M, Isoyama K,Kobayashi T, Ohashi
K,Nakajima F, Hiruma K, Makino S,
Mugishima H,Namba N,Tsuno H,Nagai
T,Muroi K, Nakajima K and on behalf of
the Japanese Red Cross KantoKoshinetsu Cord Blood Bank.

JCI inSIGHT

Essential Roles of the Transcription
Factor NR4A1 in Regulatory T Cell
48
Differentiation under the Influence of
Immunosuppressants.

Sekiya T, Kasahara H, Takemura R, Fujita
S, Kato J, Doki N, Katayama Y, Ozawa Y,
Takada S, Eto T, Fukuda T, Ichinohe T, Journal of
Takanashi M, Onizuka M, Atsuta Y,
Immunology
Okamoto S, Yoshimura A, Takaki S, MoriT.

Donor UNC-93 Homolog B1 genetic
polymorphism predicts survival outcomes
49
after unrelated bone marrowtransplantation.

Uchino K, Vu Quang L, Mizuno S, HorioT, Yamamoto H, Hanamura I, Kodera Y,
Luis Espinoza J, Onizuka M, Kashiwase
K, Morishima Y, Fukuda T, Doki N,
Miyamura K, Mori T, Morishita E, Nakao
S, Takami A.

2022

208(9):21
22-30.

U48

Genes Immun 2021

22(1):3543.

U49

2022

28(10):67
7.e1677.e6.

U50

Effect of Cryopreservation in Unrelated
Kanda Y,Doki N,Kojima M,Kako S,Inoue
Bone Marrow and Peripheral Blood Stem M,Uchida N,Onishi Y7, Kamata R,Kotaki
Transplant
50 Cell Transplantation in the Era of theM, Kobayashi R,Tanaka J, Fukuda T, Fujii
Cell Ther
COVID-19 Pandemic: An Update from the N, Miyamura K,Mori S, Mori Y, Morishima
Japan Marrow Donor Program.
Y, Yabe Y, Atsuta Y, Kodera Y.

Registry data analysis of hematopoietic
stem cell transplantation on systemic
51
chronic active Epstein-Barr virus
infection patients in Japan.

Yamamoto M, Sato M, Onishi Y,
Sasahara Y, Sano H, Masuko M, Nakamae
H, Matsuoka K, Ara T, Washio K,
Am J
Onizuka M, Watanabe K, Takahashi Y,
Hematol
Hirakawa T, Nishio M, Sakashita C,
Kobayashi T, Sawada A, Ichinohe T,
Fukuda T, Hashii Y, Atsuta Y,Arai A.

2022

1;97(6):7
80-790.

U51

Comparable survival outcomes with
haploidentical stem cell
52
transplantation and unrelated bonemarrow transplantation.

Atsuta Y, Sugita J, Nakamae H,
Maruyama Y, Ishiyama K, Shiratori S,
Fukuda T, Kurata M, Shingai N,Ozawa Y, Bone Marrow
2022
Masuko M, Nagafuji K, Takada S, Kako S, Transplant
Kanda Y, Kanda J, Ichinohe T, TeshimaT.

57(12):17
81-1787.

U52

Comparable survival outcomes with53 haploidentical stem cell transplantationand cord blood transplantation.

Sugita J, Atsuta Y, Nakamae H,
Maruyama Y, Ishiyama K, Shiratori S,
Fukuda T, Kurata M, Shingai N, Ozawa Y, Bone Marrow
2022
Masuko M, Nagafuji K, Uchida N,
Transplant
Tanaka M, Onizuka M, Kanda J, Kimura
T, Ichinohe T,Teshima T.

57(11):16
81-1688.

U53

Morishima Y, Morishima S, Phil
Stevenson, Kodera Y,
Mary Horowitz, Caroline McKallor, Mari
Malkki, Stephen R. Spellman, Ted Gooley, Transplant
EffieW. Petersdorf,on-behalf-of-theCell Ther
International HistocompatibilityWorking-Group-in-Hematopoietic-CellTransplantation .

28(7):357.e1357.e6.

U54

54

Race and Survival in Unrelated
Hematopoietic Cell Transplantation.

Reduced intensity conditioning in
55 allogeneic stem cell transplantation for
AML with Down syndrome.

2022

Muramatsu H, Sakaguchi H, Taga T,
Tabuchi K, Adachi S, Inoue M, Kitoh T,
Suminoe A, Yabe H, Azuma E, Shioda Y, Pediatr Blood
2014
Ogawa A, Kinoshita A, Kigasawa H, Osugi Cancer
Y, Koike K, Kawa K, Kato K, Atsuta Y,
Kudo K.

61(5):925 WGP-7.
1-1

Comparison of a fludarabine andmelphalan combination-based reduced
toxicity conditioning with myeloablative
56
conditioning by radiation and/or busulfan
in acute myeloid leukemia in Japanesechildren and adolescents.

Ishida H, Adachi S, Hasegawa D,
Okamoto Y, Goto H, Inagaki J, Inoue M,
Koh K, Yabe H, Kawa K, Kato K, Atsuta
Y, Kudo K.

Comparison of Outcomes for PediatricPatients With Acute Myeloid Leukemia in
Remission and Undergoing Allogeneic
Ishida H, Kato M, Kudo K, Taga T,
Hematopoietic Cell Transplantation With Tomizawa D, Miyamura T, Goto H,
57 Myeloablative Conditioning Regimens
Inagaki J, Koh K, Terui K, Ogawa A,
Based on Either Intravenous Busulfan or Kawano Y, Inoue M, Sawada A, Kato K,
Total Body Irradiation: A Report From the Atsuta Y, Yamashita T, Adachi S.
Japanese Society for Hematopoietic Cell
Transplantation.
Role of Second Transplantation for
58 Children With Acute Myeloid Leukemia
Following Posttransplantation Relapse.
Allogeneic Hematopoietic Stem Cell
Transplantation for Adolescents and59
Young Adults with Acute Myeloid
Leukemia.

Taga T, Murakami Y, Tabuchi K, Adachi
S, Tomizawa D, Kojima Y, Kato K, Koike
K, Koh K, Kajiwara R, Hamamoto K, Yabe
H, Kawa K, Atsuta Y, Kudo K.
Tomizawa D, Tanaka S, Kondo T, Hashii
Y, Arai Y, Kudo K, Taga T, Fukuda T,
Goto H, Inagaki J, Koh K, Ohashi K,
Ozawa Y, Inoue M, Kato K,Tanaka J,
Atsuta Y, Adachi S, Ishida H.

Pediatr Blood
2015
Cancer62(5):883 WGP-9.
1-2

Biol Blood
Marrow
Transplant2015

21(12):21 WGP
41-7.
1-3

Pediatr Blood
2016
Cancer63(4):701 WGP-5.
1-4

Biol Blood
Marrow
Transplant2017

23(9):151 WGP
5-22.
1-5

Allogeneic hematopoietic stem celltransplantation for children and
60 adolescents with high-risk cytogenetic
AML: distinctly poor outcomes of FUSERG-positive cases.

Tomizawa D, Yoshida M, Kondo T,
Miyamura T, Taga T, Adachi S, Koh K,
Noguchi M, Kakuda H, Watanabe K, Cho
Y, Fukuda T, Kato M, Shiba N, Goto H,
Okada K, Inoue M, Hashii Y, Atsuta Y,
Ishida H.

Bone Marrow
2019
Transplant54(3):393 WGP
-401.
1-6

Comparison of conditioning regimens forautologous stem cell transplantation in61
children with acute myeloid leukemia: A
nationwide retrospective study in Japan.

Sakaguchi H, Muramatsu H, Hasegawa D,
Kudo K, Ishida H, Yoshida N, Koh K,
Noguchi M, Shiba N, Tokimasa S, Fukuda
T, Goto H, Miyamura T, Nakazawa Y,
Pediatr Blood
2019
Hashii Y, Inoue M, Atsuta Y; PediatricCancer
AML Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

66(1):e27 WGP
459.
1-7

Hematopoietic stem-cell transplantation
62 in children with refractory acute myeloid
leukemia.

Okamoto Y, Kudo K, Tabuchi K,
Tomizawa D, Taga T, Goto H, Yabe H,
Nakazawa Y, Koh K, Ikegame K, YoshidaN, Uchida N, Watanabe K, Koga Y, Inoue
M, Kato K, Atsuta Y, Ishida H.

54(9):148 WGP
9-98.
1-8

Hematopoietic stem cell transplantation
for pediatric acute myeloid leukemia
63 patients with KMT2A rearrangement; A
nationwide retrospective analysis inJapan.

Miyamura T, Kudo K, Tabuchi K, Ishida H,
Tomizawa D, Adachi S, Goto H, Yoshida
N, Inoue M, Koh K, Sasahara Y, Fujita N, Leuk Res
Kakuda H, Noguchi M, Hiwatari M, Hashii
Y, Kato K, Atsuta Y, Okamoto Y.

Yamamoto S, Tomizawa D, Kudo K,
Hematopoietic stem cell transplantation
Hasegawa D, Taga T, Yanada M, Kondo
64 for pediatric acute promyelocytic leukemia
T, Nakazawa Y, Eto T, Inoue M, Kato K,
in Japan.
Atsuta Y, Ishida H.

Bone Marrow
2019
Transplant2019

87:10626
3.

WGP
1-9

Pediatr Blood
2020
Cancer67(5):e28 WGP
181.
1-10

Effect of extramedullary disease on
Sakaguchi H, Miyamura T, Tomizawa D,
allogeneic hematopoietic cell
Taga T, Ishida H, Okamoto Y, Koh K,
Bone Marrow
65 transplantation for pediatric acute myeloid Yokosuka T, Yoshida N, Sato M, Noguchi
2021
Transplantleukemia: a nationwide retrospective
M, Okada K, Hori T, Takeuchi M, Kosaka
study.
Y, Inoue M, Hashii Y, Atsuta Y.

56(8):185 WGP
9-65.
1-11

Haematopoietic cell transplantation for
66 children with acute megakaryoblastic
leukaemia without Down syndrome.

Hama A, Taga T, Tomizawa D,
Muramatsu H, Hasegawa D, Adachi S,
Yoshida N, Noguchi M, Sato M, Okada K, Br J
Koh K, Mitsui T, Takahashi Y, Miyamura Haematol
T, Hashii Y, Kato K, Atsuta Y, OkamotoY.

in press

WGP
1-12

Donor lymphocyte infusion for thetreatment of relapsed acute myeloid
leukemia after allogeneic hematopoietic
stem cell transplantation: a retrospective
67
analysis by the Adult Acute Myeloid
Leukemia Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.
Outcome of allogeneic hematopoietic
stem cell transplantation for acute68
myeloid leukemia patients with central
nervous system involvement.

Efficiency of high-dose cytarabine added
69 to CY/TBI in cord blood transplantation
for myeloid malignancy.

Takami A, Yano S, Yokoyama H,
Kuwatsuka Y, Yamaguchi T, Kanda Y,
Morishima Y, Fukuda T, Miyazaki Y,
Nakamae H, Tanaka J, Atsuta Y,
Kanamori H.

Biol Blood
Marrow
Transplant

Aoki J, Ishiyama K, Taniguchi S, Fukuda
Biol Blood
T, Ohashi K, Ogawa H, Kanamori H, Eto
Marrow
T, Iwato K, Sakamaki H, Morishima Y,
Transplant
Nagamura T, Atsuta Y, Takami A.
Arai Y, Takeda J, Aoki K, Kondo T,
Takahashi S, Onishi Y, Ozawa Y, Aotsuka
N, Kouzai Y, Nakamae H, Ota S,
Nakaseko C, Yamaguchi H, Kato K,
Blood
Atsuta Y, Takami A ; AML and MDSWorking Group of the Japan Society for
Hematopoietic Cell Transplantation.

2014

20(11):17 WGP
85-90.
2-1

2014

20(12):20 WGP
29-33.
2-2

2015

126(3):41 WGP
5-22.
2-3

Clinical significance of high-dose
cytarabine added tocyclophosphamide/total-body irradiation
70
in bone marrow or peripheral blood stem
cell transplantation for myeloid
malignancy.

Arai Y, Aoki K, Takeda J, Kondo T, Eto T,
Ota S, Hashimoto H, Fukuda T, Ozawa Y,
Kanda Y, Kato C, Kurokawa M, Iwato K,
J Hematol
Onizuka M, Ichinohe T, Atsuta Y, Takami
Oncol
A ; AML and MDS Working Group ofJapan Society for Hematopoietic Cell
Transplantation.

2015

8:102.

Impact of age on outcomes of allogeneic
hematopoietic stem cell transplantation
71 with reduced intensity conditioning inelderly patients with acute myeloid
leukemia.

Aoki J, Kanamori H, Tanaka M, Yamasaki
S, Fukuda T, Ogawa H, Iwato K, Ohashi
Am JK, Okumura H, Onizuka M, Maesako Y,
Hematol
Teshima T, Kobayashi N, Morishima Y,
Hirokawa M, Atsuta Y, Yano S, Takami A.

2016

91(3):302 WGP
-7.
2-5

2016

51(4):604 WGP
-6.
2-6

2016

51(5):645 WGP
-53.
2-7

2016

95(2):295 WGP
-300.
2-8

2016

47:47-53.

2017

96(2):289 WGP
-97.
2-10

2017

52(6):818 WGP
-24.
2-11

72

73

74

75

76

77

Impact of low-dose TBI on outcomes of
reduced intensity conditioning allogeneic
hematopoietic stem cell transplantation
for AML.

Aoki J, Seo S, Kanamori H, Tanaka M,
Fukuda T, Onizuka M, Kobayashi N,
Bone Marrow
Kondo T, Sawa M, Uchida N, Iwato K,
Transplant
Icihnohe T, Atsuta Y, Yano S, Takami A.
Mizutani M, Hara M, Fujita H, Aoki J,
Comparable outcomes between
Kanamori H, Ohashi K, Usuki K, Fukuda Bone Marrowautologous and allogeneic transplant for
T, Chou T, Tanaka J, Atsuta Y, Takami Transplant
adult acute myeloid leukemia in first CR.
A.
Mori J, Ishiyama K, Yamaguchi T, Tanaka
Outcomes of allogeneic hematopoietic cell J, Uchida N, Kobayashi T, Fukuda T,transplantation in patients withKanamori H, Miyamura K, Takahashi S,
Ann Hematolbiphenotypic acute leukemia.
Eto T, Hirokawa M, Mori S, Nagamura T,
Atsuta Y, Takami A.
Ishiyama K, Yamaguchi T, Eto T, Ohashi
Acute megakaryoblastic leukemia, unlike
K, Uchida N, Kanamori H, Fukuda T,
acute erythroid leukemia, predicts an
Miyamura K, Inoue Y, Taguchi J, Mori T, Leuk Res
unfavorable outcome after allogeneic
Iwato K, Morishima Y, Nagamura-Inoue T,
HSCT.
Atsuta Y, Sakamaki H, Takami A.
Yamasaki S, Hirakawa A, Aoki J, Uchida
Role of reduced-intensity conditioning
N, Fukuda T, Ogawa H, Ohashi K, Kondo
allogeneic hematopoietic cellT, Eto T, Kanamori H, Okumura H, Iwato
Ann Hematoltransplantation in older patients with deK, Ichinohe T, Kanda J, Onizuka M,
novo acute myeloid leukemia.
Kuwatsuka Y, Yanada M, Atsuta Y,
Takami A, Yano S.
Yanada M, Kurosawa S, Kobayashi T,
Reduced-intensity conditioning allogeneic
Ozawa Y, Kanamori H, Kobayashi N,
hematopoietic cell transplantation forBone Marrow
Sawa M, Nakamae H, Uchida N,
younger patients with acute myeloid
Transplant
Hashimoto H, Fukuda T, Hirokawa M,
leukemia: a registry-based study.
Atsuta Y, Yano S.

WGP
2-4

WGP
2-9

Allogeneic Hematopoietic Cell
Transplantation for Leukemic
Transformation Preceded by Philadelphia
Chromosome-Negative Myeloproliferative78
Neoplasms: A Nationwide Survey by the
Adult Acute Myeloid Leukemia Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

Takagi S, Masuoka K, Uchida N,
Biol Blood
Kurokawa M, Nakamae H, Imada K, Iwato
Marrow
K, Ichinohe T, Atsuta Y, Takami A, Yano
Transplant
S.

2016

22(12):22 WGP
08-13.
2-12

Konuma T, Kondo T, Yamashita T, UchidaN, Fukuda T, Ozawa Y, Ohashi K, Ogawa
Outcome of allogeneic hematopoietic
H, Kato C, Takahashi S, Kanamori H, Eto
stem cell transplantation in adult patients T, Nakaseko C, Kohno A, Ichinohe T,
79
Ann Hematol 2017with acute myeloid leukemia harboring
Atsuta Y, Takami A, Yano S; Adult Acutetrisomy 8.
Myeloid Leukemia Working Group of theJapan Society for Hematopoietic Cell
Transplantation (JSHCT).

96(3):469 WGP
-78.
2-13

Autologous hematopoietic celltransplantation for acute promyelocytic
80 leukemia in second complete remission:outcomes before and after the
introduction of arsenic trioxide.
Outcomes of Allogeneic Hematopoietic
Cell Transplantation in Acute Myeloid
Leukemia Patients with Abnormalities of
the Short Arm of Chromosome 17.
Effect of cytogenetic risk status on
outcomes for patients with acute myeloid
leukemia undergoing various types of82
allogeneic hematopoietic celltransplantation: an analysis of 7812
patients.
81

Yanada M, Yano S, Kanamori H, Gotoh M,
Emi N, Watakabe K, Kurokawa M,
Nishikawa A, Mori T, Tomita N, Murata M, Leuk
Hashimoto H, Henzan H, Kanda Y, Sawa Lymphoma
M, Kohno A, Atsuta Y, Ichinohe T,
Takami A.
Mori J, Yanada M, Uchida N, Fukuda T,
Biol Blood
Sakura T, Hidaka M, Watakabe-Inamoto
Marrow
K, Kanamori H, Ogawa H, Ichinohe T,
Transplant
Tanaka J, Atsuta Y, Yano S.

201758(5):106 WGP
1-7.
2-14

2017

23(8):139 WGP
8-404.
2-15

2018

59(3):601 WGP
-9.
2-16

Haematologic
2018a103(2):e6 WGP
9-72.
2-17

Yanada M, Mori J, Aoki J, Harada K,
Mizuno S, Uchida N, Kurosawa S, Toya T,
Leuk
Kanamori H, Ozawa Y, Ogawa H, Henzan
Lymphoma
H, Iwato K, Sakura T, Ota S, Fukuda T,
Ichinohe T, Atsuta Y, Yano S.

Outcomes after allogeneic hematopoietic
stem cell transplantation in patients with
83
acute myeloid leukemia harboringt(7;11)(p15;p15).

Harada K, Doki N, Aoki J, Mori J,
Machida S, Masuko M, Uchida N, Najima
Y, Fukuda T, Kanamori H, Ogawa H, Ota
S, Ogawa K, Takahashi S, Kasai M,
Maeda A, Nagafuji K, Kawakita T,
Ichinohe T, Atsuta Y.

Comparison of Autologous and Unrelated
84 Transplants for Cytogenetically Normal
Acute Myelogenous Leukemia.

Mizutani M, Takami A, Hara M, Mizuno S,
Yanada M, Chou T, Uchiyama H, Ohashi
Biol Blood
K, Miyamoto T, Ozawa Y, Imataki O,
Marrow
Kobayashi N, Uchida N, Kanamori H,
Transplant
Kamimura T, Eto T, Onizuka M, Tanaka J,
Atsuta Y, Yano S.

201723(9):144 WGP
7-54.
2-18

Allogeneic haematopoietic celltransplantation for adult acute myeloid
leukaemia in second remission: a
85 retrospective study of the Adult Acute
Myeloid Leukaemia Working Group of theJapan Society for Haematopoietic Cell
Transplantation (JSHCT).

Konuma T, Yanada M, Yamasaki S,
Kuwatsuka Y, Fukuda T, Kobayashi T,
Ozawa Y, Uchida N, Ota S, Hoshino T,
Br J
Takahashi S, Kanda Y, Ueda Y, Takanashi Haematol
M, Kanda J, Ichinohe T, Atsuta Y, Yano
S.

2018

182(2):24 WGP
5-50.
2-19

Konuma T, Mizuno S, Kondo T,
Yamaguchi H, Fukuda T, Uchida N,
Najima Y, Kanamori H, Ota S, Nakamae
H, Nakamae M, Mizuno I, Sugita J, Onishi
Y, Yokota A, Takahashi S, Kanda Y,
Ann Hematol 2018
Ichinohe T, Atsuta Y, Yano S; Adult
Acute Myeloid Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation (JSHCT).

97(11):21 WGP
73-83.
2-20

Yanada M,Masuko M,Mori J,Aoki
J,Mizuno S,Fukuda T,Kakihana K,Ozawa
Y,ota S,Kannamori H,Mori T,Nakamae
H,Eto T,Shiratori S,Maeda T,Iwato
K,Ichinohe T,Kanda Y,Tanaka J,Atsuta
Y,Yano S.

54(4):578 WGP
-86.
2-21

Allogeneic hematopoietic celltransplantation in adult acute myeloid
leukemia with 11q23 abnormality: aretrospective study of the Adult Acute86
Myeloid Leukemia Working Group of theJapan Society for Hematopoietic Cell
Transplantation (JSHCT).

Patients with acute myeloid leukemia
undergoing allogeneic hematopoietic cell87
transplantation: trends in survival during
the past two decades.

Bone Marrow
2019
TransplantPrognostic impact of melphalan dose andtotal body irradiation use in patients with
88 acute myeloid leukemia undergoing
allogeneic stem cell transplantation with
reduced-intensity conditioning.

Harada K, Yanada M, Machida S,
Kanamori H, Onizuka M, Ozawa Y,
Leuk
Kobayashi H, Sawa M, Katayama Y,
Lymphoma
Ohashi K, Kanda J, Ichinohe T, Atsuta Y,
Yano S.

201960(6):149 WGP
3-502.
2-22

Hematopoietic Cell Transplantation for
89 Acute Panmyelosis with Myelofibrosis: A
Retrospective Study in Japan.

Konuma T, Kondo T, Kawata T, Iwato K3,
Sato Y, Mori T, Ohashi K, Nakazawa H,
Sugahara H, Ago H, Eto T, Imamura Y,
Biol Blood
Fukuda T, Kanda Y, Atsuta Y, Yano S;
Marrow
Adult Acute Myeloid Leukemia Working TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.

2019

25(1):e23 WGP
-7.
2-23

2019

94(1):103 WGP
-10.
2-24

2019

8(2):509.

Konuma T, Harada K, Yamasaki S,
Mizuno S, Uchida N, Takahashi S,
Upfront allogeneic hematopoietic cell
Onizuka M, Nakamae H, Hidaka M,
transplantation (HCT) versus remission
Fukuda T, Ohashi K, Kohno A, Matsushita
induction chemotherapy followed by
Am J
90A, Kanamori H, Ashida T, Kanda J,
allogeneic HCT for acute myeloid leukemia
Hematol
Atsuta Y, Yano S; Adult Acute Myeloidwith multilineage dysplasia: A propensity
Leukemia Working Group of the Japanscore matched analysis.
Society for Hematopoietic Cell
Transplantation.
Effect of allogeneic stem cell
91 transplantation in patients with minimallydifferentiated acute myeloid leukemia.

Yamasaki S, Aoki J,Mori J, Harada K,
Sawa M, Uchida M, Ohashi K, Fukuda T, 日本造血細Koh S, Kanamori H, Ogawa H, Okumura 胞移植学会
H, Ichinohe T, Kanda Y, Tanaka J, Atsuta 雑誌
Y, Yanada M, Yano S.

WGP
2-25

Yanada M, Konuma T, Kuwatsuka Y,
Unit selection for umbilical cord blood
Kondo T, Kawata T, Takahashi S, Uchidatransplantation for adults with acute
Bone Marrow
92
N, Miyakoshi S, Tanaka M, Ozawa Y,
2019myeloid leukemia in complete remission: aTransplant
Sawa M, Nakamae H, Aotsuka N, Kanda ,Japanese experience.
Takanashi M, Kanda Y, Atsuta Y, Yano S.

54(11):17 WGP
89-98.
2-26

Risk stratification and prognosticators of
acute myeloid leukemia withmyelodysplasia-related changes patients
undergoing allogeneic stem cell
93
transplantation: a retrospective study of
the Adult Acute Myeloid Leukemia
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

2019

25(9):173 WGP
0-43.
2-27

Role of alternative donor allogeneic
Yano S, Yokoyama H, Yanada M, Mori J,
hematopoietic stem cell transplantation in Aoki J, Ohashi K, Kanomori H, Ozawa Y,
Bone Marrow
94 patients with intermediate- or poor-risk Sawa M, Nakamae H, Eto T, Ohta S,
2019
Transplant
acute myeloid leukemia in first complete Tanaka J, Ichinohe T, Atsuta Y, Takami
remission.
A.

54(12):20 WGP
04-12.
2-28

Yamasaki S, Aoki J, Mori J, Mizuno S,
Uchida N, Ohashi K, Fukuda T, Ikegame
K, Eto T, Ogawa Y, Tanaka M, Hidaka M,
Iwato K, Sawa M, Ichinohe T, Kanda Y,
Bone Marrow
2020
Atsuta Y, Yanada M, Yano S; Adult Acute Transplant
Myeloid Leukemia Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

55(1):249 WGP
-52.
2-29

Better disease control before allogeneic
stem cell transplantation is crucial to
95 improve the outcomes of transplantation
for acute myeloid leukemia patients withextramedullary disease.

Harada K, Konuma T, Machida S, Mori J,
Aoki J, Uchida N, Ohashi K, Fukuda T,
Biol Blood
Tanaka M, Ikegame K, Ozawa Y, Iwato K, Marrow
Eto T, Onizuka M, Ichinohe T, Atsuta Y, Transplant
Yano S.

Yanada M , Konuma T , Yamasaki S ,Time-Varying Effects of Graft Type on
Kuwatsuka Y , Masuko M , Tanaka M ,Biol Blood
Outcomes for Patients with Acute Myeloid Ozawa Y , Toya T , Fukuda T , Ota S ,96
Marrow
2020
Leukemia Undergoing Allogeneic
Sawa M , Uchida N , Nakamae H , Eto T ,Transplant
Hematopoietic Cell Transplantation.
Kanda J , Takanashi M , Kanda Y , Atsuta
Y , Yano S.
Yanada M, Mori J, Aoki J, Masuko M,
Allogeneic hematopoietic cell
Harada K, Uchida N, Doki N, Fukuda T,transplantation for patients with a history
97
Sakura T, Kanamori H, Sawa M, Kondo T, Ann Hematol 2019of multiple relapses of acute myeloid
Katayama Y, Kanda J, Ichinohe T, Atsuta
leukemia.
Y, Yano S.
Yanada M, Takami A, Mizuno S, Mori J,
Autologous hematopoietic cell
Chou T, Usuki K, Uchiyama H, Amano I,
98 transplantation for acute myeloid leukemia Fujii S, Miyamoto T, Saito T, Kamimura Int J Hematol 2020
in adults: 25 years of experience in Japan. T, Ichinohe T, Fukuda T, Okamoto S,
Atsuta Y, Yano S.

26(2):307 WGP
-15.
2-30

98(9):217 WGP
9-86.
2-31

111(1):93 WGP
-102.
2-32

Conditioning Intensity for Allogeneic
Hematopoietic Cell Transplantation in
99 Acute Myeloid Leukemia Patients with
Poor-Prognosis Cytogenetics in First
Complete Remission.

Konuma T, Kondo T, Mizuno S, Doki N,
Aoki J, Fukuda T, Tanaka M, Sawa M,
Katayama Y, Uchida N, Ozawa Y,
Biol Blood
Morishige S, Matsuoka KI, Ichinohe T,
Marrow
Onizuka M, Kanda J, Atsuta Y, Yanada M;
Transplant
Adult Acute Myeloid Leukemia Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

2020

26(3):463 WGP
-71.
2-33

Long-term results of reduced-intensity
conditioning allogeneic hematopoietic cell
100 transplantation for older patients withacute myeloid leukemia: a retrospective
analysis of 10-year follow-up data.

Yanada M, Fukuda T, Tanaka M, Ota S,
Toya T, Mori T, Uchida N, Ozawa Y,
Bone Marrow
2020
Nakamae H, Kanda Y, Ichinohe T, Atsuta Transplant
Y, Yano S.

55(10):20 WGP
08-16.
2-34

Yanada M, Takami A, Yamasaki S, Arai Y,
Konuma T, Uchida N, Najima Y, Fukuda T,
Tanaka M, Ozawa Y, Ikegame K,
Ann Hematol
Takanashi M, Ichinohe T, Okamoto S,
Atsuta Y, Yano S.
Mizuno S, Yanada M, Kawamura K,
Allogeneic hematopoietic cell
Masuko M, Uchida N, Ozawa Y, Iwato K,
transplantation efficacy in patients with
Bone Marrow
102
Ohashi K, Ikegame K, Kim SW, Tanaka M,
Philadelphia chromosome-positive acuteTransplant
Eto T, Kanda Y, Fukuda T, Atsuta Y,
myeloid leukemia in complete remission.
Yano S, Takami A.
Yanada M, Konuma T, Mizuno S, Saburi
Predicting non-relapse mortality following M, Shinohara A, Tanaka M, Marumo A,
allogeneic hematopoietic cell
Sawa M, Uchida N, Ozawa Y, Onizuka M, Bone Marrow
103transplantation during first remission of
Yoshioka S, Nakamae H, Kondo T, Kimura Transplant
acute myeloid leukemia.
T, Kanda J, Fukuda T, Atsuta Y,
Nakasone H, Yano S.
Yamasaki S, Mori J, Kanda J, Imahashi N,
Effect of allogeneic HCT from unrelated
Uchida N, Doki N, Tanaka M, Katayama Y,
donors in AML patients with intermediate104
Eto T, Ozawa Y, Takada S, Onizuka M,
Ann Hematolor poor-risk cytogenetics: a retrospective
Hino M, Kanda Y, Fukuda T, Atsuta Y,
study from the Japanese Society for HCT.
Yanada M.
Yanada M, Konuma T, Yamasaki S, Kondo
Relapse of acute myeloid leukemia after
T, Fukuda T, Shingai N, Sawa M, Ozawa
allogeneic hematopoietic cell
Bone Marrow
105
Y, Tanaka M, Uchida N, Nakamae H,
transplantation: clinical features andTransplant
Katayama Y, Matsuoka KI, Kimura T,
outcomes.
Kanda Y, Ichinohe T, Atsuta Y, Yano S.
Prognostic Impact of the Fractionation of Ueda N, Konuma T, Aoki J, Takahashi S,
Total Body Irradiation for Patients with
Ozawa Y, Mori T, Ota S, Eto T, Takada
Transplant
106 Acute Myeloid Leukemia Undergoing
S, Yoshioka S, Shiratori S, Kako S,
Cell Ther
Myeloablative Allogeneic Hematopoietic
Onizuka M, Fukuda T, Kanda Y, Atsuta Y,
Cell Transplantation.
Yanada M.
Konuma T, Kanda J, Yamasaki S, Harada
K, Shimomura Y, Terakura S, Mizuno S,
Single Cord Blood Transplantation Versus
Uchida N, Tanaka M, Doki N, Ozawa Y,
Unmanipulated Haploidentical
Transplant
107
Nakamae H, Sawa M, Matsuoka KI,
Transplantation for Adults with Acute
Cell Ther
Morishige S, Maruyama Y, Ikegame K,
Myeloid Leukemia in Complete Remission.
Kimura T, Kanda Y, Ichinohe T, Atsuta Y,
Yanada M.
Allogeneic hematopoietic celltransplantation for adults with acute101
myeloid leukemia conducted in Japan
during the past quarter century.

2020

99(6):135 WGP
1-60.
2-35

2021

56(1):232 WGP
-42.
2-36

2021

56(2):387 WGP
-94.
2-37

2020

99(12):29 WGP
27-37.
2-38

2021

56(5):112 WGP
6-33.
2-39

2021

27(2):185 WGP.e1-6.
2-40

2021

27(4):334 WGP.e1-11.
2-41

2021

27(4):314 WGP.e1-10.
2-42Isobe M, Konuma T, Masuko M, Uchida N,
Miyakoshi S, Sugio Y, Yoshida S, Tanaka
M, Matsuhashi Y, Hattori N, Onizuka M,
Aotsuka N, Kouzai Y, Wake A, Kimura T,
Ann Hematol 2021
Ichinohe T, Atsuta Y, Yanada M; Adult
Acute Myeloid Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

100(7):18 WGP
49-61.
2-43

Mizuno S, Takami A, Kawamura K, Arai Y,
Allogeneic Hematopoietic Cell
Kondo T, Kawata T, Uchida N, Marumo A,
Transplantation for Adolescent and Young Fukuda T, Tanaka M, Ozawa Y, Yoshida Transplant
108
Adult Patients with Acute Myeloid
S, Ota S, Takada S, Sawa M, Onizuka M, Cell Ther
Leukemia.
Kanda Y, Ichinohe T, Atsuta Y, Yanada
M.

109

Single cord blood transplantation for
acute myeloid leukemia patients aged 60
years or older: a retrospective study inJapan.

Reduced-intensity stem cellYamashita T, Takami A, Uchida N,
transplantation for acute myeloid leukemia Fukuda T, Eto T, Shiratori S, Ota S,
Bone Marrow110
2020with fludarabine-based conditioning with Akasaka T, Miyakoshi S, Kondo T, Hidaka Transplant
intravenous busulfan versus melphalan.
M, Kanda J, Atsuta Y, Yano S.

55(10):19 WGP
55-65.
2-44

Hirabayashi S, Uozumi R, Kondo T, Arai
Personalized prediction of overall survival Y, Kawata T, Uchida N, Marumo A,
111 in patients with AML in non-complete
Ikegame K, Fukuda T, Eto T, Tanaka M, Cancer Med
remission undergoing allo-HCT.
Wake A, Kanda J, Kimura T, Tabuchi K,
Ichinohe T, Atsuta Y, Yanada M, Yano S.

2021

10(13):42 WGP
50-68.
2-45

Yanada M, Mizuno S, Yamasaki S, Harada
K, Konuma T, Tamaki H, Shingai N,
Uchida N, Ozawa Y, Tanaka M, Onizuka
LeukM, Sawa M, Nakamae H, Shiratori S,
LymphomaMatsuoka KI, Eto T, Kawakita T,
Maruyama Y, Ichinohe T, Kanda Y, Atsuta
Y, Aoki J, Yano S.

2021

62(14):34 WGP
11-9.
2-46

Difference in outcomes following
allogeneic hematopoietic cell
112 transplantation for patients with acute
myeloid leukemia and myelodysplastic
syndromes.

Yanada M, Konuma T, Yamasaki S,
The differential effect of disease status at Mizuno S, Hirabayashi S, Nishiwaki S,
allogeneic hematopoietic cell
Uchida N, Doki N, Tanaka M, Ozawa Y,
113
Ann Hematol 2021
transplantation on outcomes in acute
Sawa M, Eto T, Kawakita T, Ota S,
myeloid and lymphoblastic leukemia.
Fukuda T, Onizuka M, Kimura T, Atsuta
Y, Kako S, Yano S.
Kurosawa S, Mizuno S, Arai Y, Masuko
Syngeneic hematopoietic stem cellM, Kanda J, Kohno K, Onai D, Fukuda T,transplantation for acute myeloid
Ozawa Y, Katayama Y, Tanaka M,
Blood Cancer
114
2021
leukemia: a propensity score-matched
Ikegame K, Uchida N, Eto T, Ota S,
Janalysis.
Tanaka J, Ichinohe T, Atsuta Y, Yanada
M.

100(12):3 WGP
017-27.
2-47

11(9):159 WGP.
2-48

Allogeneic Hematopoietic Cell
Transplantation from Alternative Donors
115
in Acute Myelogenous Leukemia: A
Comparative Analysis.

Yanada M, Konuma T, Yamasaki S,
Harada K, Iwasaki M, Kobayashi A,
Nishijima A, Tanaka M, Uchida N,
Transplant
Nakamae H, Fukuda T, Onizuka M, Ozawa
Cell Ther
Y, Sawa M, Katayama Y, Yoshioka S,
Kimura T, Ichinohe T, Atsuta Y, Kanda J,
Yano S.

2021

27(12):10 WGP
05.e1-8. 2-49

Autologous hematopoietic celltransplantation during second or
116 subsequent complete remission of acutepromyelocytic leukemia: a prognostic
factor analysis.

Yanada M, Ota S, Mukae J, Nara M, Kako
S, Nishikawa A, Uchida N, Sawa M,
Bone Marrow
2022
Nakano N, Onizuka M, Kanda Y, Ichinohe Transplant
T, Atsuta Y, Yano S.

57(1):78- WGP
82.
2-50

Donor lymphocyte infusion after
haploidentical hematopoietic stem cell
117
transplantation for acute myeloid
leukemia.

Harada K, Mizuno S, Yano S, Takami A,
Ishii H, Ikegame K, Najima Y, Kako S,
Ashida T, Shiratori S, Ota S, Onizuka M, Ann Hematol 2022
Fukushima K, Fukuda T, Ichinohe T,
Atsuta Y, Yanada M.

101(3):64 WGP
3-53.
2-51

Prognostic value of measurable residual
disease at allogeneic transplantation for
118
adults with core binding factor acute
myeloid leukemia in complete remission.

Konuma T, Kondo T, Masuko M, Shimizu
H, Shiratori S, Fukuda T, Kato J, Sawa
M, Ozawa Y, Ota S, Uchida N, Kanda Y,
Kako S, Fujisawa S, Fukushima K,
Bone Marrow
2021
Ichinohe T, Atsuta Y, Yanada M; Adult
Transplant
Acute Myeloid Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

56(11):27 WGP
79-87.
2-52

Comparison of fludarabine, amyeloablative dose of busulfan, andmelphalan vs conventional myeloablative
119
conditioning regimen in patients withrelapse and refractory acute myeloid
leukemia in non-remission status.

Shimomura Y, Hara M, Hirabayashi S,
Kondo T, Mizuno S, Uchida N, Mukae J,
Kawakita T, Fukuda T, Kanda Y, Ota S,
Bone Marrow
2021
Ozawa Y, Eto T, Maruyama Y, Tanaka M, Transplant
Nakano N, Kimura T, Ichinohe T, Atsuta
Y, Yanada M.

56(9):230 WGP
2-4.
2-53

Shimomura Y, Sobue T, Hirabayashi S,
Kondo T, Mizuno S, Kanda J, Fujino T,
Comparing cord blood transplantation and Kataoka K, Uchida N, Eto T, Miyakoshi S,
120 matched related donor transplantation in Tanaka M, Kawakita T, Yokoyama H, Doki Leukemia
non-remission acute myeloid leukemia.
N, Harada K, Wake A, Ota S, Takada S,
Takahashi S, Kimura T, Onizuka M,
Fukuda T, Atsuta Y, Yanada M.

2022

36(4):113 WGP
2-8
2-54

Mizuno S, Takami A, Kawamura K,
Shimomura Y, Arai Y, Konuma T, Ozawa
Y, Sawa M, Ota S, Takahashi S, Anzai N,
Hiramoto N, Onizuka M, Nakamae H,
Tanaka M, Murata M, Kimura T, Kanda J,
Fukuda T, Atsuta Y, Yanada M.
Yanada M, Matsuda K, Ishii H, Fukuda T,
Allogeneic Hematopoietic Cell
Ozeki K, Ota S, Tashiro H, Uchida N,
122 Transplantation for Patients with
Kako S, Doki N, Kawakita T, Onishi Y,
Relapsed Acute Promyelocytic Leukemia. Takada S, Kondo Y, Tanaka J, Kanda Y,
Atsuta Y, Yano S.
Yanada M, Yamasaki S, Konuma T,
Mizuno S, Uchida N, Onai D, Fukuda T,
Age and allogeneic hematopoietic cell
Tanaka M, Ozawa Y, Eto T, Ikegame K,
123 transplantation outcomes in acute myeloid
Sawa M, Katayama Y, Kawakita T,
leukemia.
Onizuka M, Kanda Y, Ichinohe T, Atsuta
Y, Yano S.
Mizumaki H, Ishiyama K, Aoki J, Mori J,
Outcomes after allogeneic hematopoietic Mizuno S, Doki N, Fukuda T, Uchida N,
124 stem cell transplantation in acute myeloid Onizuka M, Tanaka M, Katayama Y,
leukemia patients with der(1;7)(q10;p10). Ozawa Y,Ikegame K, Takada S, Kawakita
T, Aotsuka N, Atsuta Y, Yanada M.
Favorable Outcome with Conditioning
Regimen of Flu/Bu4/Mel in Acute
121 Myelogenous Leukemia Patients in
Remission Undergoing Cord Blood
Transplantation.

Improved trends in survival andengraftment after single cord blood
125
transplantation for adult acute myeloid
leukemia.

Transplant
Cell Therin press

WGP
2-55

Transplant
Cell Therin press

WGP
2-56

International
Journal of
Hematology

in press

WGP
2-57

eJHaemKonuma T, Mizuno S, Kondo T, Arai Y,
Uchida N, Takahashi S, Tanaka M,
Kuriyama T, Miyakoshi S, Onizuka M, Ota
S, Sugio Y, Kouzai Y, Kawakita T,
Blood Cancer
Kobayashi H, Ozawa Y, Kimura T,
2022
J
Ichinohe T, Atsuta Y, Yanada M; Adult
Acute Myeloid Leukemia Working Groupof the Japanese Society forTransplantation and Cellular Therapy.

Konuma T, Mizuno S, Harada K, Uchida
Reducing Mortality of Single-Unit
N, Takahashi S, Eto T, Ota S, Kobayashi
Unrelated Cord Blood Transplantation for H, Katayama Y, Mori Y, Maruyama Y,
Relapsed Acute Myeloid Leukemia after a Onizuka M, Yonezawa A, Kawakita T,
Transplant
126
Previous Allogeneic Transplantation: A
Kimura T, Kanda Y, Fukuda T, Atsuta Y, Cell Ther
Real-World Retrospective Study Over the Yanada M; Adult Acute Myeloid Leukemia
Past 19 Years in Japan.
Working Group of the Japanese Society
for Transplantation and Cellular Therapy.

Salvage single-unit unrelated cord bloodtransplantation for graft failure following
127 initial allogeneic transplantation in adultacute myeloid leukemia: trends inoutcomes over the past 20 years.

WGP
2-58

2022

12(5):81.

WGP
2-59

2022

28(11):77 WGP
7.e1-11. 2-60

Konuma T, Harada K, Kondo T, Masuko
M, Uchida N, Yano S, Kawakita T,
Onizuka M, Ota S, Sakaida E, Miyakoshi
S, Ozawa Y, Imamura Y, Kimura T, Kanda Bone Marrow
2022
Y, Fukuda T, Atsuta Y, Yanada M; Adult Transplant
Acute Myeloid Leukemia Working Groupof the Japanese Society forTransplantation and Cellular Therapy.

57(12):18 WGP
48-50.
2-61

Matsuda K, Konuma T, Fuse K, Masuko
Comparison of transplant outcomes
M, Kawamura K, Hirayama M, Uchida N,
between haploidentical transplantation and Ikegame K, Wake A, Eto T, Doki N,
Br J
128 single cord blood transplantation in non- Miyakoshi S, Tanaka M, Takahashi S,
Haematolremission acute myeloid leukaemia: A
Onizuka M, Kato K, Kimura T, Ichinohe T,
nationwide retrospective study.
Takayama N, Kobayashi H, Nakamae H,
Atsuta Y, Kanda J, Yanada M.
Kato M, Horikoshi Y, Okamoto Y,
Takahashi Y, Hasegawa D, Koh K, Takita
Second allogeneic hematopoietic SCT forBone Marrow
129
J, Inoue M, Kigasawa H, Ogawa A,
2012
relapsed ALL in children.
Transplant
Sasahara Y, Kawa K, Yabe H, Sakamaki
H, Suzuki R, Kato K.
Comparison of intravenous with oral
Kato M, Takahashi Y, Tomizawa D,
busulfan in allogeneic hematopoietic stem Okamoto Y, Inagaki J, Koh K, Ogawa A, Biol Blood
130 cell transplantation with myeloablative
Okada K, Cho Y, Takita J, Goto H,
Marrow2013
conditioning regimens for pediatric acute Sakamaki H, Yabe H, Kawa K, Suzuki R, Transplantleukemia.
Kudo K, Kato K.
Comparison of transplantation with
Kato K, Kato M, Hasegawa D, Kawasaki
reduced and myeloablative conditioning
H, Ishida H, Okamoto Y, Koh K, Inoue M,
131
Blood
2015
for children with acute lymphoblastic
Inagaki J, Kato K, Sakamaki H, Yabe H,
leukemia.
Kawa K, Suzuki R, Atsuta Y.

in pressWG
2-62

47(10):13 WGP
07-11.
3-1

19(12):16 WGP
90-4.
3-2

125(8):13 WGP
52-4.
3-3

Hematopoietic stem cell transplantation
132 for patients with acute lymphoblastic
leukemia and Down syndrome.

Goto H, Kaneko T, Shioda Y, Kajiwara M,
Sakashita K, Kitoh T, Hayakawa A, Miki
Pediatr Blood
M, Kato K, Ogawa A, Hashii Y, Inukai T,
2015
Cancer
Kato C, Sakamaki H, Yabe H, Suzuki R,
Kato K.

62(1):148 WGP
-52.
3-4

Allogeneic haematopoietic stem celltransplantation for infant acutelymphoblastic leukaemia with KMT2A
Kato M, Hasegawa D, Koh K, Kato K,(MLL) rearrangements: a retrospective
Takita J, Inagaki J, Yabe H, Goto H,
133
study from the paediatric acute
Adachi S, Hayakawa A, Takeshita Y,
lymphoblastic leukaemia working group of Sawada A, Atsuta Y, Kato K.
the Japan Society for Haematopoietic Cell
Transplantation.

Br J
Haematol

2015

168(4):56 WGP
4-70.
3-5

Comparison of chemotherapeutic agentsas a myeloablative conditioning with total
body irradiation for pediatric acute
134 lymphoblastic leukemia: A study from thepediatric ALL working group of the Japan
Society for Hematopoietic Cell
Transplantation.

Pediatr Blood
2015
Cancer62(10):18 WGP
44-50.
3-6

Kato M, Ishida H, Koh K, Inagaki J, Kato
K, Goto H, Kaneko T, Cho Y, Hashii Y,
Kurosawa H, Takita J, Hamamoto K,
Inoue M, Sawada A, Suzuki R, Kato K.

Kato M, Kurata M, Kanda J, Kato K,
Tomizawa D, Kudo K, Yoshida N,
Impact of graft-versus-host disease on
Watanabe K, Shimada H, Inagaki J, Koh Bone Marrow
135 relapse and survival after allogeneic stem
2019
K, Goto H, Kato K, Cho Y, Yuza Y, Ogawa Transplant
cell transplantation for pediatric leukemia.
A, Okada K, Inoue M, Hashii Y, TeshimaT, Murata M, Atsuta Y.
Hangai M, Urayama KY, Tanaka J, Kato
Allogeneic Stem Cell Transplantation for
Biol BloodK, Nishiwaki S, Koh K, Noguchi M, Kato
136 Acute Lymphoblastic Leukemia in
Marrow
2019
K, Yoshida N, Sato M, Goto H, Yuza Y,
Adolescents and Young Adults.
Transplant
Hashii Y, Atsuta Y, Mizuta S, Kato M.
Kawahara Y, Morimoto A, Inagaki J, KohUnrelated cord blood transplantation with
K, Noguchi M, Goto H, Yoshida N, Cho Y,
myeloablative conditioning for pediatricBone Marrow
137
Hori T, Hiwatari M, Kato K, Ogawa A,
2021
acute lymphoblastic leukemia in remission:
Transplant
Hashii Y, Inoue M, Kato K, Atsuta Y,
prognostic factors.
Kimura F, Kato M.
Ishida H, Kato M, Kawahara Y, Ishimaru
S, Najima Y, Kako S, Sato M, Hiwatari M,
Hematological
Noguchi M, Kato K, Koh K, Okada K,
2022
Iwasaki F, Kobayashi R, Igarashi S, Saito Oncology
S, Takahashi Y, Sato A, Tanaka J, Hashii
Y, Atsuta Y, Sakaguchi H, Imamura T.
Kawahara Y, Ishimaru S, Tanaka J, Kako
Impact of KIR-ligand mismatch on
S, Hirayama M, Kanaya M, Ishida H, Satopediatric T-cell acute lymphoblastic
Transplant
139
M, Kobayashi R, Kato M, Goi K, Saito S,
2022
leukemia in unrelated cord blood
Cell Ther
Koga Y, Hashii Y, Kato K, Sato A, Atsuta
transplantation.
Y, Sakaguchi H.
Hematopoietic stem cell transplantation in Okamoto Y, Nakazawa Y, Inoue M,
children and adolescents with
Watanabe K, Goto H, Yoshida N, Noguchi Pediatr Blood
140
2020
nonremission acute lymphoblastic
M, Kikuta A, Kato K, Hashii Y, Atsuta Y, Cancer
leukemia.
Kato M.
Prognostic factors of children andadolescents with T-cell acute138
lymphoblastic leukemia after allogeneictransplantation.

Reduced-intensity allogeneic stem cell
Kanamori H, Mizuta S, Kako S, Kato H,
transplantation for patients aged 50 years Nishiwaki S, Imai K, Shigematsu A,or older with B-cell ALL in remission: aNakamae H, Tanaka M, Ikegame K, Yujiri
141
retrospective study by the Adult ALL
T, Fukuda T, Minagawa K, Eto T,
Working Group of the Japan Society for
Nagamura-Inoue T, Morishima Y, Suzuki
Hematopoietic Cell Transplantation.
R, Sakamaki H, Tanaka J.

Bone Marrow
2013
Transplant

Nishiwaki S, Miyamura K, Ohashi K,
Impact of a donor source on adult
Kurokawa M, Taniguchi S, Fukuda T,
Philadelphia chromosome-negative acute
Ikegame K, Takahashi S, Mori T, Imai K,
lymphoblastic leukemia: a retrospective
Iida H, Hidaka M, Sakamaki H, Morishima
142 analysis from the Adult AcuteAnn Oncol
Y, Kato K, Suzuki R, Tanaka J; Adult
Lymphoblastic Leukemia Working Group of
Acute Lymphoblastic Leukemia Working
the Japan Society for Hematopoietic Cell
Group of the Japan Society forTransplantation.
Hematopoietic Cell Transplantation.

2013

54(1):68- WGP75.
3-725(8):159 WGP
7-602.
3-8

56(2):357 WGP
-67.
3-9

40(3):457 WGP
-68.
3-10

28(9):598 WGP.e1-8.
3-11

67(12):e2 WGP
8732.
3-12

48(12):15 WGP
13-8.
4-1

24(6):159 WGP
4-602.
4-2

Reduced-intensity vs myeloablative
conditioning allogeneic hematopoietic SCT Tanaka J, Kanamori H, Nishiwaki S,
for patients aged over 45 years with ALL Ohashi K, Taniguchi S, Eto T, Nakamae
Bone Marrow
143 in remission: a study from the Adult ALL H, Minagawa K, Miyamura K, Sakamaki H,
2013
Transplant
Working Group of the Japan Society for
Morishima Y, Kato K, Suzuki R,
Hematopoietic Cell Transplantation
Nishimoto N, Oba K, Masauzi N.
(JSHCT).

48(11):13 WGP
89-94.
4-3

Kato H, Kawase T, Kako S, Mizuta S,
Kurokawa M, Mori T, Ohashi K, Iwato K,
Analysis of outcomes following autologous
Miyamura K, Hidaka M, Sakamaki H,
stem-cell transplantation in adult patientsSuzuki R, Morishima Y, Tanaka J; Adult
144 with Philadelphia chromosome-negative
Acute Lymphoblastic Leukemia Working
acute lymphoblastic leukemia during theGroup of Japan Society forfirst complete remission.
Hematopoietic Cell Transplantation(JSHCT).

99(11):e2 WGP
28-30.
4-4

Haematologic
2014aMizuta S, Matsuo K, Nishiwaki S, Imai K,
Pretransplant administration of imatinib
Kanamori H, Ohashi K, Fukuda T, Onishi
145 for allo-HSCT in patients with BCR-ABL- Y, Miyamura K, Takahashi S, Onizuka M, Blood
2014
positive acute lymphoblastic leukemia.
Atsuta Y, Suzuki R, Morishima Y, Kato K,
Sakamaki H, Tanaka J.
Nishiwaki S, Imai K, Mizuta S, Kanamori
Impact of MRD and TKI on allogeneic
H, Ohashi K, Fukuda T, Onishi Y,
hematopoietic cell transplantation forBone Marrow
146
Takahashi S, Uchida N, Eto T, Nakamae
2016
Ph+ALL: a study from the adult ALL WG
Transplant
H, Yujiri T, Mori S, Nagamura-Inoue T,of the JSHCT.
Suzuki R, Atsuta Y, Tanaka J.
Mitsuhashi K, Kako S, Shigematsu A,
Comparison of Cyclophosphamide
Atsuta Y, Doki N, Fukuda T, Kanamori H,
Combined with Total Body Irradiation, Oral Onizuka M, Takahashi S, Ozawa Y,
Biol Blood
Busulfan, or Intravenous Busulfan for
Kurokawa M, Inoue Y, Nagamura-Inoue T,
147
Marrow
Allogeneic Hematopoietic Cell
Morishima Y, Mizuta S, Tanaka J; Adult
Transplant
Transplantation in Adults with Acute
Acute Lymphoblastic Leukemia Working
Lymphoblastic Leukemia.
Group of the Japan Society for
Hematopoietic Cell Transplantation.

22(12):21 WGP
94-200.
4-7Bone Marrow
2016
Transplant51(12):16 WGP
36-9.
4-8

Arai Y, Kondo T, Shigematsu A, Tanaka
J, Takahashi S, Kobayashi T, Uchida N,
Onishi Y, Ishikawa J, Kanamori H, Sawa
M, Yokota A, Kouzai Y, Takanashi M,
Ichinohe T, Atsuta Y, Mizuta S.

Increased non-relapse mortality due tohigh-dose cytarabine plus CY/TBI in
149
BMT/PBSCT for acute lymphoblastic
leukaemia in adults.

Arai Y, Kondo T, Shigematsu A, Tanaka
J, Ohashi K, Fukuda T, Kawakita T, MoriT, Hoshino T, Onizuka M, Ozawa Y,
Br J
Yoshida S, Ueda Y, Mizuno I, Atsuta Y,
HaematolMizuta S; Japan Society for
Haematopoietic Cell Transplantation.

Improved prognosis with additional
medium-dose VP16 to CY/TBI in
151
allogeneic transplantation for high risk
ALL in adults.

51(1):43- WGP
50.
4-6

2016

High-dose cytarabine added to CY/TBI
improves the prognosis of cord blood
148 transplantation for acute lymphoblastic
leukemia in adults: a retrospective cohort
study.

Allogeneic stem cell transplantation for
adult patients with acute lymphoblastic
leukemia who had central nervous system
150
involvement: a study from the Adult ALL
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

123(15):2 WGP
325-32.
4-5

2017

Shigematsu A, Kako S, Mitsuhashi K,
Iwato K, Uchida N, Kanda Y, Fukuda T,
Sawa M, Senoo Y, Ogawa H, Miyamura K,
Takada S, Nagamura-Inoue T, Morishima Int J Hematol 2017
Y, Ichinohe T, Atsuta Y, Mizuta S,
Tanaka J.
Arai Y, Kondo T, Shigematsu A, Tanaka
J, Ohashi K, Fukuda T, Hidaka M,
Kobayashi N, Iwato K, Sakura T, Onizuka
Am JM, Ozawa Y, Eto T, Kurokawa M, Kahata
Hematol
K, Uchida N, Atsuta Y, Mizuta S, Kako S.

Akahoshi Y, Mizuta S, Shimizu H, UchidaN, Fukuda T, Kanamori H, Onizuka M,
Additional Cytogenetic Abnormalities with
Ozawa Y, Ohashi K, Ohta S, Eto T,
Philadelphia Chromosome-Positive Acute
Biol Blood
Tanaka J, Atsuta Y, Kako S; Adult Acute
152 Lymphoblastic Leukemia on Allogeneic
Marrow
Lymphoblastic Leukemia Working Group
Stem Cell Transplantation in the Tyrosine
Transplantof the Japan Society for Hematopoietic
Kinase Inhibitor Era.
Cell Transplantation.

178(1):10 WGP
6-11.
4-9

105(6):80 WGP
5-11.
4-10

2018

93(1):47- WGP
57.
4-11

2018

24(10):20 WGP
09-16.
4-12

Akahoshi Y, Nishiwaki S, Mizuta S,
Tyrosine kinase inhibitor prophylaxis after Ohashi K, Uchida N, Tanaka M, Fukuda T,
153 transplant for Philadelphia chromosome- Ozawa Y, Takahashi S, Onizuka M,
Cancer Sci
positive acute lymphoblastic leukemia.
Shiratori S, Nakamae H, Kanda Y,
Ichinohe T, Atsuta Y, Kako S.

2019

110(10):3 WGP
255-66.
4-13

Nishiwaki S, Mizuta S, Ohashi K, Fukuda
T, Uchida N, Tachibana T, Onizuka M,
Different impact of BCR-ABL transcripts
Ozawa Y, Onishi Y, Takahashi S, Eto T,
on allogeneic hematopoietic cell
Nakamae H, Tanaka J, Ichinohe T, Atsuta Am J
154 transplantation from different graft
Y, Kako S; Adult Acute Lymphoblastic
Hematolsources for Ph + ALL with minimal residual
Leukemia Working Group of the Japandisease.
Society for Hematopoietic Cell
Transplantation.

2019

94(11):E3 WGP
01-5.
4-14

The effect of melphalan dose and total
body irradiation as reduced-intensity
155 conditioning for acute lymphoblastic
leukemia patients undergoing allogeneic
stem cell transplantation.

Harada K, Tachibana T, Ohashi K, Ozawa
Y, Sawa M, Kondo T, Ishikawa J, Onizuka Leuk
M, Imada K, Fujisaki T, Tanaka J, Fukuda Lymphoma
T, Atsuta Y, Kako S.

201960(14):35 WGP
21-8.
4-15

Allogeneic hematopoietic stem celltransplantation for adult patients with B156 cell acute lymphoblastic leukemia
harboring t(1;19)(q23;p13.3); comparison
with normal karyotype.

Kaito S, Najima Y, Harada K, Fukuda T,
Noguchi Y, Ikegame K, Tanaka M, Ozawa
Y, Yoshida S, Sawa M, Ota S, Inoue Y,
Bone Marrow
Tanaka J, Ichinohe T, Atsuta Y, Kako S;
2020
Transplant
Adult Acute Lymphoblastic Leukemia
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

55(7):133 WGP
7-46.
4-16

Akahoshi Y, Igarashi A, Fukuda T, Uchida
Impact of graft-versus-host disease andN, Tanaka M, Ozawa Y, Kanda Y, Onizuka
graft-versus-leukemia effect based on
M, Ichinohe T, Tanaka J, Atsuta Y, Kako Br J
157 minimal residual disease in Philadelphia
S; Adult Acute Lymphoblastic Leukemia Haematol
chromosome-positive acute lymphoblastic
Working Group of the Japan Society forleukemia.
Hematopoietic Cell Transplantation.

2020

190(1):84 WGP
-92.
4-17

Akahoshi Y, Nishiwaki S, Arai Y, Harada
K, Najima Y, Kanda Y, Shono K, Ota S,
Bone Marrow
2020
Fukuda T, Uchida N, Shiratori S, Tanaka Transplant
M, Tanaka J, Atsuta Y, Kako S.

55(7):131 WGP
7-25.
4-18

Tachibana T, Najima Y, Akahoshi Y,
Hirabayashi S, Harada K, Doki N, Uchida
The impacts of BCR-ABL1 mutations in
N, Fukuda T, Sawa M, Ogata M, Takada
patients with Philadelphia chromosomeS, Tanaka M, Matsuhashi Y, Tanaka J,
159 positive acute lymphoblastic leukemia who
Ann Hematol 2020
Onizuka M, Ichinohe T, Atsuta Y, Kako S;
underwent allogeneic hematopoietic cell
Adult ALL Working Group of the Japantransplantation.
Society for Hematopoietic Cell
Transplantation.

99(10):23 WGP
93-404.
4-19

Reduced-intensity Conditioning Is a
Reasonable Alternative for Philadelphia
Chromosome-Positive Acute
Lymphoblastic Leukemia Among Elderly
158
Patients Who Have Achieved Negative
Minimal Residual Disease: A Report From
the Adult Acute Lymphoblastic Leukemia
Working Group of the JSHCT.

Measurable residual disease affects
allogeneic hematopoietic cell160
transplantation in Ph+ ALL during both
CR1 and CR2.

Nishiwaki S, Akahoshi Y, Mizuta S,
Shinohara A, Hirabayashi S, Noguchi Y,
Fukuda T, Uchida N, Tanaka M, Onizuka BloodM, Ozawa Y, Ota S, Shiratori S, Onishi Y, Advances
Kanda Y, Sawa M, Tanaka J, Atsuta Y,
Kako S.

2021

Minimal residual disease (MRD) positivity
at allogeneic hematopoietic cell
Akahoshi Y, Arai Y, Nishiwaki S, Mizuta
transplantation, not the quantity of MRD, S, Marumo A, Uchida N, Kanda Y, Sakai
161
Int J Hematol 2021
is a risk factor for relapse of Philadelphia H, Takada S, Fukuda T, Fujisawa S,
chromosome-positive acute lymphoblastic Ashida T, Tanaka J, Atsuta Y, Kako S.
leukemia.
Allogeneic hematopoietic stem cell
Kurosawa S, Kaito S, Uchida N, Fukuda
transplantation for adult patients with BT, Doki N, Mori T, Hasegawa Y, Takada S, Leuk
162 cell acute lymphoblastic leukemia with
2021
Sakaida E, Tanaka M, Ikegame K, Kanda Lymphoma
high hyperdiploidy: a retrospective
J, Atsuta Y, Kako S.
nationwide study.

5(2):584- WGP
92.
4-20

113(6):83 WGP
2-9.
4-21

62(10):25 WGP
14-20.
4-22

Residual disease is a strong prognostic
marker in patients with acutelymphoblastic leukaemia with163
chemotherapy-refractory or relapsed
disease prior to allogeneic stem celltransplantation.

Nakamura M, Arai Y, Hirabayashi S,
Kondo T, Doki N, Uchida N, Fukuda T,
Ozawa Y, Tanaka M, Sawa M, Katayama
Y, Kanda Y, Shiratori S, Nakamae H,
Yoshioka S, Onizuka M, Ichinohe T,
Atsuta Y, Kako S.

Br J
Haematol

2021

194(2):40 WGP
3-13.
4-23

Newly proposed threshold and validationof white blood cell count at diagnosis for
Philadelphia chromosome-positive acutelymphoblastic leukemia: risk assessment
164 of relapse in patients with negative
minimal residual disease attransplantation-a report from the Adult
Acute Lymphoblastic Leukemia Working
Group of the JSTCT.

Akahoshi Y, Arai Y, Nishiwaki S,
Tachibana T, Shinohara A, Doki N,
Uchida N, Tanaka M, Kanda Y, Shiratori
S, Ozawa Y, Shono K, Katayama Y,
Tanaka J, Fukuda T, Atsuta Y, Kako S.

Bone Marrow
2021
Transplant56(11):28 WGP
42-8.
4-24

Kako S, Hayakawa F, Imai K, Tanaka J,
Mizuta S, Nishiwaki S, Kanamori H,
Optimal treatment for PhiladelphiaMukae J, Ozawa Y, Kondo T, Fukuda T,
negative acute lymphoblastic leukemia in
165
Ichinohe T, Ota S, Tanaka Y, Murayama Int J Hematol 2021
first remission in the era of high-intensity
T, Kurahashi S, Sakura T, Usui N, Ohtake
chemotherapy.
S, Kiyoi H, Matsumura I, Miyazaki Y,
Atsuta Y.

114(5):60 WGP
8-19.
4-25

Decision Analysis for Unrelated Bone
Marrow Transplantation or Immediate
Cord Blood Transplantation for Patients
166with Philadelphia Chromosome-Negative
Acute Lymphoblastic Leukemia in First
Complete Remission.

Kako S, Hayakawa F, Miyamura K,
Tanaka J, Imai K, Kanda J, Morishima S,
Uchida N, Doki N, Ikegame K, Ozawa Y,
Takada S, Usui N, Ohtake S, Kiyoi H,
Matsumura I, Miyazaki Y, Ichinohe T,
Fukuda T, Atsuta Y, Kanda Y.

Transplant
Cell Ther

2022

28(3):161 WGP.e1-10.
4-26

Allogeneic Hematopoietic Stem Cell
Transplantation for Adult Philadelphia
167 Chromosome-Negative B-Cell Acute
Lymphoblastic Leukemia in Second
Complete Remission.

Kaito S, Kurosawa S, Najima Y, Sakaida
E, Shingai N, Fukuda T, Tachibana T,
Uchida N, Ozawa Y, Sawa M, Nakazawa
H, Ota S, Kato J, Nakamae H, Katayama
Transplant
Y, Eto T, Tanaka J, Kanda Y, Atsuta Y,
Cell Ther
Arai Y, Kako S; Adult Acute
Lymphoblastic Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

2022

28(6):326 WGP.e1-10.
4-27

Propensity score matching/reweighting
Mizuta S, Ugai T, Kato H, Doki N, Ota S,
analysis comparing autologous and
Kawakita T, Katayama Y, Kurokawa M,
168
Int J Hematol 2022
allogeneic stem cell transplantation for B- Nakamae H, Yano S, Nawa Y, Kanda Y,
lineage acute lymphoblastic leukemia.
Fukuda T, Atsuta Y, Kako S.
Nishiwaki S, Akahoshi Y, Morita-Fujita M,
Shimizu H, Uchida N, Ozawa Y, Fukuda T,
Improvements in allogeneic hematopoietic
Tanaka M, Ikegame K, Ota S, Katayama Blood
169 cell transplantation outcomes for adults
2022
Y, Takahashi S, Kawakita T, Ara T,
Advanceswith ALL over the past 3 decades.
Onizuka M, Kimura T, Tanaka J, Atsuta
Y, Arai Y.

170

Prognostic Factors for Outcomes of
Allogeneic HSCT for Children andAdolescents/Young Adults With CML in
the TKI Era.

Effect of graft sources on allogeneic
hematopoietic stem cell transplantation
outcome in adults with chronic myeloid
171 leukemia in the era of tyrosine kinase
inhibitors: a Japanese Society of
Hematopoietic Cell Transplantation
retrospective analysis.

Shimada H, Tanizawa A, Kondo T,
Nagamura-Inoue T, Yasui M, Tojo A,
Muramatsu H, Eto T, Doki N, Tanaka M,
Sato M, Noguchi M, Uchida N, Takahashi
Transplant
Y, Sakata N, Ichinohe T, Hashii Y, Kato K,
Cell Ther
Atsuta Y, Ohashi K; Pediatric and Adult
CML/MPN Working Groups of theJapanese Society for Transplantation
and Cellular Therapy.

116(3):39 WGP
3-400.
4-28

6(15):455 WGP
8-69.
4-29

2022

28(7):376 WGP
-89.
5-1

Ohashi K, Nagamura-Inoue T, Nagamura
F, Tojo A, Miyamura K, Mori T, Kurokawa
Int J Hematol 2014
M, Taniguchi S, Ishikawa J, Morishima Y,
Atsuta Y, Sakamaki H.

100(3):29 WGP
6-306.
6-1

Kondo T, Nagamura-Inoue T, Tojo A,
Clinical impact of pretransplant use of
Nagamura F, Uchida N, Nakamae H,
multiple tyrosine kinase inhibitors on the Fukuda T, Mori T, Yano S, Kurokawa M,
172 outcome of allogeneic hematopoietic stem Ueno H, Kanamori H, Hashimoto H,
cell transplantation for chronic
Onizuka M, Takanashi M, Ichinohe T,
myelogenous leukemia.
Atsuta Y, Ohashi K.

Am J
Hematol

2017

92(9):902 WGP
-8.
6-2

2018

75:50-7.

2019

25(8):153 WGP
6-43.
6-4

Shimazu Y, Murata M, Kondo T, Minami
Y, Tachibana T, Doki N, Uchida N, Ozawa
The new generation tyrosine kinase
Y, Yano S, Fukuda T, Kato J, Ara T, Eto
inhibitor improves the survival of chronic
Hematological
175
T, Ishikawa J, Nakamae H, Tanaka J,
2022
myeloid leukemia patients after allogeneic
Oncology
Ichinohe T, Atsuta Y, Nagamura-Inoue T;
stem cell transplantation.
working group of the Japan Society forTransplantation and Cellular Therapy.

40(3):442 WGP
-56.
6-5

Okada Y, Takenaka K, Murata M,
Shimazu Y, Tachibana T, Ozawa Y,
Uchida N, Wakayama T, Doki N, Sugio Y,
Hematological
Tanaka M, Masuko M, Kobayashi H, Ino K
2022
Oncology, Ishikawa J, Nakamae H, Matsuoka K,
Kanda Y, Fukuda T, Atsuta Y,
Nagamura-Inoue T.

40(5):107 WGP
6-85.
6-6

Allogeneic hematopoietic stem celltransplantation for the treatment of BCR- Itonaga H, Ota S, Ikeda T, Taji H, Amano
ABL1-negative atypical chronic myeloid
I, Hasegawa Y, Ichinohe T, Fukuda T,
173
Leuk Res
leukemia and chronic neutrophil leukemia: Atsuta Y, Tanizawa A, Kondo T, Miyazaki
A retrospective nationwide study inY.
Japan.
Murata M, Takenaka K, Uchida N, Ozawa
Comparison of Outcomes of Allogeneic
Y, Ohashi K, Kim SW, Ikegame K, Kanda Biol Blood
Transplantation for Primary Myelofibrosis
174
Y, Kobayashi H, Ishikawa J, Ago H,
Marrowamong Hematopoietic Stem Cell Source
Hirokawa M, Fukuda T, Atsuta Y, Kondo TransplantGroups.
T.

Prognostic impact of complex karyotype
176 on post-transplant outcomes of
myelofibrosis.

The Clinical Significance of BCR-ABL1
Mutations in Patients With Philadelphia
177 Chromosome-Positive Chronic Myeloid
Leukemia Who Underwent Allogeneic
Hematopoietic Cell Transplantation.

178

Salvage allogeneic stem celltransplantation in patients with pediatricmyelodysplastic syndrome andmyeloproliferative neoplasms.

Clinical Outcomes after Allogeneic
Hematopoietic Stem Cell Transplantationin Children with Juvenile Myelomonocytic
179
Leukemia: A Report from the Japan
Society for Hematopoietic Cell
Transplantation.

Tachibana T, Kondo T, Uchida N, Doki N,
Takada S, Takahashi S, Yano S, Mori T,
Kohno A, Kimura T, Fukuda T, Atsuta Y,
Transplant
Nagamura-Inoue T; Adult-CMLMPN2022
Cell Ther
working-group-of-the-JapaneseSociety-for-Transplantation-andCellular-Therapy.
Kato M, Yoshida N, Inagaki J, Maeba H,
Kudo K, Cho Y, Kurosawa H, Okimoto Y, Pediatr Blood
2014
Tauchi H, Yabe H, Sawada A, Kato K,
CancerAtsuta Y, Watanabe K.
Yoshida N, Sakaguchi H, Yabe M,
Hasegawa D, Hama A, Hasegawa D, Kato
M, Noguchi M, Terui K, Takahashi Y, Cho
Y, Sato M, Koh K, Kakuda H, Shimada H, Biol Blood
Hashii Y, Sato A, Kato K, Atsuta Y,
Marrow
Watanabe K; Pediatric Myelodysplastic
Transplant
Syndrome Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

Prognostic value of the revised
Yamamoto S, Kato M, Watanabe K,
International Prognostic Scoring System Ishimaru S, Hasegawa D, Noguchi M,
five-group cytogenetic abnormality
Hama A, Sato M, Koike T, Iwasaki F,
180classification for the outcome prediction Yagasaki H, Takahashi Y, Kosaka Y,of hematopoietic stem cell transplantation Hashii Y, Morimoto A, Atsuta Y,
in pediatric myelodysplastic syndrome.
Hasegawa D, Yoshida N.

Allogeneic haematopoietic celltransplantation with reduced-intensity
181 conditioning for elderly patients withadvanced myelodysplastic syndromes: anationwide study.

WGP
6-3

28(6):321 WGP.e1-8.
6-7

61(10):18 WGP
60-6.
7-1

2020

26(5):902 WGP
-10.
7-2

Bone Marrow
2021
Transplant56(12):30 WGP
16-23.
7-3

Aoki K , Ishikawa T, Ishiyama K, Aoki J,
Itonaga H, Fukuda T, Kakihana K, UchidaN, Ueda Y, Eto T, Mori T, Kondo T, Iwato
K, Morishima Y, Tanaka J, Atsuta Y,
Br J
Miyazaki Y; Adult Myelodysplastic
Haematol
Syndromes Working Group of the Japan
Society for Hematopoietic Cell
Transplantation (JSHCT).

2015

168(3):46 WGP
3-6.
8-1

Konuma T, Takahashi S, Uchida N,
Kuwatsuka Y, Yamasaki S, Aoki J, Onishi
Effect of Granulocyte Colony-Stimulating Y, Aotsuka N, Ohashi K, Mori T, Masuko
Factor-Combined Conditioning in Cord
M, Nakamae H, Miyamura K, Kato K,
Biol Blood
Blood Transplantation for Myelodysplastic Atsuta Y, Kato S, Asano S, Takami A,
182
Marrow
Syndrome and Secondary Acute Myeloid Miyazaki Y; Adult Myelodysplastic
TransplantLeukemia: A Retrospective Study in
Syndrome and Adult Acute Myeloid
Japan.
Leukemia Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

201521(9):163 WGP
2-40.
8-2

Impacts of graft-versus-host disease on
outcomes after allogeneic hematopoietic
183 stem cell transplantation for chronic
myelomonocytic leukemia: A nationwide
retrospective study.

Itonaga H, Iwanaga M, Aoki K, Aoki J,
Ishiyama K, Ishikawa T, Sakura T, Fukuda
T, Najima Y, Yujiri T, Mori T, Kurokawa
M, Nawa Y, Uchida N, Morishita Y,
Leuk Res
Hashimoto H, Eto T, Hirokawa M,
Morishima Y, Nagamura-Inoue T, Atsuta
Y, Miyazaki Y.

2016

41:48-55.

Outcomes of Allogeneic Hematopoietic
Stem Cell Transplantation in Adult
184
Patients with Myelodysplastic Syndrome
Harboring Trisomy 8.

Konuma T, Miyazaki Y, Uchida N, Ohashi
K, Kondo T, Nakamae H, Takahashi S,
Mori T, Ozawa Y, Kato C, Iwato K,
Biol Blood
Fukuda T, Ichinohe T, Atsuta Y, Ishiyama Marrow
K; Adult Myelodysplastic Syndrome
Transplant
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

2017

23(1):75- WGP
80.
8-4

2018

24(4):840 WGP-8.
8-5

Prognostic Impact of Donor Source on
Allogeneic Hematopoietic Stem Cell
Transplantation Outcomes in Adults with
185
Chronic Myelomonocytic Leukemia: A
Nationwide Retrospective Analysis inJapan.

Itonaga H, Aoki K, Aoki J, Ishikawa T,
Ishiyama K, Uchida N, Sakura T, Ohashi
K, Kurokawa M, Ozawa Y, Matsuoka KI, Biol Blood
Nakamura Y, Kimura F, Iwato K, Nawa Y, Marrow
Hirokawa M, Kato K, Ichinohe T, Atsuta Transplant
Y, Miyazaki Y.

Clinical impact of the loss of chromosome Itonaga H, Ishiyama K, Aoki K, Aoki J,
7q on outcomes of patients with
Ishikawa T, Ohashi K, Fukuda T, Ozawa
Bone Marrow
186 myelodysplastic syndromes treated with Y, Ota S, Uchida N, Eto T, Iwato K, Ohno
2019
Transplant
allogeneic hematopoietic stem cellY, Takanashi M, Ichinohe T, Atsuta Y,
transplantation.
Miyazaki Y.
Shimomura Y, Hara M, Tachibana T,
Outcomes of second allogeneic
Ohashi K, Sakura T, Fukuda T, Nakazawa
haematopoietic stem cell transplantation
Br J
187
H, Iwato K, Kanda Y, Ikeda T, Eto T,2019
in patients with relapse of myelodysplastic
HaematolKanda J, Ichinohe T, Atsuta Y, Ishikawa
syndrome.
T1, Ishiyama K.
Increased opportunity for prolonged
Itonaga H, Ishiyama K, Aoki K, Aoki J,
survival after allogeneic hematopoietic
Ishikawa T, Uchida N, Ohashi K, Ueda Y,
188 stem cell transplantation in patients aged Fukuda T, Sakura T, Ohno Y, Iwato K,
Ann Hematol 201960-69 years with myelodysplastic
Okumura H, Kondo T, Ichinohe T,
syndrome.
Takanashi M, Atsuta Y, Miyazaki Y.
Graft-versus-MDS effect after unrelated Ishiyama K, Aoki J, Itonaga H, Uchida N,
cord blood transplantation: a retrospective Takahashi S, Ohno Y, Matsuhashi Y,
Blood Cancer
189 analysis of 752 patients registered at the Sakura T, Onizuka M, Miyakoshi S,
2019JJapanese Data Center for Hematopoietic Takanashi M, Fukuda T, Atsuta Y, Nakao
Cell Transplantation.
S, Miyazaki Y.
Induction chemotherapy followed byallogeneic HCT versus upfront allogeneic
190 HCT for advanced myelodysplastic
syndrome: A propensity score matchedanalysis.

Konuma T, Shimomura Y, Ozawa Y, Ueda
Y, Uchida N, Onizuka M, Akiyama M, Mori
T, Nakamae H, Ohno Y, Shiratori S,
Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Hematological
2019
Ishiyama K; Adult Myelodysplastic
Oncology
Syndrome Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

Outcome of Allogeneic Hematopoietic
Stem Cell Transplantation in Patients with Kurosawa S, Shimomura Y, Tachibana T,
Myelodysplastic/Myeloproliferative
Ishiyama K, Ota S, Kobayashi T, Uchida Biol Blood
191 Neoplasms-Unclassifiable: A
N, Fukushima K, Ashida T, Matsuoka KI, Marrow
Retrospective Nationwide Study of the
Kanda J, Ichinohe T, Atsuta Y, Murata M, Transplant
Japan Society for Hematopoietic Cell
Aoki J.
Transplantation.

2020

WGP
8-3

54(9):147 WGP
1-81.
8-6

138(1):86 WGP
-90.
8-7

98(6):136 WGP
7-81.
8-8

9(3):31.

WGP
8-937(1):85- WGP
95.
8-10

26(9):160 WGP
7-11.
8-11

Konuma T, Ishiyama K, Igarashi A, UchidaN, Ozawa Y, Fukuda T, Ueda Y, Matsuoka
Effects of Acute and Chronic GraftKI, Mori T, Katayama Y, Onizuka M,
versus-myelodysplastic Syndrome on
Clin Cancer
192
Ichinohe T, Atsuta Y; Adult
Long-term Outcomes Following Allogeneic
Res
Myelodysplastic Syndrome Working
Hematopoietic Cell Transplantation.
Group of the Japan Society for
Hematopoietic Cell Transplantation.
Outcome and Risk Factors for TherapyRelated Myeloid Neoplasms Treated with
193
Allogeneic Stem Cell Transplantation in
Japan.
Fludarabine/busulfan versus
busulfan/cyclophosphamide as
194 myeloablative conditioning for
myelodysplastic syndrome: a propensity
score-matched analysis.

195

Pretransplantation Red Blood Cell andPlatelet Transfusion Burden in De Novo
Myelodysplastic Syndrome Undergoing
Allogeneic Transplantation.

Allogeneic hematopoietic stem celltransplantation for myelodysplastic
196
syndrome in adolescent and young adultpatients.

2020

26(24):64 WGP
83-93.
8-12

2020

26(8):154 WGP
3-51.
8-13

Bone Marrow
2021
Transplant56(12):30 WGP
08-15.
8-14

Transplant
Cell Ther

2021

27(8):671 WGP
-8.
8-15

Shimomura Y, Hara M, Konuma T, Itonaga
H, Doki N, Ozawa Y, Eto T, Uchida N,
Aoki J, Kato J, Onishi Y, Takahashi S,
Bone Marrow
2021
Fukushima K, Nakamae H, Kawakita T,
Transplant
Tanaka J, Fukuda T, Atsuta Y, Ishikawa
T, Ishiyama K.

56(10):25 WGP
10-7.
8-16

Kida M, Usuki K, Uchida N, Fukuda T,
Katayama Y, Kondo T, Eto T, Matsuoka
KI, Matsuhashi Y, Ota S, Sawa M,
Miyamoto T, Ichinohe T, Kimura T,
Atsuta Y, Takami A, Miyazaki Y, Yano S,
Ishiyama K, Yanada M, Aoki J.
Kurosawa S, Shimomura Y, Itonaga H,
Najima Y, Kobayashi T, Ozawa Y, Kanda
Y, Kako S, Kawakita T, Matsuoka KI,
Maruyama Y, Ota S, Nakazawa H, Imada
K, Kanda J, Fukuda T, Atsuta Y, Aoki J.
Konuma T, Aoki J, Ozawa Y, Uchida N,
Kobayashi T, Onizuka M, Katayama Y,
Ohta T, Nakano N, Ota S, Onishi Y,
Kobayashi H, Fukuda T, Kanda Y, Atsuta
Y; Adult Myelodysplastic Syndrome
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

Outcome of therapy-related
Itonaga H, Kida M, Hamamura A, Uchida
myelodysplastic syndrome and oligoblastic N, Ozawa Y, Fukuda T, Ueda Y, Kataoka
197 acute myeloid leukemia after allogeneic
K, Katayama Y, Ota S, Matsuoka KI,
hematopoietic stem cell transplantation: A Kondo T, Eto T, Kanda J, Ichinohe T,
propensity score matched analysis.
Atsuta Y, Miyazaki Y, Ishiyama K.

Biol Blood
Marrow
Transplant

Hematological2022
Oncology

40(4):752 WGP
-62.
8-17

Transplant
Cell Ther

2022

28(6):323 WGP.e1-9.
8-18

Haploidentical transplantation with posttransplant cyclophosphamide versus single
Konuma T, Shimomura Y, Ishiyama K, Ara
cord blood transplantation for
T, Nakamae H, Hiramoto N, Eto T,
myelodysplastic syndrome: A
Maruyama Y, Nagafuji K, Ishikawa J,
Am J
199 retrospective study from the Adult
Uchida N, Tanaka M, Onizuka M, Ueda Y, Hematol
Myelodysplastic Syndrome Working Group
Anzai N, Kimura T, Kanda Y, Fukuda T,of the Japanese Society for
Atsuta Y.
Transplantation and Cellular Therapy(JSTCT).

2022

97(12):E4 WGP
47-50.
8-19

Kobayashi R, Fujita N, Mitsui T, Iwasaki
Stem cell transplantation for paediatricF, Suzumiya J, Kuroda H, Nishimura R,
200 patients with non-anaplastic peripheral T- Sasahara Y, Takeshita Y, Kato K,
cell lymphoma in Japan.
Okumura H, Sakamaki H, Yabe H, Kawa
K, Kato K, Suzuki R.

Br J
Haematol2012

159(1):88 WGP
-93.
9-1

Fukano R, Mori T, Kobayashi R, Mitsui T,
Haematopoietic stem cell transplantation
Fujita N, Iwasaki F, Suzumiya J, Chin M,
for relapsed or refractory anaplastic large
Br J
201
Goto H, Takahashi Y, Hara J, Park YD,
cell lymphoma: a study of children and
HaematolInoue M, Koga Y, Inagaki J, Sakamaki H,
adolescents in Japan.
Adachi S, Kawa K, Kato K, Suzuki R.

2015

168(4):55 WGP
7-63.
9-2

Kobayashi R, Mitsui T, Fujita N, Osumi T,
Outcome differences between children
Aoki T, Aoki K, Suzuki R, Fukuda T,
and adolescents and young adults with
Miyamoto T, Kato K, Nakamae H, Goto H,
202
Int J Hematol 2017
non-Hodgkin lymphoma following stem cell Eto T, Inoue M, Mori T, Terui K, Onizuka
transplantation.
M, Koh K, Koga Y, Ichinohe T, Sawada A,
Atsuta Y, Suzumiya J.

105(3):36 WGP
9-76.
9-3

Myeloablative Versus Reduced-Intensity
Conditioning With Fludarabine/Busulfan
198
for Myelodysplastic Syndrome: A
Propensity Score-Matched Analysis.

Kurosawa S, Shimomura Y, Itonaga H,
Najima Y, Kobayashi T, Ozawa Y, Kanda
Y, Kako S, Kawakita T, Matsuoka KI,
Maruyama Y, Ota S, Nakazawa H, ImadaK, Kimura T, Kanda J, Fukuda T, Atsuta
Y, Ishiyama K.

Fujita N, Kobayashi R, Atsuta Y, Iwasaki
Hematopoietic stem cell transplantation in
F, Suzumiya J, Sasahara Y, Inoue M, Koh
203 children and adolescents with relapsed or
Int J Hematol 2019
K, Hori T, Goto H, Ichinohe T, Hashii Y,
refractory B-cell non-Hodgkin lymphoma.
Kato K, Suzuki R, Mitsui T.
The effect of graft-versus-host disease Mitsui T, Fujita N, Koga Y, Fukano R,
on outcomes after allogeneic stem cell
Osumi T, Hama A, Koh K, Kakuda H,
Pediatr Blood
204 transplantation for refractory
Inoue M, Fukuda T, Yabe H, Takita J,
2020
Cancerlymphoblastic lymphoma in children andShimada A, Hashii Y, Sato A, Atsuta Y,
young adults.
Kanda Y, Suzumiya J, Kobayashi R.
The effectiveness of busulfan-based
Hori D, Kobayashi R, Fujita N, Suzumiya
conditioning regimens for stem cellJ, Suzuki R, Kato K, Kawata T, Fukuda T,
Pediatr Blood
205 transplantation against lymphomas inInoue M, Goto H, Hama A, Iwato K,
2019
Cancerchildren, adolescents, and young adults in Okumura H, Eto T, Hashii Y, Atsuta Y,
Japan.
Mitsui T.
Successful outcome with reducedFukano R, Mori T, Fujita N, Kobayashi R,
intensity condition regimen followed by
Mitsui T, Kato K, Suzuki R, Suzumiya J,
206 allogeneic hematopoietic stem cell
Fukuda T, Shindo M, Maseki , Shimoyama Int J Hematol 2019transplantation for relapsed or refractory T, Okada K, Inoue M, Inagaki J, Hashii Y,
anaplastic large-cell lymphoma.
Sato A, Tabuchi K.
High-dose chemotherapy with autologous Chihara D, Izutsu K, Kondo E, Sakai R,
stem cell transplantation for elderly
Mizuta S, Yokoyama K, Kaneko H, Kato Biol Blood
207 patients with relapsed/refractory diffuse K, Hasegawa Y, Chou T, Sugahara H,
Marrow
2014
large B cell lymphoma: a nationwide
Henzan H, Sakamaki H, Suzuki R,
Transplant
retrospective study.
Suzumiya J.
Kako S, Izutsu K, Kato K, Kim SW, MoriT, Fukuda T, Kobayashi N, Taji H,
The role of hematopoietic stem cell
Hashimoto H, Kondo T, Sakamaki H,
Am J
208 transplantation for relapsed and refractory Morishima Y, Kato K, Suzuki R, Suzumiya
2015
Hematol
Hodgkin lymphoma.
J; Adult Lymphoma Working Group of theJapanese Society for Hematopoietic Cell
Transplantation.
Long-term survival following autologous
Aoki T, Suzuki R, Kuwatsuka Y, Kako S,
and allogeneic stem cell transplantation
Fujimoto K, Taguchi J, Kondo T, Ohata K,
209
Blood
2015
for blastic plasmacytoid dendritic cell
Ito T, Kamoda Y, Fukuda T, Ichinohe T,
neoplasm.
Takeuchi K, Izutsu K, Suzumiya J.
Yamasaki S, Suzuki R, Hatano K,
Fukushima K, Iida H, Morishima S,
Therapy-related acute myeloid leukemia
Suehiro Y, Fukuda T, Uchida N,
and myelodysplastic syndrome after
Bone Marrow
210
Uchiyama H, Ikeda H, Yokota A,
2017
hematopoietic cell transplantation forTransplant
Tsukasaki K, Yamaguchi H, Kuroda J,
lymphoma.
Nakamae H, Adachi Y, Matsuoka KI,
Nakamura Y, Atsuta Y, Suzumiya J.
Yamasaki S, Chihara D, Yoshida I, Kohda
Impact of hematopoietic stem cell
K, Sawa M, Ago H, Togitani K, Ohno Y,
211 transplantation in patients with relapsed
Ann Hematol 2019
Tanaka J, Fukuda T, Atsuta Y, Suzumiya
or refractory marginal zone lymphoma.
J, Suzuki R.
Yamasaki S, Chihara D, Kim SW, Kawata
Risk factors and timing of autologous
T, Mizuta S, Ago H, Chou T, Yamane T,
212 stem cell transplantation for patients with Uchiyama H, Oyake T, Miura K, Saito B, Int J Hematol 2019
peripheral T-cell lymphoma.
Taji H, Nakamae H, Miyamoto T, Fukuda
T, Kanda J, Atsuta Y, Suzuki R.
Yamasaki S, Chihara D, Kim SW, Izutsu
Impact of hematopoietic stem cellK, Iwato K, Fukuda T, Uchida N, Amano I,
213 transplantation in patients with relapsed Nakazawa H, Kuroda J, Hashimoto H,
Ann Hematol 2018or refractory mantle cell lymphoma.
Ichinohe T, Kanda Y, Atsuta Y, SuzumiyaJ, Suzuki R.
Kondo E, Ikeda T, Izutsu K, Chihara D,
High-Dose Chemotherapy with Autologous
Shimizu-Koresawa R, Fujii N, Sakai T,
Stem Cell Transplantation in Primary
Kondo T, Kubo K, Kato Y, Akasaka T,
Biol BloodCentral Nervous System Lymphoma: Data214
Fukuda T, Ichinohe T, Atsuta Y,
Marrow
2019
From the Japan Society for
Suzumiya J, Suzuki R; Adult Lymphoma Transplant
Hematopoietic Cell Transplantation
Working Group of the Japan Society for
Registry.
Hematopoietic Cell Transplantation.
Effect of allogeneic hematopoietic celltransplantation for patients with Tprolymphocytic leukemia: a retrospective
215
study from the Adult Lymphoma Working
Group of the Japan Society forhematopoietic cell transplantation.

Yamasaki S, Nitta H, Kondo E, Uchida N,
Miyazaki T, Ishiyama K, Kiyota M,
Ann Hematol 2019
Matsuoka H, Ichinohe T, Fukuda T,
Atsuta Y, Suzumiya J, Suzuki R.

109(4):48 WGP
3-90.
9-4

67(4):e28 WGP
129.
9-5

66(10):e2 WGP
7918.
9-6

110(6):72 WGP
3-8.
9-7

20(5):684 WGP
-9.
10-1

90(2):132 WGP
-8.
10-2

125(23):3 WGP
559-62.
10-352(7):969 WGP
-76.
10-4

98(6):152 WGP
1-3.
10-5

109(2):17 WGP
5-86.
10-6

97(8):144 WGP
5-52.
10-7

25(5):899 WGP
-905.
10-8

98(9):221 WGP
3-20.
10-9

Clinical outcomes of hepatitis B or C virus
infections in patients with malignant
Kato H, Kato K, Kim SW, Fukuda T, Morilymphoma receiving autologous stem cellT, Sawa M, Ohno Y, Yoshioka S, Iwato Y, Br J
216 transplantation: on behalf of the Adult
Taji H, Onizuka M, Kurahashi S, Ichinohe Haematol
Lymphoma Working Group of the JapanT, Suzumiya J, Suzuki R.
Society for Haematopoietic Cell
Transplantation (JSHCT).

2019

186(6):e1 WGP
70-5.
10-10

Outcome of patients receiving
consolidative autologous peripheral blood
stem cell transplantation in the frontline
217 treatment of intravascular large B-cell
lymphoma: Adult Lymphoma Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

Kato K, Mori T, Kim SW, Sawa M, Sakai
T, Hashimoto H, Taguchi J, Oyake T,
Bone Marrow
Kurahashi S, Imada K, Ohno H, Tanaka J,
2019
Transplant
Ichinohe T, Atsuta Y, Suzuki R, SuzumiyaJ.

54(9):151 WGP
5-7.
10-11

Allogeneic haematopoietic stem celltransplantation for primary mediastinal
large B-cell lymphoma patients relapsing
after high dose chemotherapy with
218
autologous stem cell transplantation: datafrom the Japan Society for
Haematopoietic Cell Transplantation
registry.

Kondo E, Shimizu-Koresawa R, Chihara
D, Mizuta S, Izutsu K, Ikegame K, UchidaBr JN, Fukuda T, Ichinohe T, Atsuta Y,
HaematolSuzuki R; Adult Lymphoma Working
Group of the JSHCT.

2019

186(6):e2 WGP
19-23.
10-12

Bone Marrow
2021
Transplant56(2):347 WGP
-56.
10-13

Hematological2020
Oncology

38(3):266 WGP
-71.
10-14

Hematological2021
Oncology

39(1):66- WGP
74.
10-15

Ann Hematol 2020

99(7):163 WGP
5-42.
10-16

Sakurai M, Mori T, Kato K, Kanaya M,
Mizuno S, Shiratori S, Wakayama T,
Uchida N, Kobayashi H, Kubo K, Amano I,
Ohta T, Miyazaki Y, Kanda J, Fukuda T, Bone Marrow
2021
Atsuta Y, Kondo E; Adult Lymphoma
Transplant
Working Group of the Japan Society for
Hematopoietic Cell Transplantation(JSHCT).

56(6):146 WGP
2-6.
10-17

Fujimoto A, Ishida F, Izutsu K, Yamasaki
Allogeneic stem cell transplantation for
S, Chihara D, Suzumiya J, Mitsui T, Doki
219
patients with aggressive NK-cell leukemia. N, Sakai H, Kobayashi H, Kanda J,
Fukuda T, Atsuta Y, Suzuki R.
Mori T, Shiratori S, Suzumiya J,
Outcome of allogeneic hematopoietic
Kurokawa M, Shindo M, Naoyuki U,
220 stem cell transplantation for mycosis
Katsuto T, Miyamoto T, Morishige S,
fungoides and Sézary syndrome.
Hirokawa M, Fukuda T, Atsuta Y, Suzuki
R.
Takahashi T, Suzuki R, Yamamoto G,
Hematopoietic stem cell transplantation
Nakazawa H, Kurosawa M, Kobayashi T,
221 for diffuse large B-cell lymphoma having
Okada M, Akasaka T, Kim SW, Fukuda T,
8q24/MYC rearrangement in Japan.
Ichinohe T, Atsuta Y, Suzumiya J.
Outcome of stem cell transplantation for
Sakurai M, Mori T, Uchiyama H, Ago H,
Waldenström's macroglobulinemia: analysis
Iwato K, Eto T, Iwasaki H, Kawata T,
222 of the Japan Society for Hematopoietic
Takamatsu H, Yamasaki S, Takanashi M,
Cell Transplantation (JSHCT) Lymphoma
Ichinohe T, Atsuta Y, Suzuki R.
Working Group.
Outcome of allogeneic hematopoietic
stem cell transplantation for follicularlymphoma relapsing after autologous
223
transplantation: analysis of the Japan
Society for Hematopoietic Cell
Transplantation.

Fujimoto A, Anzai T, Fukuda T, Uchida N,
Ohta T, Mori T, Sawa M, Yoshioka S,
Impact of event-free survival status after
Miyamoto T, Uchiyama H, Katayama Y,
Blood
224 stem cell transplantation on subsequent
Matsuoka KI, Shiratori S, Nakazawa H,
Advances
survival of patients with lymphoma.
Kanda J, Ichinohe T, Atsuta Y, Fujita N,
Kondo E, Suzuki R.
Kameda K, Kako S, Kim SW, Usui Y, Kato
K, Fukuda T, Uchida N, Kobayashi H,
Autologous or allogeneic hematopoietic
Wakayama T, Sakaida E, Yano S, Imada
225 cell transplantation for relapsed or
Leukemia
K, Nara M, Ikeda T, Fuchida SI, Ishikawa
refractory PTCL-NOS or AITL.
J, Sugahara H, Kanda J, Kimura T,
Ichinohe T, Atsuta Y, Kondo E.
Improved survival after single-unit cord
blood transplantation using fludarabineand melphalan-based reduced-intensity
226 conditioning for malignant lymphoma:
impact of melphalan dose and graftversus-host disease prophylaxis withmycophenolate mofetil.

Sakatoku K, Kim SW, Okamura H, Kanaya
M, Kato K, Yamasaki S, Uchida N,
Kobayashi H, Fukuda T, Takayama N,
Ann Hematol
Ishikawa J, Nakazawa H, Sakurai M, Ikeda
T, Kondo T, Yoshioka S, Miyamoto T,
Kimura T, Ichinohe T, Atsuta Y, Kondo E.

2021

5(5):1412 WGP
-24.
10-18

2022

36(5):136 WGP
1-70.
10-19

in press

WGP
10-20

Fludarabine plus reduced-intensity
Kamijo K, Shimomura Y, Shinohara A,
busulfan versus fludarabine plus
Mizuno S, Kanaya M, Usui Y, Kim SW,
myeloablative busulfan in patients withAra T, Mizuno I, Kuriyama T, Nakazawa
227
Ann Hematol
non-Hodgkin lymphoma undergoing
H, Matsuoka KI, Kusumoto S, Maseki N,
allogeneic hematopoietic cell
Yamaguchi M, Ashida T, Onizuka M,
transplantation.
Fukuda T, Atsuta Y, Kondo E.
Long-term outcome of childhood aplastic Kikuchi A, Yabe H, Kato K, Koh K, Inagaki
anemia patients who underwent allogeneic J, Sasahara Y, Suzuki R, Yoshida N,
Bone Marrow
228
hematopoietic SCT from an HLA-matched Kudo K, Kobayashi R, Tabuchi K, Kawa K, Transplant
sibling donor in Japan.
Kojima S.
Yoshida N, Kobayashi R, Yabe H, Kosaka
First-line treatment for severe aplastic
Y, Yagasaki H, Watanabe K, Kudo K,
anemia in children: bone marrow
Haematologic
229
Morimoto A, Ohga S, Muramatsu H,
transplantation from a matched familyaTakahashi Y, Kato K, Suzuki R, Ohara A,
donor versus immunosuppressive therapy.
Kojima S.
Kobayashi R, Yabe H, Kikuchi A, Kudo K,
Bloodstream infection after stem cell
Yoshida N, Watanabe K, Muramatsu H,
Biol Blood
230 transplantation in children with idiopathic Takahashi Y, Inoue M, Koh K, Inagaki J, Marrowaplastic anemia.
Okamoto Y, Sakamaki H, Kawa K, Kato K, Transplant
Suzuki R, Kojima S.
Kudo K, Muramatsu H, Yoshida N,
Second allogeneic hematopoietic stem cell Kobayashi R, Yabe H, Tabuchi K, Kato K,
Bone Marrow
231 transplantation in children with severe
Koh K, Takahashi Y, Hashii Y, Kawano Y,
Transplant
aplastic anemia.
Inoue M, Cho Y, Sakamaki H, Kawa K,
Kato K, Suzuki R, Kojima S.
Kudo K, Muramatsu H, Narita A, Yoshida
Unrelated cord blood transplantation in
N, Kobayashi R, Yabe H, Endo M, Inoue
Bone Marrow
232 aplastic anemia: is antithymocyte globulin M, Hara J, Kounami S, Inagaki J, Hashii
Transplant
indispensable for conditioning?
Y, Kato K, Tabuchi K, Kojima S.

in press

WGP
10-21

2013

48(5):657 WGP
-60.
11-1

2014

99(12):17 WGP
84-91.
11-2

2014

20(8):114 WGP
5-9.
11-3

2015

50(10):13 WGP
12-5.
11-4

2017

52(12):16 WGP
59-61.
11-5

Yoshida N, Takahashi Y, Yabe H,
Kobayashi R, Watanabe K, Kudo K, Yabe
Conditioning Regimen for Allogeneic BoneM, Miyamura T, Koh K, Kawaguchi H,
Marrow Transplantation in Children With
Goto H, Fujita N, Okada K, Okamoto Y, Bone Marrow
233 Acquired Bone Marrow Failure:
2020
Kato K, Inoue M, Suzuki R, Atsuta Y,
Transplant
Fludarabine/Melphalan vs.
Kojima S; Pediatric Aplastic Anemia
Fludarabine/Cyclophosphamide.
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

55(7):127 WGP
2-81.
11-6

Impact of cyclophosphamide dose of
conditioning on the outcome of allogeneic
234 hematopoietic stem cell transplantation
for aplastic anemia from human leukocyte
antigen-identical sibling.

103(4):46 WGP
1-8.
12-1

Mori T, Koh H, Onishi Y, Kako S, Onizuka
M, Kanamori H, Ozawa Y, Kato C, Iida H,
Int J Hematol 2016
Suzuki R, Ichinohe T, Kanda Y, Maeda T,
Nakao S, Yamazaki H.

Onishi Y, Mori T, Kako S, Koh H, Uchida
N, Kondo T, Kobayashi T, Yabe H,
Outcome of Second Transplantation Using Miyamoto T, Kato K, Suzuki R, Nakao S,
Umbilical Cord Blood for Graft Failure
Yamazaki H; Adult Aplastic Anemia
235
after Allogeneic Hematopoietic Stem Cell Working Group of the Japan Society forTransplantation for Aplastic Anemia.
Hematopoietic Cell Transplantation.

Biol Blood
Marrow
Transplant

2017

Mori T, Onishi Y, Ozawa Y, Kato C, Kai T,
Outcome of allogeneic hematopoietic
Kanda Y, Kurokawa M, Tanaka M, Ashida
236 stem cell transplantation in adult patients
Int J Hematol 2019
T, Sawayama Y, Fukuda T, Ichinohe T,with hepatitis-associated aplastic anemia.
Atsuta Y, Yamazaki H.
Kako S, Yamazaki H, Ohashi K, Ozawa Y,
Ota S, Kanda Y, Maeda T, Kato J,
Mixed Chimerism and Secondary Graft
Ishiyama K, Matsuoka KI, Miyamoto T,
Biol Blood
237 Failure in Allogeneic Hematopoietic Stem Iida H, Ikegame K, Fukuda T, Ichinohe T, Marrow
2020
Cell Transplantation for Aplastic Anemia. Atsuta Y, Mori T; Adult Aplastic Anemia Transplant
Working Group of the Japanese Societyfor Hematopoietic Cell Transplantation.

23(12):21 WGP
37-42.
12-2

109(6):71 WGP
1-7.
12-3

26(3):445 WGP
-50.
12-4

Cyclosporine/methotrexate versus
tacrolimus/methotrexate with or without
238 anti-thymocyte globulin as GVHD
prophylaxis in adult patients with aplastic
anemia.

Onishi Y, Mori T, Yamazaki H, Takenaka
K, Yamaguchi H, Shingai N, Ozawa Y, Iida
H, Ota S, Uchida N, Miyamoto T,
Katayama Y, Kato J, Yoshioka S, Onizuka
Ann Hematol 2021
M, Ichinohe T, Atsuta Y; Adult Aplastic
Anemia Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

Nakamura Y, Takenaka K, Yamazaki H,
Outcome of allogeneic hematopoietic
Onishi Y, Ozawa Y, Ikegame K, Matsuoka
239 stem cell transplantation in adult patients
Int J Hematol 2021
KI, Toubai T, Ueda Y, Kanda Y, Ichinohewith paroxysmal nocturnal hemoglobinuria.
T, Atsuta Y, Mori T.
Hiramoto N, Yamazaki H, Nakamura Y,
Total body irradiation-containing
Uchida N, Murata M, Kondo T, Yoshioka
conditioning regimens without
S, Eto T, Nishikawa A, Kimura T, Ichinohe
240 antithymocyte globulin in adults withT, Atsuta Y, Onishi Y, Suzuki R, Mori T; Ann Hematol 2022
aplastic anemia undergoing umbilical cord Adult Aplastic Anemia Working Group ofblood transplantation.
the Japanese Society for Hematopoietic
Cell Transplantation.
Outcome of peripheral blood stem cell
Nakamura Y, Mori T, Kako S, Yamazaki H, Internationaltransplantation from HLA-identical sibling241
Kanda Y, Uchida N, Tanaka M, Nawa Y,
Journal ofdonors for adult patients with aplastic
Fukuda T, Ichinohe T, Atsuta Y, Onishi Y. Hematology
anemia.
Ishida T, Hishizawa M, Kato K, Tanosaki
Allogeneic hematopoietic stem cell
R, Fukuda T, Taniguchi S, Eto T,transplantation for adult T-cell leukemiaTakatsuka Y, Miyazaki Y, Moriuchi Y,
242 lymphoma with special emphasis on
Blood
2012
Hidaka M, Akashi K, Uike N, Sakamaki H,
preconditioning regimen: a nationwide
Morishima Y, Kato K, Suzuki R,
retrospective study.
Nishiyama T, Utsunomiya A.

100(1):21 WGP
7-28.
12-5

113(1):12 WGP
2-7.
12-6

101(1):16 WGP
5-75.
12-7

in pressWGP
12-8

120(8):17 WGP
34-41.
13-1

Impact of graft-versus-host disease on
allogeneic hematopoietic cell
243 transplantation for adult T cell leukemialymphoma focusing on preconditioning
regimens: nationwide retrospective study.

Ishida T, Hishizawa M, Kato K, Tanosaki
R, Fukuda T, Takatsuka Y, Eto T,
Miyazaki Y, Hidaka M, Uike N, Miyamoto
T, Tsudo M, Sakamaki H, Morishima Y,
Suzuki R, Utsunomiya A.

Biol Blood
Marrow
Transplant2013

19(12):17 WGP
31-9.
13-2

Treatment of patients with adult T cellleukemia/lymphoma with cord blood244
transplantation: a Japanese nationwide
retrospective survey.

Kato K, Choi I, Wake A, Uike N, Taniguchi
S, Moriuchi Y, Miyazaki Y, Nakamae H,
Biol Blood
Oku E, Murata M, Eto T, Akashi K,
Marrow
Sakamaki H, Kato K, Suzuki R, Yamanaka Transplant
T, Utsunomiya A.

2014

20(12):19 WGP
68-74.
13-3

Early application of related SCT might
245 improve clinical outcome in adult T-cellleukemia/lymphoma.

Fuji S, Fujiwara H, Nakano N, Wake A,
Inoue Y, Fukuda T, Hidaka M, Moriuchi Y,
Miyamoto T, Uike N, Taguchi J, Eto T,
Bone Marrow
Tomoyose T, Kondo T, Yamanoha A,
2016
Transplant
Ichinohe T, Atsuta Y, Utsunomiya A; ATL
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

51(2):205 WGP
-11.
13-4

Dismal outcome of allogeneic
hematopoietic stem cell transplantation
246 for relapsed adult T-cellleukemia/lymphoma, a Japanese nationwide study.

Fujiwara H, Fuji S, Wake A, Kato K,
Takatsuka Y, Fukuda T, Taguchi J,
Uchida N, Miyamoto T, Hidaka M,
Miyazaki Y, Tomoyose T, Onizuka M,
Bone Marrow
2017
Takanashi M, Ichinohe T, Atsuta Y,
Transplant
Utsunomiya A; ATL Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

52(3):484 WGP
-8.
13-5

Risk Assessment in Adult T Cell
Leukemia/Lymphoma Treated with
247 Allogeneic Hematopoietic Stem Cell
Transplantation.

Yoshimitsu M, Tanosaki R, Kato K, Ishida
T, Choi I, Takatsuka Y, Fukuda T, Eto T,
Hidaka M, Uchida N, Miyamoto T,
Nakashima Y, Moriuchi Y, Nagafuji K,
Biol Blood
Miyazaki Y, Ichinohe T, Takanashi M,
Marrow
Atsuta Y, Utsunomiya A; ATL Working
TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.

201824(4):832 WGP
-9.
13-6

The outcome and characteristics ofpatients with relapsed adult T cell248
leukemia/lymphoma after allogeneic
hematopoietic stem cell transplantation.

Kato K, Uike N, Wake A, Yoshimitsu M,
Tobai T, Sawayama Y, Takatsuka Y,
Fukuda T, Uchida N, Eto T, Nakashima Y,
Kondo T, Taguchi J, Miyamoto T,
HematologicalNakamae H, Ichinohe T, Kato K, Suzuki
2019
Oncology
R, Utsunomiya A; ATL Working Group of
the Japan Society for Hematopoietic
Cell Transplantation.

Yoshimitsu M, Utsunomiya A, Fuji S,
A retrospective analysis of haplo-identical Fujiwara H, Fukuda T, Ogawa H,
HLA-mismatch hematopoietic
Takatsuka Y, Ishitsuka K, Yokota A,
transplantation without
Okumura H, Ishii K, Nishikawa A, Eto T, Bone Marrow249
2019
posttransplantation cyclophosphamide for Yonezawa A, Miyashita K, Tsukada J,
Transplant
GVHD prophylaxis in patients with adult
Tanaka J, Atsuta Y, Kato K; ATL Working
T-cell leukemia-lymphoma.
Group of the Japan Society for
Hematopoietic Cell Transplantation.

37(1):54- WGP
61.
13-7

54(8):126 WGP
6-74.
13-8

Cytomegalovirus reactivation isassociated with increased mortality more
250 than 100 days after allogeneic
hematopoietic stem cell transplantation
for adult T-cell leukemia/lymphoma.

Sawayama Y, Itonaga H, Fukushima T,
Nakano N, Fujiwara H, Utsunomiya A,
Fukuda T, Miyamoto T, Eto T, Miyashita
Am J
K, Nakamae H, Ogata M, Yamanoha A,
HematolMiyazaki Y, Kanda J, Atsuta Y, Kato K;
ATL Working Group of the Japan Societyfor Hematopoietic Cell Transplantation.

2019

94(5):E14 WGP
3-6.
13-9

Outcomes of Allogeneic Hematopoietic
251 Stem Cell Transplantation for ATL with
HTLV-1 Antibody-Positive Donors.

Yoshimitsu M, Fuji S, Utsunomiya A,
Nakano N, Ito A, Ito Y, Miyamoto T,
Suehiro Y, Kawakita T, Moriuchi Y,
Biol Blood
Nakamae H, Kanda Y, Ichinohe T, Fukuda Marrow
T, Atsuta Y, Kato K; ATL Working Group Transplantof the Japan Society for Hematopoietic
Cell Transplantation.

2020

26(4):718 WGP
-22.
13-10

Fuji S, Kurosawa S, Inamoto Y, Nakano
N, Miyazaki Y, Miyashita K, Hidaka M, Eto
Does an increased probability of graft‐vs‐
T, Uchida N, Ito A, Sawayama Y,
host disease improve the survival of
Miyamoto T, Suzumiya J, Utsunomiya A, Adv Cell
252 patients with adult T‐cell leukemia‐
Kanda J, Atsuta Y, Fukuda T, Kato K, on Gene Therlymphoma? A simulation analysis using abehalf of Adult T‐cell Leukemia‐Working
Markov model.
Group of Japan Society of
Hematopoietic Cell Transplantation.

2019

2:e56.

Muranushi H, Shindo T, Hishizawa M,
Tokunaga M, Wake A, Nakano N, Eto T,
GVHD-free, relapse-free survival provides Hidaka M, Choi I, Miyamoto T, Uchida N,
novel clues for optimizing allogeneicMoriuchi Y, Miyazaki Y, Fukuda T,
Bone Marrow
253
2021
HSCT for adult T-cell
Ichinohe T, Atsuta Y; ATL Working Group Transplantleukemia/lymphoma.
of the Japanese Society for
Hematopoietic Cell Transplantation, KatoK.
Chromosomal defects and survival inpatients with adult T-cell254
leukemia/lymphoma after allogeneic
HSCT.

Nakano N, Utsunomiya A, Matsuo K,
Yoshida N, Seto M, Ohshima K, Fujiwara
H, Fuji S, Takatsuka Y, Ito A, Miyamoto Blood
T, Suehiro Y, Nakamae H, Sawayama Y, Advances
Yuasa M, Miyazaki Y, Ota S, Imada K,
Fukuda T, Ichinohe T, Atsuta Y, Kato K.

2021

Inoue Y, Nakano N, Fuji S, Eto T,
Kawakita T, Suehiro Y, Miyamoto T,
Sawayama Y, Uchida N, Kondo T, Kanda
Bone Marrow
J, Atsuta Y, Fukuda T, Yoshimitsu M,
2021
Transplant
Kato K; ATL Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.
Utsunomiya A, Tokunaga M, Nakano N,
Fujiwara H, Miyamoto T, Ogata M,
Long-term follow-up of patients with ATL
Bone Marrow
256
Miyazaki Y, Ishitsuka K, Sakaida E, Taji H,
2022
after autologous stem cell transplantation.
Transplant
Wakayama T, Ichinohe T, Fukuda T,
Atsuta Y, Kato K, Yoshimitsu M.
Impact of conditioning intensity andregimen on transplant outcomes in255
patients with adult T-cell leukemialymphoma.

WGP
13-11

56(1):155 WGP
-66.
13-12

5(2):475- WGP
86.
13-13

56(12):29 WGP
64-74.
13-14

57(2):323 WGP
-5.
13-15

Changing trends in prognostic factors forpatients with multiple myeloma after
257 autologous stem cell transplantation
during the immunomodulator
drug/proteasome inhibitor era.

Takamatsu H, Honda S, Miyamoto T,
Yokoyama K, Hagiwara S, Ito T, Tomita
N, Iida S, Iwasaki T, Sakamaki H, Suzuki
R, Sunami K.

2015

106(2):17 WGP
9-85.
14-1

2015

21(7):129 WGP
1-8.
14-2

2016

57(9):207 WGP
7-83.
14-3

2018

139(1):35 WGP
-44.
14-4

2019

25(3):474 WGP
-9.
14-5

Bone Marrow
2019
Transplant54(10):15 WGP
95-604.
14-6

Hematological2019
Oncology

37(5):586 WGP
-94.
14-7

Cancer Sci

Kawamura K, Takamatsu H, Ikeda T,
Komatsu T, Aotsuka N, Amano I,
Biol Blood
Yamamoto G, Watanabe K, Ohno Y,
Marrow
Matsue K, Kouzai Y, Tsukada N, Ishiyama
Transplant
K, Anzai N, Kato K, Suzuki R, Sunami K,
Kanda Y.
Kawamura K, Ikeda T, Hagiwara S, Mori
Tandem autologous versus
T, Shinagawa A, Nishiwaki K, Ohashi K,
autologous/allogeneic transplantation for
Leuk
259
Kubonishi S, Fukuda T, Ito T, Tomita N,
multiple myeloma: propensity score
LymphomaIchinohe T, Kato K, Morishima Y, Atsuta
analysis.
Y, Sunami K, Kanda Y.
Significance of Salvage Autologous Stem Muta T, Miyamoto T, Kamimura T, Kanda
Cell Transplantation for Relapsed Multiple Y, Nohgawa M, Ueda Y, Iwato K, Sasaki Acta
260
Myeloma: A Nationwide Retrospective
O, Mori T, Uchida N, Iida S, Fukuda T,
HaematolStudy in Japan.
Atsuta Y, Sunami K.
Cord Blood Transplantation for Multiple
Myeloma:A Study from the Multiple
258 Myeloma Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

Takamatsu H, Yamashita T, Kurahashi S,
Clinical Implications of t(11;14) in Patients Saitoh T, Kondo T, Maeda T, Nakazawa Biol Blood
261 with Multiple Myeloma Undergoing
H, Murata M, Narita T, Kuroda J,
Marrow
Autologous Stem Cell Transplantation.
Hashimoto H, Kawamura K, Miyamoto T, Transplant
Honda S, Ichinohe T, Atsuta Y, Sunami K.
Mizuno S, Kawamura K, Hanamura I,
Efficacy and safety of autologous stem
Sunami K, Mori T, Nakamura F, Iida S,
cell transplantation in patients aged ≥ 65
262
Nakazawa H, Makita M, Kako S, Sawa M,
years with multiple myeloma in the era of
Ueda Y, Takahashi H, Kanda Y, Ichinohe
novel agents.
T, Atsuta Y, Takamatsu H, Takami A.
Ikeda T, Mori K, Kawamura K, Mori T,
Comparison between autologous andHagiwara S, Ueda Y, Kahata K, Uchida N,
allogeneic stem cell transplantation as
Tsukada N, Murakami S, Yamamoto M,
263 salvage therapy for multiple myeloma
Takahashi T, Ichinohe T, Onizuka M,
relapsing/progressing after autologous
Atsuta Y, Kanda Y, Okamoto S, Sunami
stem cell transplantation.
K, Takamatsu H.

Improved survival of multiple myeloma
patients treated with autologous
264
transplantation in the modern era of new
medicine.

Shimazu Y, Mizuno S, Fuchida SI, Suzuki
K, Tsukada N, Hanagaishi A, Itagaki M,
Kataoka K, Kako S, Sakaida E, Yoshioka
S, Iida S, Doki N, Oyake T, Ichinohe T,
Cancer Sci
Kanda Y, Astuta Y, Takamatsu H; working
group of the Japan Society forTransplantation, Cellular Therapy.

2021

112(12):5 WGP
034-45.
14-8

Retrospective Analysis of Autologous
Stem Cell Transplantation for AL
Amyloidosis: A Study from the Multiple
265
Myeloma Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

Fuchida SI, Kawamura K, Sunami K,
Tsukada N, Fujii S, Ohkawara H, Usuki K,
Transplant
Wake A, Endo S, Ishiyama K, Ueda Y,
Cell Ther
Nakamura Y, Miyamoto T, Fukuda T,
Ichinohe T, Atsuta Y, Takamatsu H.

2022

28(2):76- WGP
82.
14-9

Autologous hematopoietic celltransplantation for myeloma patients with266
hepatitis B virus or hepatitis C virus in
the era of novel agents.

Mizuno S, Takami A, Takamatsu H,
Hanamura I, Shimazu Y, Hangaishi A,
Tsukada N, Kako S, Kikuchi T, Ota S,
Bone Marrow
2022
Shimizu H, Iida S, Yoshioka S, Sawa M, Transplant
Fukuda T, Kanda Y, Atsuta Y, KawamuraK.
山本将平，渡邊健一郎，井上雅美，橋井 日本小児血佳子，菊田 敦，金子 隆，加藤剛二，原 液・がん学会 2017
純一，田渕 健，高橋義行.
雑誌

Efficacy of high-dose chemotherapy with
267 stem cell transplantation
for hepatoblastoma in Japan.
Autologous Stem Cell Transplantation for
Kobayashi R, Inoue M, Takahashi Y,Children With Renal Tumors, and Adults
J Pediatr
Kikuta A, Ogawa A, Koga Y, Koh K, Hashii
268 With Wilms Tumor: Retrospective Analysis
Hematol
Y, Hara J, Kato K, Tabuchi K, Matsumotoof the Japanese Transplant Registry
Oncol
K.
Unified Management Program.

2020

57(5):846 WGP
-8.
14-10

54(2):126 WGP
-32.
15-1

42(4):251 WGP
-5.
15-2

Effect of high-dose chemotherapy plus
Saito Y, Urashima M, Takahashi Y,
stem cell rescue on the survival of
Ogawa A, Kiyotani C, Yuza Y, Koh K,
patients with neuroblastoma modified byBone Marrow
269
Watanabe K, Kosaka Y, Goto H, Kikuta A,
2021
MYCN gene gain/amplification andTransplant
Okada K, Koga Y, Fujimura J, Inoue M,
remission status: a nationwide registration
Sato A, Atsuta Y, Matsumoto K.
study in Japan.
Umeda K, Adachi S, Tanaka S, Miki M,
Comparison of second transplantation and Okada K, Hashii Y, Inoue M, Cho Y, Kohdonor lymphocyte infusion for donor
K, Goto H, Kajiwara R, Hyakuna N, Kato Pediatr Blood
270
2016
mixed chimerism after allogeneic stem cell K, Morio T, Yabe H; Inherited Disease
Cancertransplantation for nonmalignant diseases. Working Group of the Japan Society for
Hematopoietic Cell Transplantation.
Horikoshi Y, Umeda K, Imai K, Yabe H,
Allogeneic Hematopoietic Stem Cell
Sasahara Y, Watanabe K, Ozawa Y,
J Pediatr
Transplantation for Leukocyte Adhesion
271
Hashii Y, Kurosawa H, Nonoyama S,
Hematol
2018
Deficiency.
Morio T.
Oncol

Impact of low-dose irradiation and in vivo
T-cell depletion on hematopoietic stem
272 cell transplantation for non-malignant
diseases using fludarabine-based
reduced-intensity conditioning.

Umeda K, Yabe H, Kato K, Imai K,
Kobayashi M, Takahashi Y, Yoshida N,
Sato M, Sasahara Y, Kato K, Adachi S,
Koga Y, Okada K, Inoue M, Hashii Y,
Atsuta Y, Morio T; Inherited Disease
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

56(9):217 WGP
3-82.
15-3

63(12):22 WGP
21-9.
16-1

40(2):137 WGP
-40.
16-2

Bone Marrow
2019
Transplant54(8):122 WGP
7-36.
16-3

Iguchi A, Cho Y, Yabe H, Kato S, Kato K,
Long-term outcome and chimerism inHara J, Koh K, Takita J, Ishihara T, Inouepatients with Wiskott-Aldrich syndrome
M, Imai K, Nakayama H, Hashii Y,
273 treated by hematopoietic cell
Morimoto A, Atsuta Y, Morio T;
Int J Hematol 2019transplantation: a retrospective nationwide Hereditary disorder Working Group of thesurvey.
Japan Society for Hematopoietic Cell
Transplantation.

110(3):36 WGP
4-9.
16-4

Umeda K, Imai K, Yanagimachi M, Yabe H,
Kobayashi M, Takahashi Y, Kajiwara M,
Yoshida N, Cho Y, Inoue M, Hashii Y,
Int J Hematol 2020
Atsuta Y, Morio T; Inherited Disease
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.
Yabe M, Morio T, Tabuchi K, Tomizawa
Long-term outcome in patients with
D, Hasegawa D, Ishida H, Yoshida N,
Fanconi anemia who received
Koike T, Takahashi Y, Koh K, Okamoto Y,
275
Int J Hematol 2021
hematopoietic stem cell transplantation: a Sano H, Kato K, Kanda Y, Goto H, Takita
retrospective nationwide analysis.
J, Miyamura T, Noguchi M, Kato K, Hashii
Y, Astuta Y, Yabe H.
Yanagimachi M, Kato K, Iguchi A, Sasaki
K, Kiyotani C, Koh K, Koike T, Sano H,
Hematopoietic Cell Transplantation for
Shigemura T, Muramatsu H, Okada K,
Front
276
2020
Chronic Granulomatous Disease in Japan. Inoue M, Tabuchi K, Nishimura T,
Immunol
Mizukami T, Nunoi H, Imai K, Kobayashi
M, Morio T.
Impact of Graft-Versus-Host Disease on
the Clinical Outcome of Allogeneic
274
Hematopoietic Stem Cell Transplantation
for Non-Malignant Diseases.

111(6):86 WGP
9-76.
16-5

113(1):13 WGP
4-44.
16-6

11:1617.

WGP
16-7

Miyamoto S, Umeda K, Kurata M,
Nishimura A, Yanagimachi M, Ishimura M,
Hematopoietic Cell Transplantation for
Sato M, Shigemura T, Kato M, Sasahara J Clin
277 Severe Combined Immunodeficiency
Y, Iguchi A, Koike T, Takahashi Y,
Immunol
Patients: a Japanese Retrospective Study.
Kajiwara M, Inoue M, Hashii Y, Yabe H,
Kato K, Atsuta Y, Imai K, Morio T.

2021

41(8):186 WGP
5-77.
16-8

Stem cell transplantation for pediatricpatients with adrenoleukodystrophy: A
278
nationwide retrospective analysis inJapan.

2022

26(1):e14 WGP
125.
16-9

2022

42(3):529 WGP
-45.
16-10

Hematopoietic Cell Transplantation forInborn Errors of Immunity Other than279 Severe Combined Immunodeficiency inJapan: Retrospective Analysis for 19852016.

Kato K, Yabe H, Shimozawa N, Adachi S,
Kurokawa M, Hashii Y, Sato A, Yoshida Pediatr
N, Kaga M, Onodera O, Kato S, Atsuta Y, TransplantMorio T.
Miyamoto S, Umeda K, Kurata M,
Yanagimachi M, Iguchi A, Sasahara Y,
Okada K, Koike T, Tanoshima R, Ishimura
J ClinM, Yamada M, Sato M, Takahashi Y,
Immunol
Kajiwara M, Kawaguchi H, Inoue M, Hashii
Y, Yabe H, Kato K, Atsuta Y, Imai K,
Morio T.

Graft-versus-host disease-free, relapsefree, second transplant-free survival in
280
allogeneic hematopoietic celltransplantation for genetic disorders.

Kawaguchi K, Umeda K, Miyamoto S,
Yoshida N, Yabe H, Koike T, Kajiwara M,
Kawaguchi H, Takahashi Y, Ishimura M,
Sakaguchi H, Hama A, Cho Y, Sato M,
Kato K, Sato A, Kato K, Tabuchi K,
Atsuta Y, Imai K.

Impact of a single human leucocyte
antigen (HLA) allele mismatch on theoutcome of unrelated bone marrow
Kanda Y, Kanda J, Atsuta Y, Maeda Y,
transplantation over two time periods. A Ichinohe T, Ohashi K, Fukuda T,
281
retrospective analysis of 3003 patients
Miyamura K, Iida H, Mori T, Iwato K, Etofrom the HLA Working Group of the Japan T, Kawa K, Morita S, Morishima Y.
Society for Blood and Marrow
Transplantation.

Bone Marrow
Transplant

Br J
Haematolin press

2013

Tanaka J, Morishima Y, Takahashi Y,
Yabe T, Oba K, Takahashi S, Taniguchi S,
Blood Cancer
Ogawa H, Onishi Y, Miyamura K,
2013
J
Kanamori H, Aotsuka N, Kato K, Kato S,
Atsuta Y, Kanda Y.
Atsuta Y, Kanda J, Takanashi M,
Morishima Y, Taniguchi S, Takahashi S,
Different effects of HLA disparity on
Ogawa H, Ohashi K, Ohno Y, Onishi Y,
transplant outcomes after single-unit cord
Haematologic
283
Aotsuka N, Nagamura-Inoue T, Kato K,
2013
blood transplantation between pediatricaKanda Y; HLA Working Group of theand adult patients with leukemia.
Japan Society for Hematopoietic Cell
Transplantation.
Effects of KIR ligand incompatibility on
clinical outcomes of umbilical cord blood282
transplantation without ATG for acuteleukemia in complete remission.

Impact of the direction of HLA mismatch
284 on transplantation outcomes in single
unrelated cord blood transplantation.

Kanda J, Atsuta Y, Wake A, Ichinohe T,
Takanashi M, Morishima Y, Taniguchi S,
Takahashi S, Ogawa H, Ohashi K, Ohno
Y, Aotsuka N, Onishi Y, Kato K,
Nagamura-Inoue T, Kanda Y; HLA
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

WGP
16-11

161(4):56 WGP
6-77.
17-1

3:e164.

WGP
17-2

98(5):814 WGP
-22.
17-3

Biol Blood
Marrow
Transplant2013

19(2):247 WGP
-54.
17-4

Kanda Y, Kanda J, Atsuta Y, Fuji S,
Maeda Y, Ichinohe T, Takanashi M,
Changes in the clinical impact of high-risk
Ohashi K, Fukuda T, Miyamura K, Mori T, Biol Blood
human leukocyte antigen allele mismatch
285
Sao H, Kobayashi N, Iwato K, Sawada A, Marrowcombinations on the outcome of unrelatedMori S; HLA working group of the Japan Transplantbone marrow transplantation.
Society for Hematopoietic Cell
Transplantation.

2014

20(4):526 WGP
-35.
17-5

Kanda J, Fuji S, Kato S, Takami A,
Tanaka J, Miyamura K, Ohashi K, Fukuda
T, Ozawa Y, Kanamori H, Eto T,
Decision analysis for donor selection in
Kobayashi N, Iwato K, Morishima Y,
stem cell transplantation-HLA-8/8 alleleBlood Cancer
286
Sakamaki H, Atsuta Y, Kanda Y; HLA
2014
matched unrelated donor vs HLA-1 AG
J
Working Group; Donor/Source Working
mismatched related donor.
Group; Adult AML Working Group; Adult
ALL Working Group of the Japan Societyfor Hematopoietic Cell Transplantation.

Impact of HLA allele mismatch on the
287 clinical outcome in serologically matched
related hematopoietic SCT.

Fuji S, Kanda J, Kato S, Ikegame K,
Morishima S, Miyamoto T, Hidaka M,
Kubo K, Miyamura K, Ohashi K,
Kobayashi H, Maesako Y, Adachi S,
Ichinohe T, Atsuta Y, Kanda Y; HLA
Working Group of Japan Society for
Hematopoietic Cell Transplantation.

Bone Marrow
2014
Transplant

Kanda J, Ichinohe T, Fuji S, Maeda Y,
Impact of HLA mismatch direction on the Ohashi K, Fukuda T, Miyamura K, Iwato
outcome of unrelated bone marrow
K, Eto T, Nakamae H, Kobayashi N, Mori Biol Blood
288 transplantation: a retrospective analysis
T, Mori S, Morishima Y, Atsuta Y, Kanda Marrowfrom the Japan Society for Hematopoietic Y; HLA Working Group of the Japan
Transplant
Cell Transplantation.
Society for Hematopoietic Cell
Transplantation.

2015

4:e263.

WGP
17-6

49(9):118 WGP
7-92.
17-7

21(2):305 WGP
-11.
17-8

A single high-resolution HLA mismatch
has a similar adverse impact on the
289 outcome of related hematopoietic stem
cell transplantation as a single lowresolution HLA mismatch.

Fuji S, Kanda J, Kato S, Ikegame K,
Morishima S, Miyamoto T, Hidaka M,
Kubo K, Miyamura K, Tsudo M, Kobayashi
Am J
H, Maesako Y, Eto T, Adachi S, Ichinohe
HematolT, Atsuta Y, Kanda Y; HLA Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

2015

90(7):618 WGP
-23.
17-9

Unrelated bone marrow transplantation or
immediate umbilical cord blood
290 transplantation for patients with acute
myeloid leukemia in first complete
remission.

Yanada M, Kanda J, Ohtake S, Fukuda T,
Sakamaki H, Miyamura K, Miyawaki S,
Uchida N, Maeda T, Nagamura-Inoue T, Eur J
Asou N, Morishima Y, Atsuta Y, Miyazaki HaematolY, Kimura F, Kobayashi Y, Takami A,
Naoe T, Kanda Y.

2016

97(3):278 WGP
-87.
17-10

Influence of Differently Licensed
KIR2DL1-Positive Natural Killer Cells in
291 Transplant Recipients with Acute
Leukemia: A Japanese National Registry
Study.

Arima N, Nakamura F, Yabe T, Tanaka J,
Fuji S, Ohashi K, Fukuda T, Miyamura K, Biol Blood
Iwato K, Eto T, Mori T, Kobayashi N,
Marrow
Hoshino T, Kato C, Kanamori H, Nakamae Transplant
H, Atsuta Y, Morishima Y, Kanda Y.

201622(3):423 WGP
-31.
17-11

Haploidentical and Matched Sibling Donor
Hematopoietic Cell Transplantation for
292
Patients with HLA-Homozygous
Haplotypes.

Kanda J, Ikegame K, Fuji S, Kurokawa M,
Kanamori H, Fukuda T, Ohashi K,
Biol Blood
Ishikawa J, Ogawa H, Inoue M, Ichinohe
Marrow
T, Atsuta Y, Kanda Y; HLA Working
TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.

2016

22(11):20 WGP
31-7.
17-12

2017

23(2):300 WGP
-9.
17-13

Yokoyama H, Kanda J, Fuji S, Kim SW,
Fukuda T, Najima Y, Ohno H, Uchida N,
Impact of Human Leukocyte Antigen Allele Ueda Y, Eto T, Iwato K, Kobayashi H,
Biol Blood
Mismatch in Unrelated Bone Marrow
Ozawa Y, Kondo T, Ichinohe T, Atsuta Y,
293
Marrow
Transplantation with Reduced-Intensity
Kanda Y; HLA Working Group of theTransplant
Conditioning Regimen.
Japan Society for Hematopoietic Cell
Transplantation.

Impact of the presence of HLA 1-locus
mismatch and the use of low-dose294
antithymocyte globulin in unrelated bonemarrow transplantation.

Homozygous HLA-C1 is Associated with
Reduced Risk of Relapse after HLA295
Matched Transplantation in Patients with
Myeloid Leukemia.

Comparison of HLA Allele Mismatch andAntigen Mismatch in Unrelated Bone
296
Marrow Transplantation in Patients with
Leukemia.

HLA discrepancy between graft and host297 rather than that graft and first donor
impact the second transplant outcome.

Kawamura K, Kanda J, Fuji S, Murata M,
Ikegame K, Yoshioka K, Fukuda T, Ozawa
Y, Uchida N, Iwato K, Sakura T, Hidaka
Bone Marrow
2017
M, Hashimoto H, Ichinohe T, Atsuta Y,
Transplant
Kanda Y.
Arima N, Kanda J, Tanaka J, Yabe T,
Morishima Y, Kim SW, Najima Y, Ozawa
Biol Blood
Y, Eto T, Kanamori H, Mori T, Kobayashi
Marrow
2018
N, Kondo T, Nakamae H, Uchida N, Inoue
TransplantM, Fukuda T, Ichinohe T, Atsuta Y, Kanda
Y.
Atsuta Y , Kato S , Morishima Y , Ohashi
K , Fukuda T , Ozawa Y , Eto T , Iwato K
Biol Blood, Uchida N , Ota S , Onizuka M , Ichinohe
Marrow
2019
T , Kanda J , Kanda Y ; HLA Working
TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.
Maeda Y , Ugai T , Kondo E , Ikegame K ,Murata M , Uchida N , Miyamoto T ,Takahashi S , Ohashi K , Nakamae H ,Haematologic
2019
Fukuda T , Onizuka M , Eto T , Ota S ,aHirokawa M , Ichinohe T , Atsuta Y ,Kanda Y , Kanda J.

Yokoyama H, Kanda J, Kato S, Kondo E,
Maeda Y, Saji H, Takahashi S, Onizuka M,
Effects of HLA mismatch on
Onishi Y, Ozawa Y, Kanamori H, Ishikawa
Bone Marrow
298 cytomegalovirus reactivation in cord blood J, Ohno Y, Ichinohe T, Takanashi M, Kato
2019
Transplanttransplantation.
K, Atsuta Y, Kanda Y; HLA Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

52(10):13 WGP
90-8.
17-14

24(4):717 WGP
-25.
17-15

25(3):436 WGP
-42.
17-16

104(5):10 WGP
55-61.
17-17

54(7):100 WGP
4-12.
17-18

Clinical significance of low-dose total
body irradiation in HLA-mismatched299
reduced-intensity stem celltransplantation.

Fujiwara SI, Kanda J, Tatara R, Ogawa H,
Fukuda T, Okumura H, Ohashi K, Iwato K,
Ueda Y, Ishiyama K, Eto T, Matsuoka KI,
Bone Marrow
Nakamae H, Onizuka M, Atsuta Y, Kanda
2019
Transplant
Y, HLA Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

54(8):132 WGP
7-36.
17-19

Effects of Haplotype Matching on
300 Outcomes after Adult Single-Cord Blood
Transplantation.

Kanda J, Kawase T, Tanaka H, Kojima H,
Morishima Y, Uchida N, Nagafuji K,
Matsuhashi Y, Ohta T, Onizuka M, Sakura
Biol Blood
T, Takahashi S, Miyakoshi S, Kobayashi
Marrow
H, Eto T, Tanaka J, Ichinohe T, Atsuta Y,
Transplant
Morishima S; HLA Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

2020

26(3):509 WGP
-18.
17-20

Impact of High-Frequency HLA
Haplotypes on Clinical Cytomegalovirus
301
Reactivation in Allogeneic Hematopoietic
Stem Cell Transplantation.

Kawase T, Tanaka H, Kojima H, Uchida N,
Ohashi K, Fukuda T, Ozawa Y, Ikegame
K, Eto T, Mori T, Miyamoto T, Hidaka M, Biol Blood
Shiratori S, Takanashi M, Atsuta Y,
Marrow
Ichinohe T, Kanda Y, Kanda J; HLA
Transplant
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

2019

25(12):24 WGP
82-9.
17-21

Impact of Homozygous Conserved
Morishima Y, Morishima S, Murata M,
Extended HLA Haplotype on Single Cord Arima N, Uchida N, Sugio Y, Takahashi S, Biol Blood
302 Blood Transplantation: Lessons for
Matsuhashi Y, Onizuka M, Eto T, Nagafuji Marrow
Induced Pluripotent Stem Cell Banking
K, Onishi Y, Inoue M, Atsuta Y, Fukuda T, Transplant
and Transplantation in Allogeneic Settings. Ichinohe T, Kato S, Kanda J.

2020

26(1):132 WGP
-8.
17-22

Int J Hematol 2019109(6):68 WGP
4-93.
17-23

Short-term clinical outcomes after HLA
1-locus mismatched uPBSCT are similar303
to that after HLA-matched uPBSCT anduBMT.

Fuji S, Miyamura K, Kanda Y, Fukuda T,
Kobayashi T, Ozawa Y, Iwato K, Uchida
N, Eto T, Ashida T, Mori T, Sawa M,
Ichinohe T, Atsuta Y, Kanda J; HLA
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

Yokoyama H, Morishima Y, Fuji S, Uchida
N, Takahashi S, Onizuka M, Tanaka M,
Impact of HLA Allele Mismatch at HLA-A, Yuju O, Eto T, Ozawa Y, Takada S,
Biol Blood
304 -B, -C, and -DRB1 in Single Cord Blood Takanashi M, Kato K, Kanda Y, Ichinohe Marrow
Transplantation.
T, Atsuta Y, Kanda J; HLA Working
TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.
Increased Relapse Risk of Acute
Arima N, Kanda J, Yabe T, Morishima Y,
Lymphoid Leukemia in Homozygous HLA- Tanaka J, Kako S, Sakaguchi H, Kato M, Biol Blood
305 C1 Patients after HLA-Matched
Ohashi K, Ozawa Y, Fukuda T, Ota S,
Marrow
Allogeneic Transplantation: A JapaneseTachibana T, Onizuka M, Ichinohe T,
Transplant
National Registry Study.
Atsuta Y, Kanda Y.
Kawamura K, Kanda J, Ohashi K, Fukuda
Influence of HLA 1-3-locus mismatch andT, Iwato K, Eto T, Fujiwara SI, Mori T,
306 antithymocyte globulin administration in
Ann Hematol
Fukushima K, Ozawa Y, Uchida N, Ashidaunrelated bone marrow transplantation.
T, Ichinohe T, Atsuta Y, Kanda Y.
Morishima S, Fukuda T, Doki N, Mori T,
Onizuka M, Kawakita T, Kato C, Ozawa Y,
Individual HLAs influence immunological
Tanaka M, Kurokawa M, Kamimura T,
events in allogeneic stem cell
Bone Marrow
307
Inoue M, Tanaka J, Ichinohe T, Atsuta Y,
transplantation from HLA-identical sibling
Transplant
Morishima Y; HLA Working Group of thedonors.
Japan Society for Hematopoietic Cell
Transplantation.
Kawajiri A, Kawase T, Tanaka H, Fukuda
T, Mukae J, Ozawa Y, Eto T, Uchida N,
Human leukocyte antigen (HLA) haplotype Mori T, Ashida T, Kondo T, Onizuka M,
Bone Marrow
308 matching in unrelated single HLA allele
Ichinohe T, Atsuta Y, Morishima S, Kanda
Transplantmismatch bone marrow transplantation.
J; HLA Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

2020

26(3):519 WGP
-28.
17-24

2020

26(3):431 WGP
-7.
17-25

2020

99(5):109 WGP
9-110.
17-26

2021

56(3):646 WGP
-54.
17-27

in press

WGP
17-28

Shiratori S, Sugita J, Fuji S, Aoki J,
Sawa M, Ozawa Y, Hashimoto D,
Matsuoka KI, Imada K, Doki N, Ashida T, Bone Marrow
2021
Ueda Y, Tanaka M, Sawayama Y,
Transplant
Ichinohe T, Terakura S, Morishima S,
Atsuta Y, Fukuda T, Teshima T.
Fuji S, Hakoda A, Kanda J, Murata M,
Impact of HLA disparity on the risk ofTerakura S, Inamoto Y, Uchida N, Toya
overall mortality in patients with grade IIT, Eto T, Nakamae H, Ikegame K, Tanaka Bone Marrow
310 IV acute GVHD on behalf of the HLA
2021
M, Kawakita T, Kondo T, Miyamoto T,
Transplant
Working Group of Japan Society for
Fukuda T, Ichinohe T, Kimura T, Atsuta
Hematopoietic Cell Transplantation.
Y, Shintani A, Morishima S.
Yokoyama H, Kanda J, Kawahara Y,
Reduced leukemia relapse throughUchida N, Tanaka M, Takahashi S,
cytomegalovirus reactivation in killer cell Onizuka M, Noguchi Y, Ozawa Y,
Bone Marrow
311
2021
immunoglobulin-like receptor-ligandKatsuoka Y, Ota S, Ohta T, Kimura T,
Transplantmismatched cord blood transplantation.
Kanda Y, Ichinohe T, Atsuta Y, Nakasone
H, Morishima S.
Low-dose antithymocyte globulin inhibits
chronic graft-versus-host disease in309
peripheral blood stem cell transplantationfrom unrelated donors.

56(9):223 WGP
1-40.
17-29

56(12):29 WGP
90-6.
17-30

56(6):135 WGP
2-63.
17-31

Yokoyama H, Hirayama M, Takahashi Y,
Altered effect of killer immunoglobulin-like Uchida N, Tanaka M, Onizuka M, Ozawa
receptor-ligand mismatch by graft versus Y, Onai D, Katsuoka Y, Wake A, Sawa M, Bone Marrow
312
2021
host disease prophylaxis in cord blood
Kobayashi H, Maruyama Y, Ozeki K,
Transplanttransplantation.
Kimura T, Kanda J, Fukuda T, Atsuta Y,
Terakura S, Morishima S.

56(12):30 WGP
59-67.
17-32

Kanda J, Hirabayashi S, Yokoyama H,
Kawase T, Tanaka H, Uchida N, Taniguchi
Effect of multiple HLA-locus mismatches
S, Takahashi S, Onizuka M, Tanaka M,
Transplant
313 on outcomes after single cord blood
Sugio Y, Eto T, Kanda Y, Kimura T,
Cell Thertransplantation.
Ichinohe T, Atsuta Y, Morishima S;
JSTCT HLA Working Group.

2022

28(7):398 WGP.e1-9.
17-33

Impact of human leukocyte antigen
mismatch on outcomes after unrelated
314 bone marrow transplantation in paediatricpatients: A retrospective analysis by the
JSTCT HLA working group.

Br J
Haematol

2022

199(3):39 WGP
2-400.
17-34

Kanda J, Ichinohe T, Kato S, Uchida N,
Terakura S, Fukuda T, Hidaka M, Ueda Y,
Unrelated cord blood transplantation vsKondo T, Taniguchi S, Takahashi S,
related transplantation with HLA 1Nagamura-Inoue T, Tanaka J, Atsuta Y,
315
Leukemia
antigen mismatch in the graft-versus-host Miyamura K, Kanda Y; Donor/Source
direction.
Working Group and HLA Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

2013

27(2):286 WGP
-94.
18-1

Kuwatsuka Y, Atsuta Y, Horowitz MM,
Inagaki J, Kanda J, Kato K, Koh K, Zhang
Graft-versus-host disease and survival
MJ, Eapen M; Center for International
Biol Blood
after cord blood transplantation for acute Blood and Marrow Transplant Research
316
Marrow
leukemia: a comparison of Japanese(CIBMTR), and Donor/Source and GVHD
Transplantversus White populations.
Working Group of the Japan Society for
Hematopoietic Cell Transplantation(JSHCT).

2014

20(5):662 WGP
-7.
18-2

2015

21(3):517 WGP
-25.
18-3

2016

22(2):330 WGP
-8.
18-4

Kato I, Sakaguchi H, Kato S, Sato M,
Noguchi M, Yoshida N, Koh K, Koike T,
Yanagimachi M, Kato K, Takahashi Y,
Fujita N, Sato A, Hashii Y, Tabuchi K,
Atsuta Y, Morishima S, Kanda J.

Tanaka M, Miyamura K, Terakura S, Imai
Comparison of cord blood transplantation
K, Uchida N, Ago H, Sakura T, Eto T,
Biol Bloodwith unrelated bone marrow
317
Ohashi K, Fukuda T, Taniguchi S, Mori S, Marrowtransplantation in patients older than fifty
Nagamura-Inoue T, Atsuta Y, Okamoto Transplant
years.
S.
Terakura S, Atsuta Y, Tsukada N,
Comparison of Outcomes of 8/8 and 7/8
Kobayashi T, Tanaka M, Kanda J, Najima
Allele-Matched Unrelated Bone Marrow
Biol Blood
Y, Fukuda T, Uchida N, Takahashi S,
318 Transplantation and Single-Unit Cord
Marrow
Nagamura-Inoue T, Morishima Y,
Blood Transplantation in Adults withTransplant
Miyamura K; Japan Society for
Acute Leukemia.
Hematopoietic Cell Transplantation.

Kumar R, Kimura F, Ahn KW, Hu ZH,
Kuwatsuka Y, Klein JP, Pasquini M,
Comparing Outcomes with Bone Marrow Miyamura K, Kato K, Yoshimi A, Inamotoor Peripheral Blood Stem Cells as Graft
Y, Ichinohe T, Wood WA Jr, Wirk B,
Biol Blood
319 Source for Matched Sibling Transplants in Seftel M, Rowlings P, Marks DI, Schultz Marrow
Severe Aplastic Anemia across Different KR, Gupta V, Dedeken L, George B, Cahn Transplant
Economic Regions.
JY, Szer J, Lee JW, Ho AY, Fasth A,
Hahn T, Khera N, Dalal J, Bonfim C,
Aljurf M, Atsuta Y, Saber W.

201622(5):932 WGP
-40.
18-5

Kanda J, Brazauskas R, Hu ZH,
Kuwatsuka Y, Nagafuji K, Kanamori H,
Kanda Y, Miyamura K, Murata M, Fukuda Biol Blood
T, Sakamaki H, Kimura F, Seo S, Aljurf M, Marrow
Yoshimi A, Milone G, Wood WA, Ustun C, Transplant
Hashimi S, Pasquini M, Bonfim C, Dalal J,
Hahn T, Atsuta Y, Saber W.

201622(4):744 WGP
-51.
18-6

Sakaguchi H, Watanabe N, Matsumoto K,
Yabe H, Kato S, Ogawa A, Inagaki J,
Goto H, Koh K, Yoshida N, Kato K, Cho Biol Blood
Y, Kosaka Y, Takahashi Y, Inoue M, Kato Marrow
K, Atsuta Y, Miyamura K; Donor/Source Transplant
Working Group of Japan Society of
Hematopoietic Cell Transplantation.

2016

22(12):22 WGP
26-34.
18-7

Kuwatsuka Y, Kanda J, Yamazaki H, Mori
T, Miyamura K, Kako S, Uchida N, Ohashi
A Comparison of Outcomes for Cord
K, Ozawa Y, Takahashi Y, Kato C, Iwato
Biol Blood
Blood Transplantation and Unrelated Bone K, Ishiyama K, Kobayashi H, Eto T,
322
Marrow
Marrow Transplantation in Adult Aplastic Kahata K, Kato J, Miyamoto T, Kato K,
Transplant
Anemia.
Mori S, Atsuta Y, Kimura F, Kanda Y;
Japan Society for Hematopoietic Cell
Transplantation.

2016

22(10):18 WGP
36-43.
18-8

Konuma T, Tsukada N, Kanda J, UchidaN, Ohno Y, Miyakoshi S, Kanamori H,
Comparison of transplant outcomes from Hidaka M, Sakura T, Onizuka M,
matched sibling bone marrow or peripheral Kobayashi N, Sawa M, Eto T, Matsuhashi Am J
323
blood stem cell and unrelated cord blood Y, Kato K, Ichinohe T, Atsuta Y,
Hematolin patients 50 years or older.
Miyamura K; Donor/Source Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

2016

91(5):E28 WGP
4-92.
18-9

Kimura F, Kanda J, Ishiyama K, Yabe T,
Yoshifuji K, Fukuda T, Ozawa Y, Iwato K,
Eto T, Mori T, Uchida N, Ota S, Sakura
Bone Marrow
T, Ichinohe T, Atsuta Y, Kanda Y;
2019
Transplant
donor/source working group of theJapan Society for Hematopoietic Cell
Transplantation.

54(10):16 WGP
76-85.
18-10

Graft-versus-Host Disease after HLAMatched Sibling Bone Marrow orPeripheral Blood Stem Cell
320
Transplantation: Comparison of North
American Caucasian and Japanese
Populations.

321

Comparison of Donor Sources in
Hematopoietic Stem Cell Transplantation
for Childhood Acute Leukemia: A
Nationwide Retrospective Study.

ABO blood type incompatibility lost the
324 unfavorable impact on outcome inunrelated bone marrow transplantation.

Kanda J, Hayashi H, Ruggeri A, Kimura F,
Volt F, Takahashi S, Labopin M, Kako S,
Prognostic factors for adult single cord
Tozatto-Maio K, Yano S, Sanz G, Uchidablood transplantation among European andN, Van Lint MT, Kato S, Mohty M,
325 Japanese populations: the
Leukemia
Forcade E, Kanamori H, Sierra J, Ohno Y,
Eurocord/ALWP-EBMT and
Saccardi R, Fukuda T, Ichinohe T,
JSHCT/JDCHCT collaborative study.
Takanashi M, Rocha V, Okamoto S,
Nagler A, Atsuta Y, Gluckman E.

202034(1):128 WGP
-37.
18-11

Improvement of early mortality in single326 unit cord blood transplantation forJapanese adults from 1998 to 2017.

Konuma T, Kanda J, Inamoto Y, Hayashi
H, Kobayashi S, Uchida N, Sugio Y,
Tanaka M, Kobayashi H, Kouzai Y,
Am JTakahashi S, Eto T, Mukae J, Matsuhashi Hematol
Y, Fukuda T, Takanashi M, Kanda Y,
Atsuta Y, Kimura F.

2020

95(4):343 WGP
-53.
18-12

Comparison of ReducedIntensity/Toxicity Conditioning Regimens
327
for Umbilical Cord Blood Transplantation
for Lymphoid Malignancies.

Imahashi N, Terakura S, Kondo E, Kako
S, Uchida N, Kobayashi H, Inamoto Y,
Sakai H, Tanaka M, Ishikawa J, Kozai Y,
Bone Marrow
Matsuoka KI, Kimura T, Fukuda T, Atsuta
2020
Transplant
Y, Kanda J; Donor/Source Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

55(11):20 WGP
98-108. 18-13

Miyao K, Terakura S, Kimura F, Konuma
T, Miyamura K, Yanada M, Kako S,
Updated Comparison of 7/8 HLA AlleleMorhishima S, Uchida N, Toya T, Ozawa
Matched Unrelated Bone Marrow
Biol Blood
Y, Fukuda T, Tanaka M, Sawa M, Takada
328 Transplantation and Single-Unit Umbilical
Marrow
S, Yoshida S, Kimura T, Ichinohe T,
Cord Blood Transplantation as Alternative
Transplant
Atsuta Y, Kanda J; Donor/Source
Donors in Adults with Acute Leukemia.
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

2020

26(11):21 WGP
05-14.
18-14

Kobayashi S, Kanda Y, Konuma T,
Outcomes of third allogeneic
Inamoto Y, Matsumoto K, Uchida N,
hematopoietic stem cell transplantation in Ikegame K, Miyamoto T, Doki N, Nakamae Bone Marrow329
2022
relapsed/refractory acute leukemia after a H, Katayama Y, Takahashi S, Shiratori S, Transplantsecond transplantation.
Saito S, Kawakita T, Kanda J, Fukuda T,
Atsuta Y, Kimura F.

57(1):43- WGP
50.
18-15

Kanda J, Hayashi H, Ruggeri A, Kimura F,
Volt F, Takahashi S, Kako S, TozattoMaio K, Yanada M, Sanz G, Uchida N,
Angelucci E, Kato S, Mohty M, Forcade Bone Marrow
2022
E, Tanaka M, Sierra J, Ohta T, Saccardi Transplant
R, Fukuda T, Ichinohe T, Kimura T,
Rocha V, Okamoto S, Nagler A, Atsuta Y,
Gluckman E.

57(1):57- WGP
64.
18-16

Imahashi N, Terakura S, Kondo E, Kato K,
Kim SW, Shinohara A, Watanabe M,
Impact of donor types on reducedFukuda T, Uchida N, Kobayashi H,
intensity conditioning allogeneic stem cell
Bone Marrow
331
Ishikawa J, Kataoka K, Shiratori S, Ikeda
2022
transplant for mature lymphoidTransplant
T, Matsuoka KI, Yoshida S, Kondo T,
malignancies.
Kimura T, Onizuka M, Ichinohe T, Atsuta
Y, Kanda J.

57(2):243 WGP
-51.
18-17

The impact of GVHD on outcomes after
330 adult single cord blood transplantation in
European and Japanese populations.

Differential Effect of Graft-versus-Host
332 Disease on Survival in Acute Leukemia
according to Donor Type.

Konuma T, Kanda J, Kuwatsuka Y,
Yanada M, Kondo T, Hirabayashi S, Kako
S, Akahoshi Y, Uchida N, Doki N, Ozawa Clin Cancer
Y, Tanaka M, Eto T, Sawa M, Yoshioka S, Res
Kimura T, Kanda Y, Fukuda T, Atsuta Y,
Kimura F.

2021

27(17):48 WGP
25-35.
18-18

Wada F, Watanabe M, Konuma T, Okabe
M, Kobayashi S, Uchida N, Ikegame K,
HLA 1-3 antigen-mismatched related
Tanaka M, Sugio Y, Mukae J, Onizuka M,
peripheral blood stem cells transplantation Kawakita T, Kuriyama T, Takahashi S,
Am J
333 using low-dose antithymocyte globulin
Fukuda T, Nakano N, Sawa M, Kimura T,
Hematolversus unrelated cord blood
Ichinohe T, Atsuta Y, Kanda J;
transplantation.
Donor/Source Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

2022

97(3):311 WGP
-21.
18-19

Ideal Body Weight Is Useful For Predicting Okada Y, Nakasone H, Konuma T, Uchida
Neutrophil Engraftment and Platelet
N, Tanaka M, Sugio Y, Aotsuka N,
Transplant
334 Recovery for Overweight and Obese
Nishijima A, Katsuoka Y, Ara T, Ota S,
Cell Ther
Recipients in Single-Unit Cord Blood
Onizuka M, Sawa M, Kimura T, Fukuda T,
Transplantation.
Atsuta Y, Kanda J, Kimura F.

2022

28(8):504 WGP.e1-7.
18-20

Clinical factors predicting the response of Murata M, Nakasone H, Kanda J, Nakane
acute graft-versus-host disease toT, Furukawa T, Fukuda T, Mori T,
Biol Bloodcorticosteroid therapy: an analysis from
Taniguchi S, Eto T, Ohashi K, Hino M,
335
Marrow
the GVHD Working Group of the Japan
Inoue M, Ogawa H, Atsuta Y, NagamuraTransplantSociety for Hematopoietic Cell
Inoue T, Yabe H, Morishima Y, Sakamaki
Transplantation.
H, Suzuki R.

2013

19(8):118 WGP
3-9.
19-1

A case-control study of bronchiolitis
336 obliterans syndrome following allogeneic
hematopoietic stem cell transplantation.

337

Risk factors and organ involvement ofchronic GVHD in Japan.

Nakasone H, Kanda J, Yano S, Atsuta Y,
Ago H, Fukuda T, Kakihana K, Adachi T,
Yujiri T, Taniguchi S, Taguchi J,
Morishima Y, Nagamura T, Sakamaki H, Transpl Int
2013
Mori T, Murata M; GVHD Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.
Kanda J, Nakasone H, Atsuta Y, Toubai
T, Yokoyama H, Fukuda T, Taniguchi S,
Bone Marrow
Ohashi K, Ogawa H, Eto T, Miyamura K,
2014
Transplant
Morishima Y, Nagamura-Inoue T,
Sakamaki H, Murata M.

26(6):631 WGP
-9.
19-2

49(2):228 WGP
-35.
19-3

Impact of conditioning intensity and TBI
338 on acute GVHD after hematopoietic celltransplantation.

Nakasone H, Fukuda T, Kanda J, Mori T,
Yano S, Kobayashi T, Miyamura K, Eto T,
Kanamori H, Iwato K, Uchida N, Mori S,
Bone Marrow
Nagamura-Inoue T, Ichinohe T, Atsuta Y,
2015
Transplant
Teshima T, Murata M; GVHD working
group of the Japan Society of
Hematopoietic Cell Transplantation.

50(4):559 WGP
-65.
19-4

Age influences post-graft-versus-hostdisease non-relapse mortality in adults
339 with acute graft-versus-host disease ofvarying severity following allogeneic
hematopoietic cell transplant.

Nakane T, Fukuda T, Kanda J, Taniguchi
S, Eto T, Ohashi K, Nakamae H,
Leuk
Kurokawa M, Mori T, Morishima Y,
Lymphoma
Nagamura-Inoue T, Sakamaki H, Atsuta
Y, Murata M.

2015

56(8):239 WGP
2-7.
19-5

Umeda K, Adachi S, Tanaka S, Ogawa A,
Hatakeyama N, Kudo K, Sakata N,
Comparison of continuous and twice-daily Igarashi S, Ohshima K, Hyakuna N, Chin
infusions of cyclosporine A for graftM, Goto H, Takahashi Y, Azuma E, Koh K,
Pediatr Blood
340 versus-host-disease prophylaxis in
Sawada A, Kato K, Inoue M, Atsuta Y,
2015
Cancerpediatric hematopoietic stem cell
Takami A, Murata M; on behalf of thetransplantation.
GVHD Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

62(2):291 WGP
-8.
19-6

Sakai R, Taguri M, Oshima K, Mori T, Ago
A comparison of tacrolimus and
H, Adachi S, Morita S, Taniguchi S,
cyclosporine combined with methotrexate
Fukuda T, Ohashi K, Eto T, Miyamura K,
341 for graft-versus-host disease prophylaxis,
Int J Hematol 2016
Iwato K, Kobayashi N, Kanamori H,
stratified by stem cell source: aMorishima Y, Nagamura-Inoue T,
retrospective nationwide survey.
Sakamaki H, Atsuta Y, Murata M.
Arai Y, Kanda J, Nakasone H, Kondo T,
Risk factors and prognosis of hepatic
Uchida N, Fukuda T, Ohashi K, Kaida K,
Bone Marrow
342 acute GvHD after allogeneic
Iwato K, Eto T, Kanda Y, Nakamae H,
2016
Transplant
hematopoietic cell transplantation.
Nagamura-Inoue T, Morishima Y,
Hirokawa M, Atsuta Y, Murata M.
Kanda J, Morishima Y, Terakura S, Wake
A, Uchida N, Takahashi S, Ono Y, Onishi
Impact of graft-versus-host disease on
Y, Kanamori H, Aotsuka N, Ozawa Y,
343 outcomes after unrelated cord blood
Leukemia
2017
Ogawa H, Sakura T, Ohashi K, Ichinohe
transplantation.
T, Kato K, Atsuta Y, Teshima T, Murata
M.
Murata M, Ikegame K, Morishita Y, Ogawa
H, Kaida K, Nakamae H, Ikeda T, Nishida
Low-dose thymoglobulin as second-line
T, Inoue M, Eto T, Kubo K, Sakura T,
Bone Marrow
344 treatment for steroid-resistant acute2017
Mori T, Uchida N, Ashida T, Matsuhashi Transplant
GvHD: an analysis of the JSHCT.
Y, Miyazaki Y, Ichinohe T, Atsuta Y,
Teshima T.

103(3):32 WGP
2-33.
19-7

51(1):96- WGP
102.
19-8

31(3):663 WGP
-8.
19-9

52(2):252 WGP
-7.
19-10

Terakura S, Wake A, Inamoto Y, Murata
Exploratory research for optimal GvHD
M, Sakai R, Yamaguchi T, Takahashi S,
prophylaxis after single unit CBT in adults:
Uchida N, Onishi Y, Ohashi K, Ozawa Y,
345 short-term methotrexate reduced theKanamori H, Yamaguchi H, Fukuda T,
incidence of severe GvHD more than
Ichinohe T, Takanashi M, Atsuta Y,
mycophenolate mofetil.
Teshima T.

Bone Marrow
2017
Transplant52(3):423 WGP
-30.
19-11

Inamoto Y, Kimura F, Kanda J, Sugita J,
Comparison of graft-versus-host diseaseIkegame K, Nakasone H, Nannya Y,
free, relapse-free survival according to a
Uchida N, Fukuda T, Yoshioka K, Ozawa
346 variety of graft sources: antithymocyte
Y, Kawano I, Atsuta Y, Kato K, Ichinohe
globulin and single cord blood provide
T, Inoue M, Teshima T; JSHCT GVHD
favorable outcomes in some subgroups.
Working Group.

Haematologic2016a101(12):1 WGP
592-602. 19-12

Arai Y, Kondo T, Yamazaki H, Takenaka
K, Sugita J, Kobayashi T, Ozawa Y,
Uchida N, Iwato K, Kobayashi N,
Haematologic
Takahashi Y, Ishiyama K, Fukuda T,
2016aIchinohe T, Atsuta Y, Mori T, Teshima T;
Japan Society for Hematopoietic Cell
Transplantation.

101(5):64 WGP
4-52.
19-13

347

Allogeneic unrelated bone marrowtransplantation from older donors resultsin worse prognosis in recipients withaplastic anemia.

Terakura S, Kuwatsuka Y, Yamasaki S,
Wake A, Kanda J, Inamoto Y, Mizuta S,
GvHD prophylaxis after single-unit
Yamaguchi T, Uchida N, Kouzai Y,
reduced intensity conditioning cord blood Aotsuka N, Ogawa H, Kanamori H,
Bone Marrow
348
2017transplantation in adults with acuteNishiwaki K, Miyakoshi S, Onizuka M,
Transplantleukemia.
Amano I, Fukuda T, Ichinohe T, Atsuta Y,
Murata M, Teshima T.

52(9):126 WGP
1-7.
19-14

Impacts of thymoglobulin in patients with
349 acute leukemia in remission undergoing
allogeneic HSCT from different donors.

Wakamatsu M, Terakura S, Ohashi K,
Fukuda T, Ozawa Y, Kanamori H, Sawa
M, Uchida N, Ota S, Matsushita A, Kanda
Blood
Y, Nakamae H, Ichinohe T, Kato K,
Advances
Murata M, Atsuta Y, Teshima T; GVHDWorking Group of the Japan Society for
Hematopoietic Cell Transplantation.

2019

3(2):105- WGP
15.
19-15

Effect of Graft-Versus-Host Disease on
350 Outcomes After Pediatric Single Cord
Blood Transplantation.

Kanda J, Umeda K, Kato K, Murata M,
Sugita J, Adachi S, Koh K, Noguchi M,
Goto H, Yoshida N, Sato M, Koga Y, Hori Bone Marrow
2020
T, Cho Y, Ogawa A, Inoue M, Hashii Y,
Transplant
Atsuta Y, Teshima T; JSHCT GVHDWorking Group.

55(7):143 WGP
0-7.
19-16

Effect of methotrexate dose in graftversus-host disease prophylaxis after
single-unit cord blood transplantation in
adult acute myeloid leukemia.

Terakura S, Kuwatsuka Y, Sugita J,
Takahashi S, Ozawa Y, Ozeki K, Yoshioka
S, Nakamae H, Kawakita T, Sawa M,
Morishige S, Najima Y, Katsuoka Y,
Int J Hematol 2021
Sakaida E, Kouzai Y, Kimura T, Ichinohe
T, Fukuda T, Atsuta Y, Murata M,
Teshima T.

113(6):84 WGP
0-50.
19-17

Off-the-shelf bone marrow-derived
mesenchymal stem cell treatment for
352
acute graft-versus-host disease: realworld evidence.

Murata M, Terakura S, Wake A, Miyao K,
Ikegame K, Uchida N, Kataoka K,
Miyamoto T, Onizuka M, Eto T, Doki N,
Bone Marrow
2021
Ota S, Sato M, Hashii Y, Ichinohe T,
Transplant
Fukuda T, Atsuta Y, Okamoto S, TeshimaT.

56(10):23 WGP
55-66.
19-18

Antithymocyte Globulin Potentially Could
Overcome an Adverse Effect of Acute
353 Graft-versus-Host Disease in MatchedRelated Peripheral Blood Stem Cell
Transplantation.

Miyao K, Kuwatsuka Y, Murata M,
Nagafuji K, Teshima T, Takeuchi Y,
Shiratori S, Najima Y, Uchida N, Tanaka
M, Sawa M, Ota S, Fukuda T, Ozawa Y,
Transplant
Kako S, Kawakita T, Ara T, Tanaka J,
Cell Ther
Kanda Y, Atsuta Y, Kanda J, Terakura S;
GVHD Working Group and Donor/Source
Working Group of the Japanese Society
for Transplantation and Cellular Therapy.

2022

28(3):153 WGP.e1-11.
19-19

Impact of hepatitis C virus infection onclinical outcome in recipients after
354
allogeneic hematopoietic celltransplantation.

Nakasone H, Kurosawa S, Yakushijin K,
Taniguchi S, Murata M, Ikegame K,
Kobayashi T, Eto T, Miyamura K,
Sakamaki H, Morishima Y, Nagamura T,
Suzuki R, Fukuda T.

2013

88(6):477 WGP
-84.
20-1

Pre-transplant risk factors forcryptogenic organizing
355 pneumonia/bronchiolitis obliteransorganizing pneumonia after hematopoietic
cell transplantation.

Nakasone H, Onizuka M, Suzuki N, Fujii
N, Taniguchi S, Kakihana K, Ogawa H,
Bone Marrow
2013
Miyamura K, Eto T, Sakamaki H, Yabe H, Transplant
Morishima Y, Kato K, Suzuki R, Fukuda T.

48(10):13 WGP
17-23.
20-2

Kato M, Matsumoto K, Suzuki R, Yabe H,
Salvage allogeneic hematopoietic SCT for Inoue M, Kigasawa H, Inagaki J, Koh K,
Bone Marrow356
2013
primary graft failure in children.
Hashii Y, Tauchi H, Suminoe A, Kikuta A, Transplant
Sakamaki H, Kawa K, Kato K, Fukuda T.

48(9):117 WGP
3-8.
20-3

Fuji S, Takano K, Mori T, Eto T,
Taniguchi S, Ohashi K, Sakamaki H,
Bone Marrow
2014
Morishima Y, Kato K, Miyamura K, Suzuki Transplant
R, Fukuda T.

49(12):15 WGP
05-12.
20-4

351

Impact of pretransplant body mass index
357 on the clinical outcome after allogeneic
hematopoietic SCT.

Am J
HematolCytomegalovirus Reactivation after
Allogeneic Hematopoietic Stem Cell
Transplantation is Associated with a
Reduced Risk of Relapse in Patients with
358 Acute Myeloid Leukemia Who Survived to
Day 100 after Transplantation: The Japan
Society for Hematopoietic Cell
Transplantation Transplantation-related
Complication Working Group.

Takenaka K, Nishida T, Asano-Mori Y,
Oshima K, Ohashi K, Mori T, Kanamori H, Biol Blood
Miyamura K, Kato C, Kobayashi N, Uchida Marrow
N, Nakamae H, Ichinohe T, Morishima Y, Transplant
Suzuki R, Yamaguchi T, Fukuda T.

2015

21(11):20 WGP
08-16.
20-5

Pre-transplant diabetes mellitus is a risk
factor for non-relapse mortality,359
especially infection-related mortality,
after allogeneic hematopoietic SCT.

Takano K, Fuji S, Uchida N, Ogawa H,
Bone Marrow
Ohashi K, Eto T, Sakamaki H, Morishima
2015
Transplant
Y, Kato K, Suzuki R, Fukuda T.

50(4):553 WGP
-8.
20-6

Yakushijin K, Atsuta Y, Doki N, Yokota A,
Sinusoidal obstruction syndrome after
Kanamori H, Miyamoto T, Ohwada C,
allogeneic hematopoietic stem cell
Miyamura K, Nawa Y, Kurokawa M,
Bone Marrow
360
2016
transplantation: Incidence, risk factors and Mizuno I, Mori T, Onizuka M, Taguchi J, Transplant
outcomes.
Ichinohe T, Yabe H, Morishima Y, Kato K,
Suzuki R, Fukuda T.
Kato M, Yamashita T, Suzuki R,
Donor cell-derived hematologic
Matsumoto K, Nishimori H, Takahashi S,
361 malignancy: A survey by the Japan society Iwato K, Nakaseko C, Kondo T, Imada K, Leukemia
2016
for hematopoietic cell transplantation.
Kimura F, Ichinohe T, Hashii Y, Kato K,
Atsuta Y, Taniguchi S, Fukuda T.

362

Impact of total body irradiation on
successful neutrophil engraftment in
unrelated bone marrow or cord bloodtransplantation.

Clinical characteristics and outcome ofhuman herpesvirus-6 encephalitis after
363
allogeneic hematopoietic stem celltransplantation.

Nakasone H, Fuji S, Yakushijin K, Onizuka
M, Shinohara A, Ohashi K, Miyamura K,
Uchida N, Takanashi M, Ichinohe T,
Am J
Atsuta Y, Fukuda T, Ogata M;
Hematol
Complication Working Group of JapaneseSociety for Hematopoietic Cell
Transplantation.
Ogata M, Oshima K, Ikebe T, Takano K,
Kanamori H, Kondo T, Ueda Y, Mori T,
Hashimoto H, Ogawa H, Eto T, Ueki T,
Miyamoto T, Ichinohe T, Atsuta Y,
Fukuda T.

51(3):403 WGP
-9.
20-7

30(8):174 WGP
2-5.
20-8

2017

92(2):171 WGP
-8.
20-9

Bone Marrow
2017
Transplant

52(11):15 WGP
63-70.
20-10

BM is preferred over PBSCs in
364 transplantation from an HLA-matched
related female donor to a male recipient.

Nakasone H, Kawamura K, Yakushijin K,
Shinohara A, Tanaka M, Ohashi K, Ota S,
Blood
Uchida N, Fukuda T, Nakamae H,
Advances
Matsuoka KI, Kanda J, Ichinohe T, Atsuta
Y, Inamoto Y, Seo S, Kimura F, Ogata M.

20193(11):175 WGP
0-60.
20-11

Clinical course of autologous recovery
with chromosomal abnormalities after
365
allogeneic hematopoietic stem celltransplantation.

Kato M, Nakasone H, Nakano N, Fuji S,
Shinohara A, Yokoyama H, Sakashita K,
Hori T, Takahashi S, Nara M, Kanda Y,
Mori T, Takita J, Kawaguchi H, Kawakita Bone Marrow
2020
T, Ichinohe T, Fukuda T, Atsuta Y, Ogata Transplant
M; Transplantation Complication Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

55(6):102 WGP
3-8.
20-12

Risk Factors and Predictive Scoring
System For Post-Transplant
366
Lymphoproliferative Disorder after
Hematopoietic Stem Cell Transplantation.

Fujimoto A, Hiramoto N, Yamasaki S,
Inamoto Y, Uchida N, Maeda T, Mori T,
Biol Blood
Kanda Y, Kondo T, Shiratori S, Miyakoshi
Marrow
S, Ishiyama K, Ikegame K, Matsuhashi Y,
Transplant
Tanaka J, Ichinohe T, Atsuta Y, Ogata M,
Suzuki R.

201925(7):144 WGP
1-9.
20-13

Low incidence of post-transplant
lymphoproliferative disorder after
367 allogeneic stem cell transplantation inpatients with lymphoma treated withrituximab.

Fujimoto A, Hiramoto N, Yamasaki S,
Inamoto Y, Ogata M, Sugio Y, Fukuda T,
Uchida N, Ikegame K, Matsuoka KI,
Shiratori S, Kondo T, Miyamoto T, Eto T, Hematological
2020
Ichinohe T, Kanda Y, Atsuta Y, Suzuki R; Oncology
Complication Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

38(2):146 WGP
-52.
20-14

Impact of pretransplant donor-specificanti-HLA antibodies on cord bloodtransplantation on behalf of the368
Transplant Complications Working Groupof Japan Society for Hematopoietic Cell
Transplantation.

Fuji S, Oshima K, Ohashi K, Sawa M,
Saito T, Eto T, Tanaka M, Onizuka M,
Bone Marrow
Nakamae H, Shiratori S, Ozawa Y, Hidaka
2020
Transplant
M, Nagamura-Inoue T, Tanaka H, Fukuda
T, Ichinohe T, Atsuta Y, Ogata M.

55(4):722 WGP
-8.
20-15

Comparison of the outcomes after
haploidentical and cord blood salvage
369 transplantations for graft failure following
allogeneic hematopoietic stem celltransplantation.

Harada K, Fuji S, Seo S, Kanda J, Ueki T,
Kimura F, Kato K, Uchida N, Ikegame K,
Onizuka M, Matsuoka KI, Doki N,
Kawakita T, Onishi Y, Yano S, Fukuda T, Bone Marrow
2020
Takanashi M, Kanda Y, Atsuta Y, Ogata Transplant
M; transplant complications working
group of the Japan Society for
Hematopoietic Cell Transplantation.

55(9):178 WGP
4-95.
20-16

Comparison of immunosuppressantregimens in salvage cord blood
370 transplantation for graft failure after
allogeneic hematopoietic stem celltransplantation.

Harada K, Fuji S, Seo S, Uchida N,
Kawakita T, Yano S, Ozawa Y, Yoshioka
S, Onishi Y, Noguchi Y, Onizuka M,
Matsuhashi Y, Kimura T, Ichinohe T,
Atsuta Y; Transplant Complications
Bone Marrow
2021
Working Group of the Japan Society for Transplant
Hematopoietic Cell Transplantation;
GVHD Working Group of the Japan
Society for Hematopoietic Cell
Transplantation, Terakura S, Nakasone H.

56(2):400 WGP
-10.
20-17

Severe acute graft-versus-host disease
increases the incidence of blood stream
371 infection and mortality after allogeneic
hematopoietic cell transplantation:
Japanese transplant registry study.

Inoue Y, Okinaka K, Fuji S, Inamoto Y,
Uchida N, Toya T, Ikegame K, Eto T,
Ozawa Y, Iwato K, Kanda Y, Atsuta Y,
Ogata M, Fukuda T; Transplant
Complications Working Group of The
Japan Society for Hematopoietic Cell
Transplantation.

56(9):212 WGP
5-36.
20-18

Effect of cytomegalovirus reactivation
with or without acute graft-versus-host372
disease on the risk of nonrelapse
mortality.

Akahoshi Y, Kimura SI, Inamoto Y, Seo S,
Muranushi H, Shimizu H, Ozawa Y,
Tanaka M, Uchida N, Kanda Y, Katayama Clin InfectY, Shiratori S, Ota S, Matsuoka KI,
Dis
Onizuka M, Fukuda T, Atsuta Y, Murata
M, Terakura S, Nakasone H.

2021

73(3):e62 WGP
0-8.
20-19

Cytomegalovirus reactivation isassociated with an increased risk of lateonset invasive aspergillosis independently
373 of grade II-IV acute graft-versus-hostdisease in allogeneic hematopoietic stem
cell transplantation: JSTCT Transplant
Complications Working Group.

Kimura SI, Tamaki M, Okinaka K, Seo S,
Uchida N, Igarashi A, Ozawa Y, Ikegame
K, Eto T, Tanaka M, Shiratori S, Nakamae
Ann Hematol 2021
H, Sawa M, Kawakita T, Onizuka M,
Fukuda T, Atsuta Y, Kanda Y, Nakasone
H.

100(12):3 WGP
029-38. 20-20

Prognostic factors in salvagetransplantation for graft failure following
374
allogeneic hematopoietic stem celltransplantation.

Cytomegalovirus gastroenteritis in
375 patients with acute graft-versus-hostdisease.

Risk and Predictive Factors for
Candidemia After Allogeneic
376 Hematopoietic Cell Transplantation:
JSTCT Transplant Complications Working
Group.

Bone Marrow
2021
Transplant

Harada K, Kimura SI, Fuji S, Najima Y,
Yakushijin K, Uchida N, Onizuka M,
Ikegame K, Yano S, Shingai N, Matsuoka Bone Marrow
2021
KI, Onishi Y, Sawa M, Takada S, Kawakita TransplantT, Fukuda T, Kanda J, Atsuta Y,
Nakasone H.
Akahoshi Y, Kimura SI, Tada Y,
Matsukawa T, Tamaki M, Doki N, Uchida
N, Tanaka M, Nakamae H, Kuriyama T,
Blood
2022
Matsuoka KI, Ikeda T, Kimura T, Fukuda Advances
T, Kanda Y, Atsuta Y, Murata M,
Terakura S, Nakasone H.
Kimura SI, Kameda K, Harada K, Saburi
M, Okinaka K, Shinohara A, Uchida N,
Nishijima A, Ozawa Y, Tanaka M,
Kuriyama T, Katayama Y, Sawa M,
Ikegame K, Kawakita T, Kanda Y,
Nakamae H, Ara T, Kimura T, Sato A,
Fukuda T, Atsuta Y, Nakasone H.

Transplant
Cell Ther

2022

56(9):218 WGP
3-93.
20-21

25;6(2):5 WGP
74-84.
20-22

28(4):209 WGP.e1-9.
20-23

Risk factors and prognosis of noninfectious pulmonary complications after
377
allogeneic hematopoietic stem celltransplantation.

Onizuka M, Fujii N, Nakasone H, Ogata M,
Atsuta Y, Suzuki R, Uchida N, Ohashi K,
Ozawa Y, Eto T, Ikegame K, Nakamae H, International
Inoue M, Fukuda T; Transplant
Journal ofComplications Working Group of theHematology
Japan Society for Hematopoietic Cell
Transplantation.

Risk factors for fatal cardiac
complications after allogeneic
hematopoietic cell transplantation:
378
Japanese Society for Transplantation andCellular Therapy transplant complications
working group.

Yanagisawa R, Tamaki M, Tanoshima R,
Misaki Y, Uchida N, Koi S, Tanaka T,
Ozawa Y, Matsuo Y, Tanaka M, Ikegame Hematological
K, Katayama Y, Matsuoka KI, Ara T,
Oncology
Kanda Y, Matsumoto K, Fukuda T, Atsuta
Y, Kato M, Nakasone H.

Deletion of Y chromosome before
allogeneic hematopoietic stem cell379
transplantation in male recipients withfemale donors.

Tamaki M, Kameda K, Kimura SI, HaradaN, Uchida N, Doki N, Tanaka M, Ikegame
Blood
K, Sawa M, Katayama Y, Miyakoshi S, Ara
Advances
T, Kanda J, Onizuka M, Fukuda T, Atsuta
Y, Kanda Y, Yakushijin K, Nakasone H.

2022

6(6):1895 WGP
-903.
20-26

Outcomes of salvage haploidenticaltransplantation using posttransplant
380 cyclophosphamide for graft failure
following allogeneic hematopoietic stem
cell transplantation.

Harada K, Najima Y, Kato M, Fuji S,
Shinohara A, Nakamae H, Toyosaki M,
Int J Hematol 2022
Ashiarai M, Onizuka M, Hashii Y, Ichinohe
T, Atsuta Y, Nakasone H.

116(5):74 WGP
4-53.
20-27

Late Mortality and Causes of Death
381 among Long-Term Survivors after
Allogeneic Stem Cell Transplantation.

Atsuta Y, Hirakawa A, Nakasone H,
Kurosawa S, Oshima K, Sakai R, Ohashi
K, Takahashi S, Mori T, Ozawa Y, Fukuda
Biol Blood
T, Kanamori H, Morishima Y, Kato K,
Marrow
Yabe H, Sakamaki H, Taniguchi S,
Transplant
Yamashita T; Late Effect and Quality ofLife Working Group of the Japan Societyfor Hematopoietic Cell Transplantation.

201622(9):170 WGP
2-9.
21-1

2018

2(15):190 WGP
1-13.
21-2

2022

97(2):185 WGP
-93.
21-3

2020

3:11-7.

WGP
21-4

in press

WGP
22-1

Outcomes of patients who developed
382 subsequent solid cancer after
hematopoietic cell transplantation.

Characterization of myeloid neoplasms
383 following allogeneic hematopoietic celltransplantation.

Inamoto Y, Matsuda T, Tabuchi K,
Kurosawa S, Nakasone H, Nishimori H,
Yamasaki S, Doki N, Iwato K, Mori T,
Takahashi S, Yabe H, Kohno A, Nakamae
H, Sakura T, Hashimoto H, Sugita J, Ago
Blood
H, Fukuda T, Ichinohe T, Atsuta Y,
Advances
Yamashita T; Japan Society for
Hematopoietic Cell Transplantation Late
Effects and Quality of Life Working
Group.
Kuno M, Yamasaki S, Fujii N, Ishida Y,
Fukuda T, Kataoka K, Uchida N,
Katayama Y, Sato M, Onai D, Miyamoto
T, Ota S, Yoshioka S, Ara T, Hangaishi A,
Am J
Hashii Y, Onizuka M, Ichinohe T, Atsuta
Hematol
Y, Inamoto Y; on behalf of the Japan
Society for Hematopoietic Cell
Transplantation Late Effects and Qualityof Life Working Group.

Iida M, Nakasone H, Yamashita T, Inoue
M, Ishida Y, Uchiyama H, Katayama Y,
Miyamoto T, Yoshioka S, Shiratori S,
Late mortality and causes of death among
Mori T, Sawa M, Sugio Y, Fukuda T,
Blood Cell
384 long-term survivors after autologous
Ichinohe T, Atsuta Y, Inamoto Y, for the Therapy
hematopoietic stem cell transplantation.
Late Effect and Quality of Life Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.
Severe short-term adverse events in
385 related bone marrow or peripheral blood
stem cell donors.

Yanagisawa R, Hirakawa T, Doki N,
Ikegame K, Matsuoka KI, Fukuda T,
Nakamae H, Ota S, Hiramoto N, Ishikawa
Int J HematolJ, Ara T, Tanaka M, Koga Y, Kawakita T,
Maruyama Y, Kanda Y, Hino M, Atsuta Y,
Yabe H, Tsukada N.

2022

115(4):53 WGP
4-44.
20-24

in press

WGP
20-25